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ABSTRACT 
Ribozymes are RNA sequences capable of carrying out catalytic 
functions. This thesis has investigated the application of hammerhead 
ribozymes for the specific inactivation of a target gene in plants. 
111 
Results were obtained for 2 types of RNA transcripts containing 
hammerhead ribozyme sequences designed to inactivate the CAT target gene. 
Initial in vivo screening of the hammerhead ribozymes was done using transient 
expression in N. tabacum plant cells. To increase ribozyme and CAT 
expression in the plant cells, both sequences were expressed from a self-
replicating viral vector, pACMV. Expression from this vector, as judged by CAT 
enzyme activity, was 19 times greater than from a non-replicating vector in 
which CAT was expressed from the 35S promoter. 
The first ribozyme construction analysed (Chapter 3) was a long 
ribozyme in which four hammerhead domains were incorporated within the 
complete CAT-antisense sequence. Previous analyses, in which expression of 
this ribozyme and corresponding antisense was obtained from the 35S 
promoter, had suggested that the long ribozyme could enhance antisense-
mediated inhibition of the CAT target by 30°/o (Perriman et al, 1993). In 
contrast to these data, the results presented in chapter 3 show that co-
transfection of pACMV expressing CAT and either antisense or ribozyme-
antisense, gave significant but equivalent reductions in CAT enzyme activity. 
The second ribozyme constructions were two short molecules, Rz12 and 
RzCA, which were embedded within a tobacco tyrosine tRNA (tRNA Tyr) 
sequence (Chapter 4). These ribozymes, and the corresponding control 
antisense sequences, were assayed both in vitro and in vivo. The in vitro 
analyses included monitoring the steps of tRNATyr maturation, and ribozyme-
cleavage rates induced by the tRNATYr-embedded and analogous non-
embedded ribozymes. The maturation assays showed that the chimeric tRNAs 
were not processed to completion; a 13 base intron contained within the 
IV 
molecule was not spliced out during processing of these tRNA sequences. The 
cleavage assays showed that the Rz12 ribozyme, in the non-tRNATyr_ 
embedded form, was the most efficient at cleaving the CAT target. The 
tRNATYr-embedded Rz12 was approximately 50°/o less efficient, although rates 
of cleavage were significantly increased when the tRNARz12 ribozyme was 
processed prior to cleavage. 
Co-transfection of pACMV expressing CAT target, Rz12 ribozymes or 
control antisense constructs into plant cells, and the subsequent analysis of 
CAT enzyme activities, showed that CAT activity was 85°/o reduced in the 
presence of the tRNARz12 ribozyme construct (Chapter 5). This was 
significantly more than the reduction in the presence of non-embedded Rz12 
ribozyme, or tRNATYr-embedded and non-embedded antisense. A mutant CAT 
sequence, CM2, which contained a non-cleavable target site, gave CAT activity 
which was reduced to the same level in the presence of all antisense and Rz12 
ribozyme constructs. This suggested that the greater reduction observed for 
the wildtype CAT target and tRNARz12 ribozyme, was due to ribozyme-
mediated cleavage. CAT mRNA analysis supported this view by showing, in 
the presence of the tRNATyr_ribozyme, a reduction in full length message and a 
significant accumulation of RNA representing the 3' cleavage product. 
The tRNATyr_ribozyme constructs contained active RNA polymerase 11 
and Ill promoters. Mutagenesis of these promoter sequences revealed that the 
active and predominant ribozyme transcript was derived from the RNA 
polymerase 111 promoter of the tRNA Tyr sequence. This transcript was present 
in a 620 molar excess over the CAT mRNA in the plant cells. 
Following the transient studies, the tRNATyr_ribozyme and tRNATyr_ 
antisense were transformed into N tabacum Ti68 plants (Chapter 6). The CAT 
target was expressed as a single homozygous insertion in a separate Ti68 
plant. CAT x tRNATyr_ribozyme or tRNATYr-antisense crosses were carried out 
and the progeny assayed for relative CAT activties. No reduction in CAT 
enzyme activity or CAT mRNA levels were observed in the presence of the 
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tRNATyr_ribozyme or tRNATYr-antisense transgenes. The analysis of tRNATyr_ 
ribozyme expression showed significantly reduced levels relative to the 
transient expression obtained from the replicating vectors in plant cells. This 
resulted in a molar ratio of 0-0. 7 ribozyme : 1 CAT substrate. This reduction in 
the ribozyme: substrate ratio was probably responsible for the lack of effect on 
CAT mRNA observed in this study. 
1 
INTRODUCTION 
1.1 Enzymes 
Most chemical reactions that take place within biological systems are 
catalysed by proteinaceous enzymes. These enzymes accelerate the rate of a 
reaction by providing an alternate reaction pathway which has a lower 
activation energy. They are highly specific with regard to the substrates they 
act upon and the products they generate, and are not consumed within the 
reaction (Alberts et al., 1989). Recently several RNA molecules, found in a 
wide range of systems have been shown to catalyse the cleavage and ligation 
of phosphodiester bonds within specific nucleic acid sequences. These RNA 
molecules have been collectively called 11 ribozymes 11 (Kruger et al., 1982). 
Ribozymes exhibit many catalytic activities including cleavage, replication and 
ligation of nucleic acid substrates (for review see Pyle, 1993). 
In many cases ribozymes, and their site of cleavage, are intramolecular. 
Such ribozymes can only catalyse a single reaction and are often modified 
during this process. These ribozymes have been termed 11 quasi-catalytic 11 
(Cech and Bass, 1986). Other ribozymes can act in trans, and take part in 
multiple reactions without being modified themselves. These ribozymes act in 
a truly catalytic manner and can therefore be classified as enzymes. The study 
of one such ribozyme, the hammerhead ribozyme, forms the basis of this 
thesis. However, before I describe the hammerhead ribozyme in detail, it is 
important to introduce and summarise some of the other catalytic RNAs and 
also to provide an historical perspective to the origins of the discovery of these 
novel RNA molecules. 
1.2. Ribozymes 
1.2.1 Group I intrans 
The first ribozyme to be described was a 413 nucleotide intron found in 
the nuclear rRNA precursor of the protozoan Tetrahymena thermophila 
(Kruger et al., 1982). This intron is one of almost 100 which have been 
2 
classified as group I intrans. Group 1 intrans are characterised by conserved 
sequence homologies and secondary structures which mediate self-splicing. 
To date, at least twelve group I intrans have exhibited self-splicing. The self-
splicing process involves the covalent bonding of a guanosine nucleotide to the 
51 end of the intron which acts as a nucleophile in producing the first excision 
step. An internal guide sequence (IGS) 11 CUCUCU 11 , forms base-pairing with 
sequences adjacent to, and including the 51 splice site. Base-pairing of this 
region must occur for the nucleophilic attack by the guanosine nucleotide. 
Excision at the 31 end of the intron is catalysed by ligation of the 31-hydroxyl on 
the 51 exon to the 51-phosphate on the 31 exon, thus excluding the intron. After 
excision, the intron forms a circular RNA, covalently closed by a 51-3 1 
phosphodiester bond (Cech, 1987). This whole process can occur in the 
complete absence of any protein interaction. 
1.2.2 RNase P 
At around the same time as the Tetrahymena self-splicing intron was 
discovered, Altman and colleagues demonstrated the first trans acting 
ribozyme (Guerrier-Takada et al., 1983). The RNase P enzyme is responsible 
for the maturation of pre-tRNA molecules. This enzyme is made up of two 
subunits, an RNA and a protein. In bacteria, the 400 nucleotide RNA 
component of the RNase P enzyme was found to cleave the precursor tRNA in 
the absence of the protein subunit (Guerrier-Takada et al., 1983). The RNase 
P RNA exhibited multiple turnover and remained unmodified during the 
reaction. This difference, along with the fact that this is a trans reaction (as 
distinct from the cis acting Tetrahymena self-splicing intron) made the RNase 
P RNA the first truly catalytic RNA enzyme to be described. 
Soon after this discovery, Cech and co-workers showed that by 
separating the 51 and 31 exons from the intron, the Tetrahymena self-splicing 
intron could also catalyse a number of novel trans reactions. The novel RNA 
substrates required only complementary sequence with which to 11 base-pair 11 to 
the IGS sequence (see Cech, 1990 for review). This discovery demonstrated 
3 
that the Tetrahymena self-splicing intron was also capable of behaving in a 
catalytic fashion. 
In their native state, both of these ribozymes, are relatively large 
(approximately 400 nucleotides) and require specific "guide" sequences on 
their target RNA. In the case of the Tetrahymena intron, the six base 
sequence 11 CUCUCU 11 acts as a recognition site for the initial guanosine 
bonding (Cech, 1987). However, mutagenic analysis has established that as 
few as two bases ("CU") are sufficient for cleavage to occur (Murphy and Cech, 
1989). For the RNase P RNA, the acceptor stem at the 3' end of the tRNA acts 
as an "external guide sequence" (EGS). The nucleotide sequence of the EGS 
is not conserved but identifies the site of cleavage by forming base-pairs with 
the segment that is cleaved (Forster and Altman, 1990). Additionally, the 
conserved triplet 11 CCA 11 at the 3' end of the acceptor stem of the tRNA is 
essential for the cleavage reaction. 
Since both ribozymes are able to act in trans, application of these to 
novel RNA substrates could provide a powerful tool for targeting, cleaving and 
inactivating specific RNAs. Application of the Tetrahymena self-splicing 
process has been limited, due mainly to the lack of target specificity (Zaug and 
Cech, 1986; Sullenger and Cech, 1994). In contrast, the RNase P protein-RNA 
moiety from both E.coli and human cells have been successfully used to cleave 
new mRNA targets (Li et al., 1992; Yuan et al., 1992; Yuan and Altman, 1994, 
1995). By delivering specifically designed EGS guide sequences, which can 
anneal to the target mRNA, the endogenous RNase P recognises the 
engineered target-EGS hybrid as a site of cleavage and cleaves the mRNA. 
1.2.3 Other catalytic RNAs 
Since the discovery of the Tetrahymena and RNAse P ribozymes, 
several other catalytic RNA sequences have been described (for reviews see 
Cech and Bass, 1986; Symons, 1992, 1994). In addition to the group I intrans, 
to which the Tetrahymena sequence belongs, a second class of self-splicing 
intrans called group II have been described (Michel and Dujon, 1983). Group II 
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intrans contain conserved structures which are different from those found in 
group I intrans. In addition, group II intron excision does not require a 
guanosine nucleotide and the excised intron is held together by a 2'-5' 
phosphodiester bond (i.e. unlike the 3'-5' bond found in the circularised group I 
intrans). 
Along with these self-splicing intrans, several small circular RNAs have 
been found to contain sequences capable of undergoing autocatalytic cleavage 
(see Bruening, 1990 for review). These include two mitochondrial sequences 
from Neurospora , the genomic(+) and antigenomic(-) sequences from hepatitis 
delta virus (HOV) and several small parasitic RNAs sometimes found 
associated with plant viruses (i.e. satellite or viroid RNAs). In addition, similar 
sequences have been found in transcripts of a nuclear satellite DNA from newt. 
Like the Tetrahymena self-splicing intron, the naturally occurring 
cleavage process in these small circular RNAs acts in cis. Mutagenic analysis 
has identified the sequences within these RNAs that are responsible for the 
self-cleaving process. This has led to their successful separation into trans 
ribozyme-mediated cleavage reactions (e.g. Haseloff and Gerlach, 1988; 
Feldstein et al., 1989; Branch and Robertson, 1991; Guo and Collins, 1995). 
Of these reactions, the isolation and manipulation of two distinct ribozyme 
sequences has attracted much attention for their use as potential gene therapy 
agents. The respective two-dimensional folded conformations of these two 
ribozymes has led to their naming as hairpin (or paperclip; Buzayan et al., 
1986; Hampel and Tritz, 1989; Feldstein et al., 1989; Haseloff and Gerlach, 
1989) and hammerhead ribozymes (Forster and Symons, 1987a). 
1.2.4 The hairpin ribozyme 
Unlike the hammerhead motif , which is present in several naturally 
occurring self-cleaving RNAs, the only hairpin ribozyme so far identified derives 
from the satellite RNA associated with tobacco ringspot virus (sTobRV). The 
replication of sTobRV involves the autolytic cleavage of positive and negative 
strand RNA ( see also section 1 .4). The positive strand RNA is cleaved by a 
I 
I 
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hammerhead ribozyme, and the negative strand by a hairpin ribozyme 
(Buzayan et al., 1986; Hampel and Tritz, 1989; Feldstein et al., 1989; Haseloff 
and Gerlach, 1989). 
Site specific cleavage, by the hairpin ribozyme, is 5' of a "GUC" triplet 
and the reaction is readily reversible (i.e. ligation). Like the hammerhead, the 
adaptation of the hairpin from a cis to a trans reaction has led to the 
development of hairpin ribozymes designed to target and cleave new RNA 
substrates (e.g. Yu et al., 1993). As this thesis involves the use of the 
hammerhead ribozyme, and the literature involving this ribozyme is extensive, 
the hairpin ribozyme will not be further discussed. 
This thesis details investigations toward optimising the stability, 
expression and intracellular location of hammerhead ribozymes for in vivo 
applications. The remainder of this review will focus on hammerhead 
ribozymes, and include a detailed analysis of the literature concerning the in 
vitro optimisation of the hammerhead ribozyme reaction, followed by the data 
available for the in vivo activity. The research carried out in this thesis is put 
into the context of the current literature. 
1.3. Hammerhead ribozymes: an introduction 
Hammerhead ribozymes are characterised by the presence of self-
cleaving sequences which, in neutral or higher pH, autolytically cleave RNA to 
generate a 5' hydroxyl group on the 3' fragment and a 2', 3' cyclic phosphate on 
the 5' fragment (Fig. 1.1 a; Prody et al., 1986; Forster and Symons, 1987a & _b; 
Buzayan et al., 1986; ). The overall number of phosphodiester bonds does not 
change during the reaction, nor is there the addition or removal of a nucleotide 
at the cleavage site. As might be expected from an enzymic reaction, the 
reverse reaction (i.e. ligation) has been shown to occur in vitro, but at a low 
efficiency(Prody et al., 1986). The only exogenous requirement for the reaction 
is a divalent cation such as magnesium. The exact function of this cation in the 
cleavage reaction is unknown. In most instances, this self-cleaving 
Figure 1.1 
a: The self-cleavage reaction of RNA catalysed by the presence of a hammerhead ribozyme 
and divalent cations (Mg2+). The susceptible phosphodiester bond in the substrate RNA is 
cleaved to produce products with a 2'3' cyclic phosphate at the 3' terminus and a 5' hydroxyl at 
the 5' terminus. 
b: The hammerhead cleavage domain. It consists of three helices (I, II and Ill) which radiate from 
the central core. The arrow indicates the susceptible phosphodiester bond which is cleaved as 
described in (a). Watson-Crick base pairing in helices I, II and Ill is shown. Non-conserved 
nucleotides are designated "N". 
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phosphotransfer has been mapped to sequences of 100 or fewer 
ribonucleotides within the satellite or viroid RNA (i.e. the hammerhead domain; 
Bruening, 1990). 
The hammerhead domain consists of three helices radiating from a 
central core (see Fig. 1.1 b). The nucleotide component of the hammerhead 
domain will be discussed in more detail later. In order to understand the 
discovery and development of hammerhead ribozymes as potential therapeutic 
agents, it is important to introduce their functions in nature; i.e. their role in the 
replication of small circular RNAs which are often associated with plant viruses. 
Such RNAs are called satellites, while similar molecules which occur in the 
absence of virus are termed viroids. 
1.4. Satellites and Viroids 
Satellite RNAs cannot replicate when inoculated alone onto a plant. 
They require infection of the plant host with the appropriate support virus. 
Upon infection, the satellite RNA becomes encapsidated in the coat protein of 
the virus as a predominantly circular molecule, but has no extensive nucleotide 
homology with the plant virus. Despite this, the satellite has an absolute 
dependence upon that virus for replication. Satellites are less than 400 
ribonucleotides in length and do not appear to encode for any protein. In 
contrast to satellite RNAs, viroids can replicate independently and are not 
encapsidated. Like the satellites, viroid RNAs have fewer than 400 nucleotides 
and there is no evidence that they are messenger RNAs (Bruening, 1990). It is 
believed that plant RNA polymerase II is involved in the synthesis of most viroid 
RNAs. The encapsidated forms of satellite RNAs are of one polarity, 
designated positive(+) (Prody et al., 1986). 
A rolling circle model for replication of both satellite and viroid RNAs (see 
Fig. 1 .2) has been postulated and is supported by several pieces of 
experimental evidence. Tissues in which satellite and plant virus are 
replicating, or viroid alone, have been found to contain RNA of both polarities. 
Figure 1.2: Rolling circle model for replication by which satellite and viroid RNAs are thought 
to replicate. The steps are: 1, the circular plus(+ - green) strand is copied to form tandemly 
repeated multimeric minus(-) RNA; 2, Site specific cleavage of this strand produces - strand 
monomers: in sTobRV, this process is catalysed by the hairpin ribozyme; 3, circularisation of -
strand monomer; 4, circular - strand is copied to produce multimeric + strand; 5, Site specific 
cleavage produces monomeric + strand: this process is catalysed by the hammerhead 
ribozyme; 6, circularisation of the + strand monomers: this is the dominant form found in vivo. 
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This RNA is found not only as the unit length sequence but also as tandemly 
repeated multimeric sequences. The positive polarity multimers contain 
conserved hammerhead sequences and are the precursors of the monomeric 
RNA (Buzayan et al., 1986; Hutchins et al., 1986; Forster and Symons, 1987a). 
The formation of monomeric RNAs is the consequence of the self-cleaving 
hammerhead ribozyme reaction. 
1.5. The hammerhead domain 
The regions surrounding the self-cleaving sites of several satellite and 
viroid RNAs were found to contain highly conserved secondary structures. 
These structures are found in both the + and - strand RNAs of avocado 
sunblotch viroid (ASBV), the virusoid (a subclass of the satellites) of lucerne 
transient streak virus (vl TSV) and the+ strand of the sTobRV (Hutchins et al., 
1986, Forster and Symons, 1987a). This consensus domain was termed the 
"hammerhead". 
Within these naturally occurring RNAs, the hammerhead ribozymes work 
in cis . That is, the satellite or viroid RNA folds into a structure capable of self-
cleavage. Several important studies carried out in the late 1980's led to the 
manipulation of this cis reaction. Forster and Symons (1987a) delimited the 
minimum sequence requirements for self-cleavage of the + strand of the 
virusoid lucerne transient streak (vl TSV) to 52 nucleotides (Fig. 1.3a). As well, 
they proposed that the "hammerhead" structure was sufficient and necessary 
for self-cleavage (Forster and Symons, 1987b). Following this, Uhlenbeck 
transcribed two RNA molecules in vitro from synthetic deoxyoligonucleotides, 
and showed that a 19 nucleotide RNA fragment could rapidly and specifically 
induce cleavage of a 24 nucleotide fragment (Fig. 1.3b.; Uhlenbeck, 1987). 
Although this work showed that the reaction could occur in trans as well as cis, 
the active structure, as depicted by Uhlenbeck, required that the "substrate" 
RNA contain several conserved nucleotides and a stem-loop. These 
requirements significantly reduced the applicability of this ribozyme sequence 
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to new RNA targets. Haseloff and Gerlach (1988) while carrying out structure-
function analysis of the sTobRV sequences, identified a non-essential loop of 
the hammerhead structure. The removal of this loop allowed them to separate 
target and catalytic domains of the self-cleaving sequence, thereby creating the 
hammerhead ribozyme as depicted in figure 1.3c. Unlike the Uhlenbeck 
design, the Haseloff and Gerlach hammerhead ribozyme required only a three 
base recognition sequence on the target RNA. By altering the sequence of 
helix I and Ill on the catalytic domain, they designed a hammerhead ribozyme 
to target and cleave a completely unrelated RNA in vitro. This work was 
successful and the first synthetic hammerhead ribozyme had been used to 
cleave an unrelated RNA in vitro. 
This trans-acting hammerhead ribozyme had a number of advantages 
over other catalytic RNA molecules. It was much smaller than both the 
Tetrahymena and RNaseP ribozymes and required only a three base target 
sequence on the substrate RNA. Additionally, the added requirement for 
sequence complementarity of helices I and 111 meant that highly specific 
synthetic hammerhead ribozymes could be designed to hybridise and cleave at 
a number of sites on any given RNA. The work of Haseloff and Gerlach (1988) 
led to the establishment of simple rules for the design of short hammerhead 
ribozymes sequences. Adherence to these rules can theoretically allow for the 
specific targeting, cleaving and inactivating of any designated RNA sequence, 
potentially making the hammerhead ribozyme a powerful tool. These rules are: 
1. the presence of the highly conserved "catalytic domain" in the 
ribozyme RNA 
2. a cleavage site on the substrate RNA, generally a GUC triplet, 
although other triplets have also been shown to cleave in vitro 
(Koizumi et al., 1989; Sheldon et al., 1989; Ruffner et al., 1990; 
Perriman et al., 1992). 
3. complementary sequences between the substrate RNA and the 
hammerhead ribozyme in "hybridising arms" flanking the active site. 
Figure 1.3 
a: Minimal sequence requirements for obtaining cis cleavage of the virusoid, lucerne transient 
streak (Forster and Symons, 1987a). The three helices are indicated, and the arrow shows the 
site of cleavage. This structure led to self-cleavage reactions of this type being designated 
"hammerhead ribozymes". 
b: Manipulation of the hammerhead ribozyme from a cis to a trans reaction (Uhlenbeck, 1987). 
The loops connecting helices I and 11 have been removed and replaced by a connecting loop at 
helix Ill. Cleavage site and designation of helices are as in (a). Using this design, the "substrate" 
RNA is required to contain several conserved nucleotides and a stem-loop 5' of the site of 
cleavage. 
c: Further modification of the trans hammerhead cleavage reaction (Haseloff and Gerlach, 
1988). In this design, helices I and Ill are unconnected and helix II contains a connecting loop. 
Using this design, the two RNA sequences can be separated as "substrate" and "enzyme" (i.e. 
ribozyme) and the substrate is required to contain only three conserved nucleotides for 
cleavage (i.e. nucleotides 16.1, 16.2 and 17 depicted in green). Annealing of the ribozyme to 
the substrate is via Watson-Crick base-pairing of helices I and Ill. Apart from the two base-pairs at 
the cleavage site (i.e. nucleotides 15.1 and 15.2 depicted in green), the nucleotide component 
of helices I and Ill is not conserved. The unpaired core and helix II make up the "catalytic 
domain" of the ribozyme and contains several conserved nucleotides. These are discussed in 
detail in the text and figures 1.4-1.11. The numbering of this catalytic domain conforms with 
Hertel et al., 1992 and is used throughout this review. 
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1.6. In vitro mutagenesis of the catalytic core 
Since the determination of these general rules, there has been a large 
number of mutational analyses carried out on the catalytic core of the 
hammerhead ribozyme. These studies, although far from complete, have 
determined the flexibility of ribonucleotide substitutions within the hammerhead 
ribozyme domain. In addition, they have analysed the effect of substituting 
deoxynucleotides or chemically modified nucleotides in place of the standard 
ribonucleotides of the hammerhead domain. In this way the requirements for 
specific components of the ribonucleotides within the hammerhead structure 
can be dissected. The following sections will outline what is known from in vitro 
studies for obtaining optimal hammerhead ribozyme derived cleavage. 
1.6.1. Ribonucleotide substitutions 
1.6.1.1 The unpaired core and helix II 
Mutational analysis has revealed that ribonucleotide substitutions within 
the unpaired core of the catalytic domain are tolerated poorly, if at all (Fig. 1.4-
Koizumi et al., 1988a & b; Sheldon et al., 1989; Ruffner et al., 1990). An 
exception is nucleotide 7, which varies in naturally occurring hammerhead 
sequences, and can be altered with minimal affect, although a G or a U appear 
favourable over an A or a C (Sheldon et al., 1989; Ruffner et al., 1990). 
As helix II also varies in naturally occurring hammerhead RNAs, reports 
have suggested that the specific nucleotide component of this region may not 
greatly affect cleavage activity. This has been supported by the creation of a 
11 minizyme 11 in which helix II has been deleted and replaced with a 4 base loop 
(i.e. tetraloop). All derivatives of the minizyme showed observable rates of 
cleavage with some constructions equalling the rate obtained with the original 
helix II containing ribozyme (McCall et al., 1992). The minizyme constructions 
will be discussed in more detail in section 1 .6.2. 
Despite the fact that minizymes lacking helix II are still functional, 
several lines of evidence have now shown that alterations to certain base-pairs 
Figure 1.4: Conserved nucleotides (red) in the unpaired core of the catalytic domain which 
are required for in vitro hammerhead ribozyme cleavage. The single variable nucleotide, U7 
(shown boxed) can be substituted with minimal effect. 
Figure 1.5: Analysis of the requirements of helix II and the tetraloop of the catalytic domain of 
the hammerhead ribozyme. G1 O - C11 (shown in blue) must be conserved for efficient in vitro 
cleavage. The remaining three base-pairs in helix II can be altered in sequence as well as the 
number of base-pairs (see section 1.6.1.1 for details). The four base tetraloop joining helix 11 
can also be altered although most efficient cleavage has been obtained with 5'GNRA 3' loops 
(i.e. N = A, C, G or U; R = G or A; see boxed blue nucleotides) as detailed in the text. 
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within helix II, as well as the joining tetraloop, can affect cleavage rates in vitro 
(Fig. 1.5 - Tuschl and Eckstein, 1993; Keese and Stapper, unpublished). The 
G1 O-C11 base-pair adjacent to the unpaired core is conserved in naturally 
occurring hammerhead sequences. Alterations to either of these two bases 
reduces cleavage efficiency and even maintaining the "G-C" base pair (i.e. as 
C1 O-G11) does not ensure efficient cleavage (Ruffner et al., 1990; Tuschl and 
Eckstein, 1993; Keese and Stapper, unpublished). Several workers have also 
shown that the length of helix II can affect cleavage rates (Tuschl and Eckstein, 
1993; Keese and Stapper, unpublished). Studies in which helix I and Ill are 
held constant and helix II was altered in length have shown a lack of any 
simple correlation between helix 11 length and cleavage rates. Both studies 
suggest that under certain conditions a 2 bp stem is more efficient than control 
4 bp stem. However, this conclusion is further complicated by the effect 
induced by the nucleotides comprising the tetraloop at the base of helix II. 
Tuschl and Eckstein (1993) found that ribozymes with the same 2 bp helix II 
stems, but with variable tetraloop sequence showed very different rates of 
cleavage. Tetraloops which conformed to the 51GNRA3 1 (R = A, G; N = A, C, 
G, U; Woese et al., 1990) structure gave the highest activity. 
Clearly there are several competing factors in helix II which influence 
cleavage rates. These include stem-loop stability, flexibility and sequence 
components. As it is likely that further influence is also conferred by helices I 
and Ill (i.e. in both length and sequence), the efficiency of helix II ribozyme 
variants for independent target sequences may vary. Despite this, some 
general rules for the design of helix II of the ribozyme are evident: the G1 O-C11 
basepair must be strictly conserved, a tetraloop which enhances stem stability 
(i.e. 51 GNRA 31) should be included and a helix II stem of at least 2 bp is 
desirable (Fig. 1.5). 
1.6.1.2. Helices I and Ill and the target site 
The nucleotide component of helices I and 111 has been the most varied 
in the mutagenic analyses, with each study using different target sequences 
11 
and lengths. This has led to some confusion as to the effect these sequences 
may have on cleavage rates. Clearly, secondary structure within either the 
substrate or the ribozyme can play a role in cleavage efficiency. Fedor and 
Uhlenbeck (1990) found that certain substrate RNA sequences can form 
aggregates that are virtually non-reactive. van der Vlugt et al. (1993) found 
that ribozymes against the viral target potato virus Y showed no detectable 
cleavage products. Analysis of the ribozyme/substrate interaction in this study 
indicated that incorrect base-pairing of helices I and 111 were responsible for the 
lack of cleavage observed. This situation was reversed when the same 
cleavage site was targeted with a ribozyme providing much longer hybridisation 
of helices I and Ill. Similarly an A or a C residue at position 16.2 have shown 
differential rates of cleavage in different systems varying from equivalent to a G 
(Koizumi et al., 1988b; Ruffner et al., 1990) to no cleavage at all (Perriman et 
al., 1992). This strongly suggests that sequences in helices I and Ill are having 
a profound effect on cleavage rates. 
There has been extensive mutational analysis of the three nucleotides 
which make up the target site triplet. Independent laboratories have analysed 
single and double ribonucleotide substitutions and determined a number of 
effective target site triplets (Fig. 1.6). Nucleotide 17 can be substituted with an 
A or a U, although the U residue does show reduced cleavage rates (Koizumi 
et al., 1989; Ruffner et al., 1990; Perriman et al., 1992). There is also evidence 
to suggest that a G can be placed at this position, however this appears to be 
dependent upon the nucleotide sequence or context of helix II (Sheldon et al., 
1989; Perriman et al., 1992). Reductions in cleavage rates due to alterations at 
nucleotide 17 have been attributed to the formation of alternate and/or inactive 
conformations between or within the substrate and ribozyme sequences 
(Ruffner et al., 1990; Heus et al., 1990; Fedor and Uhlenbeck, 1990; Perriman 
et al., 1992). For example, a G or U at position 17 can pair with C3 or A 14 
respectively, thereby disrupting the critical catalytic core structure. 
Figure 1.6: Summary of the nucleotide requirements at the cleavage site of the hammerhead 
ribozyme reaction (shown in green). The unpaired C17 can be substituted for an A or a U and 
G16.2 - C15.2 can be altered to C16.2 - G15.2 or A 16.2 - U15.2. U16.1 and A15.1 must be 
conserved for efficient cleavage. 
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The central residue of the target site, nucleotide 16.1 (and 15.1 on the 
ribozyme) is the most inflexible nucleotide. It must be a U residue (with base-
pairing A at 15.1) in order to obtain good rates of cleavage (Koizumi et al., 
1988b; Ruffner et al., 1990; Perriman et al., 1992). An A or a Cat this position 
do show cleavage in vitro however rates are drastically reduced (Perriman et 
al., 1992). Position 16.2 is a G in all naturally occurring hammerhead ribozyme 
sequences. In vitro data has shown that a C or U at this position can also 
cleave (provided base-pairing is maintained with 15.2 - Koizumi et al., 1989; 
Ruffner et al., 1990; Perriman et al., 1992), although rates vary between 
systems. Because of the differences observed between systems it is difficult to 
deduce rules for predicting available cleavage sites on all RNAs. Despite this, 
the evidence suggests that the triplets GUC, CUC, GUA and UUC can be 
efficiently cleaved provided the surrounding sequence is not incompatible with 
the formation of the active hybrid (Fig. 1.6). 
1.6.2. Deoxyribonucleotide substitutions 
While ribonucleotide substitutions within the hammerhead self-cleaving 
domain have given some insight into the optimal ribozyme/substrate reaction 
hybrid, several studies have also analysed the effect of deoxyribonucleotide 
substitutions (DNA) on in vitro cleavage rates. There are several advantages 
for RNA/DNA chimeric ribozymes over the all RNA ribozymes. These include 
greater ease of chemical synthesis, improved in vivo stability and faster 
product dissociation. As well, DNA substitutions have allowed for the analysis 
of the importance of the 21-hydroxyl on the ribose sugar of ribonucleotides 
within the ribozyme domain. 
DNA substitutions are tolerated to some degree in all positions, except 
the conserved core and nucleotide 17 (Dahm and Uhlenbeck, 1990; Perrault et 
al., 1990, 1991; Yang et al., 1990; Paolella et al., 1992). 21-hydroxyl groups 
which have been identified as particularly important for full catalytic activity are 
those at positions 5, 9, 15.1, 16.1 and 17 (Fig. 1.7). The absence of the 21-
hydroxyl at position 17 completely abolishes cleavage activity thus confirming 
Figure 1.7: Nucleotides within the hammerhead ribozyme reaction which must maintain a 2'-
hydroxyl (i.e. as established by deoyribonucleotide substitutions) for efficient cleavage. 
Nucleotides are boxed and indicated in red. 
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the importance of this group in the nucleophilic attack on the phosphate at the 
cleavage site. Yang et al. (1990) have determined that the minimum 2'-
hydroxyl content required to sustain some activity of the ribozyme is five ribose 
residues at positions 5, 8, 9, 15.1 and 17. In fact, several laboratories have 
now shown that ribozyme/substrate hybrids containing DNA residues can have 
equivalent or enhanced in vitro catalytic efficiencies over their ribonucleotide 
(RNA) counterparts (Hendry et al., 1992; McCall et al., 1992; Shimayama et 
al., 1992, 1993; Taylor et al., 1992). 
McCall et al. (1992) found the most active minizyme in their study was 
one which had DNA in helices I and 111 as well as a DNA tetraloop. This 
minizyme had cleavage rates equivalent to the all RNA ribozyme used in their 
study. In another study, DNA substitutions at stem-loop II were also tolerated 
although a significant enhancement of the cleavage rate was observed when 
both strands of helices I and Ill were DNA (except the three bases at the target 
site) and helix II was maintained as RNA {Taylor et al., 1992). This contrasts 
with the work of Shimayama et al. (1992, 1993) who found increased cleavage 
with DNA at helices I and Ill but a further enhancement when DNA was present 
in stem-loop 11. An analysis of the two studies reveals a difference in the length 
of helices I and 11 suggesting that the rate limiting step in each study may differ. 
In the case of Taylor et al. (1992), the rate limiting step is most likely to be 
product dissociation while Shimayama et al. (1992, 1993) are probably 
observing the chemical cleavage as being rate limiting. In any case, it seems 
that provided nucleotide 17 remains a ribonucleotide, these DNA substitutions 
can enhance the cleavage efficiency over that observed for the RNA ribozyme 
(Hendry et al., 1992; Shimayama et al., 1992, 1993; Taylor et al., 1992). In 
general, the increase in cleavage observed by a DNA substituted ribozyme can 
be attributed to a faster rate of dissociation of the cleavage products. As well 
as providing faster rates of cleavage the chimeric DNA/RNA ribozymes also 
exhibit enhanced levels of stability when transfected into human T-lymphocytes 
{Taylor et al., 1992). 
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Despite the inherent advantages of the chimeric DNA/RNA ribozyme, 
the requirement for continual chemical synthesis and topical application makes 
its use unsuitable in some circumstances. In human therapeutics, where 
exogenous delivery is the likely mode of introduction, the enhanced stability 
provided by these chimeric ribozymes makes them desirable alternatives. The 
first example of this was recently published by Snyder et al. (1993) who 
designed and tested a chimeric DNA/RNA ribozyme against the BCRABL 
oncogene. The ribozyme contained DNA in helices I, II and Ill and was able to 
reduce bcr-abl mRNA by 49o/o while control antisense was able to inhibit by 
25°/o. Unfortunately, no in vivo comparison was carried out between the DNA-
RNA construct and the analogous all-RNA ribozyme so the direct advantage of 
the DNA-RNA chimera cannot be assessed. In contrast, in most plant 
applications, foreign genes are delivered as stably integrated sequences which 
are endogenously expressed. Thus in this situation, chimeric sequences such 
as the DNA-RNA ribozyme cannot be employed. 
1.6.3. Chemically modified nucleotide substitutions 
With the development of chemical synthesis of nucleic acids, it is now 
possible to introduce chemically modified analogues of nucleotides into RNA 
and DNA strands. These types of substitutions have an added advantage over 
the traditional forms of deoxy and ribo-nucleotide sequences listed above, as 
they allow for the analysis of the effect of each of the three constituents of the 
ribonucleotide (i.e. the base, the sugar and the phosphate bond). As with 
ribozymes containing deoxyribonucleotide substitutions, ribozymes containing 
certain modified nucleotides can have equivalent rates of cleavage and 
enhanced stability compared to standard RNA ribozymes (e.g. Pieken et al., 
1991; Paolella et al., 1992; Heidenreich and Eckstein, 1992; Heidenreichet al., 
1994). 
1.6.3.1 The base 
The importance of various functional groups on the bases has been 
assessed by incorporating nucleotide analogues. The 2-amino group on 
15 
guanosine (see Fig. 1.8a) was analysed by replacing all guanosines with 
inosine which differs only by lacking this 2-amino group (Odai et al., 1990; Fu 
and McLaughlin, 1992a; Slim and Gait, 1992). These substitutions showed 
that the 2-amino group on guanosine residues at positions 5 and 12 are critical 
for catalytic activity. The G at position 5 (the 21-0H of which is also required) is 
extremely important for obtaining cleavage activity by the hammerhead 
ribozyme. Along with the requirement for a 2-amino base at this position, this 
base has also been implicated in cation 11 binding 11 • This will be discussed in 
more detail in section 1.6.4. 
Substitution of adenosine with nebularine (an adenosine analogue) 
which lacks the 6-amino group did not affect cleavage activity (Fu and 
McLaughlin, 1992a; Slim and Gait, 1992). Further studies have shown that the 
N7 group of adenosine is important at A6 within the unpaired core where its 
elimination causes a 35-fold reduction in cleavage (Fig. 1.8b - Fu and 
McLaughlin, 1992b). 
1.6.3.2 The phosphodiester linkage 
The role of the phosphate backbone in ribozyme cleavage has been 
studied by using phosphorothioate-containing nucleotide derivatives (Eckstein, 
1985). The phosphorothioate (which replaces the phosphate) contains sulphur 
in place of oxygen at either or both internucleotide linkages (i.e. the Rp or the 
Sp configuration - see Fig. 1.9a). They are ideally suited for determining the 
importance of particular phosphate groups within the hammerhead ribozyme 
since they introduce minimal structural change. The difference between the 
phosphate and phosphorothioate lies in their contrasting ability to co-ordinate 
11 hard 11 and 11 soft 11 metal ions. Hard metal ions, such as magnesium (Mg2+), co-
ordinate to oxygen and not sulphur, whereas soft metal ions such as 
manganese (Mn2+) can co-ordinate to either oxygen or sulphur (Jaffe and 
Cohn, 1979; Pecoraro et al., 1984). Cleavage rates of ribozyme/substrate 
complexes containing phosphorothioate insertions can be compared in the 
presence of either divalent metal ion. In this way, the role of each 
Figure 1.8 
a: Determination of the importance of the 2-amino group on the guanosine nucleotides within 
the catalytic domain of the hammerhead ribozyme. lnosine substitutions have shown that the 2-
amino groups at GS and G12 (boxed in blue) are essential for efficient cleavage. 
b: Analysis of the importance of N7 on the adenosine nucleotides within the unpaired region of 
the catalytic domain of the hammerhead ribozyme. The N7 on nucleotide A6 is required for 
efficient cleavage (boxed in green). 
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phosphodiester linkage in cation co-ordination of the hammerhead ribozyme 
cleavage reaction can be analysed. Additionally, phosphorothioate bonds have 
been shown to be more resistant to nucleases than the normal phosphodiester 
bond (Zan and Stec, 1991 ). 
By incorporating phosphorothioate linkages, workers have determined 
those phosphates necessary for efficient cleavage by the hammerhead 
ribozyme. In the presence of Mg2+, phosphorothioate linkages in the Rp 
configuration showed significantly reduced cleavage rates when incorporated 31 
of nucleotides 8, 12, 13 and 17 of the hammerhead domain (Fig. 1 .9b -
Buzayan et al., 1988; Ruffner and Uhlenbeck, 1990; Dahm and Uhlenbeck, 
1991; Slim and Gait, 1991 ). Further analysis of the phosphorothioate linkage 
between nucleotides 17 and 1 showed that when Mn2+ was the active cation 
(rather than Mg2+), cleavage rates approached those for the phosphate-
containing substrate (Dahm and Uhlenbeck, 1990; Slim and Gait, 1991 ). Since 
we know that Mg2+ and Mn2+ co-ordinate preferentially to oxygen or sulphur 
and oxygen respectively, these results suggest that the metal ion responsible 
for catalysis is co-ordinated to the Rp oxygen between nucleotides 17 and 1 on 
the substrate RNA. This is further supported by experiments analysing the 
effect of phosphorothiates in the Sp configuration. In the presence of Mg2+, Sp 
phosphorothiates gave cleavage rates comparable to the unmodified molecule 
(Slim and Gait, 1991; Koizumi and Ohtsuka, 1991 ). Also, limited modelling 
studies have suggested that C 17 sits on the surface of the complex and does 
not directly interact with other bases. This, in turn, forces the phosphodiester 
linkage between C17 and N1 to direct both the Rp and Sp oxygens toward the 
inward side of the hammerhead where either may form a complex with the 
Mg2+ cofactor (Mei et al., 1989). Since there are no x-ray studies of the 
structure adopted by the ribozyme and its substrate in the active catalytic 
complex, these data must await further verification. The three dimensional 
structure of the hammerhead domain will be discussed in more detail in section 
1.8. 
Figure 1.9 
a: The structure of the phosphorothioate - containing nucleotides (Eckstein, 1985) used to 
probe the importance of specific phosphate groups within the hammerhead domain. Oxygen is 
replaced by sulphur in either the Sp or Rp configuration as shown. 
b: Phosphate linkages determined to be important for efficient in vitro hammerhead cleavage 
by phosphorothioate (Rp) substitutions. Phosphate groups (designated as green circles) 
between nucleotides G8/A9, G12/A13/A14 and C17/N1 have been shown to be required for 
hammerhead cleavage. 
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1.6.3.3. The ribose 
The effect of removing the 2' hydroxyl of the ribose has been discussed 
above in the analysis of the deoxy substitutions. However, the lack of a 2'-
hydroxyl is not the only difference between deoxy and ribo-nucleotides. The 
ribose moiety of RNA predominantly adopts the 3'-endo configuration whereas 
the deoxyribose is usually in the 2' configuration (Fig. 1.1 Oa - Saenger, 1984). 
This difference , which alters the folding of the sugar-phosphate backbone, 
may in turn affect the activity of the ribozyme. By using chemical analogues of 
nucleotides which adopt the 3'-endo conformation, several laboratories have 
investigated the role of the ribose in the hammerhead cleavage reaction. 
In one study (Pieken et al., 1991) it was found that substitutions of all 
pyrimidines in the hammerhead domain with the appropriate nucleotide 
derivatives (i.e. 2'-fluoro and/or 2'-aminouridines and 2'-fluorocytidines) showed 
no effect on cleavage activity. Additionally, both the 2'-fluoro and 2'-amino 
containing ribozymes were shown to be at least 1000 times more stable than 
the standard RNA ribozyme in rabbit serum. Olsen et al. (1991) systematically 
substituted each adenosine with 2'-fluoroadenosine nucleotide analogues and 
also found no loss of catalytic activity. However, when all the adenosines were 
substituted at the same time, cleavage was greatly impaired. This large 
decrease in activity was attributed to the cumulative effect of small 
conformational changes. An even more systematic study was carried out by 
Paolella et al. (1992). They found that provided nucleotides 4, 5, 6, 8, 12, 15.1 
and 17 were maintained as standard ribonucleotides, the remaining 
hammerhead ribozyme sequence could contain modified nucleotides without 
loss of cleavage activity (Fig. 1.1 Ob). As with the work of Pieken et al. (1991 ), 
Paolella et al. (1992) also found that the modified ribozyme was more stable 
than the standard RNA ribozyme when incubated in bovine serum. 
Shimayama et al. (1993) and Heidenreich et al. (1994) have shown that 
it may be possible to "stack" the ribozyme with several synthetic features for 
optimal cleavage and in vivo stability. Shimayama and colleagues combined 
Figure 1.10 
a: The configuration of the ribose moiety in deoxy and ribo-nucleotides. The ribose moiety of 
RNA predominantly forms the 3'-endo configuration while the deoxyribose usually has the 2'-
endo configuration. This difference alters the folding of the sugar-phosphate backbone, which 
may in turn affect cleavage. The use of nucleotides containing chemical analogues of the 
ribose moiety that conform to the 3'-endo structure means that these substitutions can be 
incorporated without altering backbone folding (see section 1.6.3.3 for further details). 
b: Nucleotides (shown in yellow) within the hammerhead cleavage reaction required to contain 
standard ribose moieties for efficient cleavage. 
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21-deoxynucleotides and phosphorothioate linkages to produce a chimeric 
ribozyme which was more than 100 times more stable than the all-RNA 
ribozyme in fetal bovine serum. Additionally, this ribozyme exhibited a rate of 
cleavage equal to that for the all-RNA ribozyme (Shimayama et al., 1993). 
Heidenreich et al. (1994) designed a ribozyme which contained four 
phosphorothioate (Rp) linkages (i.e. at the three 31 and last 51 terminal linkages) 
, two 21-aminouridine analogues at positions 4 and 7, and the replacement of all 
remaining pyrimidines within the ribozyme with 21-fluorocytidine and 21-
fluorouridine. This ribozyme was two times more stable in fetal calf serum than 
the analogous sequence containing only the pyrimidine substitutions (i.e. 
lacking the phoshorothioates), and 100 times more stable than the unmodified 
ribozyme. Additionally, this ribozyme was able to cleave the substrate RNA in 
vitro with essentially the same catalytic efficiency as the unmodified ribozyme. 
Interestingly, 21-fluoro or 21-deoxyuridine nucleotides at positions 4 and 7 (as 
distinct from the 21-amino) greatly reduced catalytic activity of the ribozyme 
(Heidenreich and Eckstein, 1992). This is analogous to the results of Williams 
et al. (1992) who found that 21-aminoguanosines at positions 5 and 8 showed 
much higher cleavage activity than 21-fluoro or 21-deoxyguanosine substitutions. 
A synthetic ribozyme containing deoxyribonucleotides, 21-fluorocytidine 
and 21-fluorouridine, as well as phosphorothioate linkages was recently tested 
against a drug resistance gene found in human cancer cells (Kiehntopf et al., 
1994). A cell-line previously determined to be resistant to anti-cancer drugs 
was transfected with either the all-RNA or modified-ribozyme. Both ribozymes 
were able to increase the cell-lines sensitivity to two anti-cancer drugs, 
however the modified-ribozyme was able to increase the sensitivity 6-7 fold 
more than the RNA-ribozyme. To date, this is the only example of chemically 
modified ribozymes being tested against a target sequence in vivo. 
It is clear from this result that chemically-modified ribozymes, which 
exhibit enhanced stabilities in vivo, and maintain reasonable or equivalent 
catalytic functions in vitro , are excellent candidates for exogenous delivery of 
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hammerhead ribozymes to cells. Future work, where exogenous delivery of 
ribozymes is applicable, will determine whether these sequences are truly 
viable alternatives to all-RNA ribozymes. 
1.6.4. Role of divalent metal ions in cleavage 
Although cleavage by the hammerhead ribozyme is generally carried out 
in the presence of magnesium ions, several other cations can also support the 
reaction (Dahm and Uhlenbeck, 1991 ). I have already discussed cleavage in 
the presence of manganese (Mn2+) but other active cations include cobalt 
(Co2+), zinc (Zn2+), cadmium (Cd2+) and strontium (Sr2+). This work has 
provided some clues as to the exact function the divalent metal ion may play in 
the cleavage process. Correct folding of the hammerhead ribozyme in the 
presence of Zn2+ or Cd2+ required the addition of the primary amine, spermine. 
Spermine also increased the rate of cleavage induced by Sr2+ although low 
levels of cleavage were also observed in the absence of spermine. This 
suggests that while these three metal ions were not able to promote correct 
folding of the hammerhead very efficiently, once folded, they were able to 
stimulate cleavage. Co2+, Mn2+ and Mg2+ exhibited rapid cleavage in the 
presence or absence of spermine. Larger ions tested such as lead (Pb2+) and 
barium (Ba2+) induced very slow or no cleavage rates, even in the presence of 
spermine. The conclusions of this study were that all ions with an ionic radius 
of less than 1 A were able to induce cleavage while those greater than 1 A were 
not . This suggests that the divalent binding site(s) within the hammerhead 
domain must have very specific size requirements. 
Several lines of evidence are now accumulating concerning ribozyme 
cleavage catalysis and cation binding. The phosphorothioate substitutions 
outlined in section 1.6.3.2 strongly suggest that one important binding site is 
closely associated with the Rp-oxygen of the phosphodiester linkage between 
nucleotides 17 and 1. Some of the DNA substitutions have also provided 
valuable information. Based on a series of DNA-containing ribozymes and 
varying Mg2+ concentrations, Perreault et al. (1991) suggest that the 2'-
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hydroxyls on residues 5, 9 and 16.1 are involved in the low-affinity binding of 
Mg2+. It could be envisaged that, during the cleavage process, the magnesium 
enters a pre-existing "cavity" in the ribozyme/substrate complex and is rapidly 
directed toward the phosphodiester linkage between nucleotides 17 and 1 by 
specific and highly conserved residues in the ribozyme domain. Three 
dimensional studies of the mechanism of catalysis will be required to verify this 
hypothesis. 
1.6.5. The optimal conditions for in vitro hammerhead cleavage 
Although there is a large volume of literature regarding the effect of 
substitutions within the hammerhead ribozyme complex, many aspects of the 
cleavage process are still poorly understood. All but nucleotides 7 and 17 
within the conserved core of the hammerhead domain must be conserved for 
cleavage. Analysis of some of these conserved residues has revealed the 
absolute requirement for the 2'-hydroxyl of the ribose component on the 
ribonucleotide. Further studies have shown that the Rp-oxygen on the 
phosphodiester linkage between several nucleotides is required. Other work 
has suggested that the composition of the base moiety of at least 4 sites is 
crucial for obtaining cleavage. While the stringency of these requirements for 
the conserved core is essential, analysis of the remaining regions of the 
hammerhead ribozyme complex has revealed a large degree of flexibility. Helix 
II and the tetraloop can be altered in both length and complexity, although 
certain general rules for this region should be adhered to. Helices I and 111 can 
also tolerate what appears to be infinite base combinations varying in both 
length and sequence. However, despite this apparent flexibility in the design of 
these regions, variation in cleavage efficiencies does occur. This variation is 
due, in part, to intra and intermolecular aggregations which can severely affect 
accessibility of the target site triplet. Extracting general rules from these data is 
complex, as many of the studies contain variables which make direct 
comparison difficult. Nevertheless, several common features are prevalent and 
should be observed when attempting to design a hammerhead ribozyme for 
21 
optimal target RNA destruction. The combined results of all these studies are 
shown in figure 1 .11. 
1.7. RNA binding proteins and cleavage 
One important difference between the in vitro cleavage assays 
described above, and ribozyme-catalysed cleavage within living cells is that 
most RNAs within a cell exist as tightly folded RNA-protein complexes, not as 
free molecules. Such RNA-protein complexes have been shown to affect 
annealing, unwinding and strand exchange of the nucleic acids (Rozen et al., 
1990; Wassarman and Steitz, 1991; Casas-Finet et al., 1993; Kumar and 
Wilson, 1990; Pontius and Berg, 1990; Lee et al., 1993; Portman and Dreyfuss, 
1994; Pontius and Berg, 1992). Clearly cellular proteins binding to a target 
RNA or to an introduced ribozyme could have an effect on the cleavage rate. 
Preliminary studies have indicated that certain proteins can enhance the 
efficiency of ribozyme action (Tsuchihashi et al., 1993; Herschlag et al., 1994; 
Bertrand and Rossi, 1994; Coatzee et al., 1994, Sioud, 1994). 
Several laboratories are beginning to investigate the effect some of 
these proteins have on cleavage rates. Although this work is being carried out 
in vitro with purified proteins, the results are providing valuable information for 
the future design of hammerhead ribozymes for in vivo application. 
Tsuchihashi et al. (1993) have shown that the nucleocapsid protein from 
human immune deficiency virus (HIV, p7) is able to enhance cleavage by a 
hammerhead ribozyme 10-20 fold. The p7 protein had been implicated in 
increasing the rates of helix association and dissociation and therefore was a 
good candidate for enhancing the catalytic efficiency of the hammerhead 
ribozyme. In the absence of p7, the rate limiting step in this reaction was 
binding of the substrate and ribozyme and subsequent dissociation of products. 
When p7 was added to in vitro cleavage reactions, association of the two 
molecules was increased at least 10 fold and dissociation of products improved 
20-30 fold (Herschlag et al., 1994). Later work has shown that increased 
Figure 1.11: The combined results of available data derived from deoxy, ribo and chemically 
modified nucleotide substitutions for efficient in vitro cleavage of a hammerhead ribozyme 
cleavage reaction. This figure provides a guide toward the design of an efficient hammerhead 
ribozyme cleavage reaction. The key to colored and/or boxed nucleotides, as well as circle 
linkages is shown beneath the substrate/ribozyme hybrid. Further details of the studies from 
which this data is derived can be found in section 1.6. Note that all nucleotides, except C17, 
which require an unmodified ribose moiety (shown in yellow) are also invariant. 
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product dissociation in the presence of p7, is greatly decreased when the 
complex is greater than 14 bp in length. Interestingly, substrate/ribozyme 
complexes greater than 16 bp were actually inhibited in the presence of p7. 
Short ribozyme binding to longer substrates, such as mRNAs which contain 
internal structures that inhibit binding, was also shown to be enhanced in the 
presence of p7 (Bertrand and Rossi, 1994). 
Four other RNA binding proteins have subsequently been analysed for 
the effect they induce on the hammerhead cleavage reaction. Three of these, 
the heterogenous nuclear ribonucleoprotein (hnRNP) A 1, the bacteriophage T 4 
gene 32 protein (gp32), and the bacterial ribosomal protein S12, are all 
relatively non-specific RNA binding proteins which exhibit annealing and 
unwinding activities (Karpel et al., 1982; Kumar and Wilson, 1990; Munroe and 
Dong, 1992; Coatzee et al., 1994). In contrast, the fourth protein, isolated from 
cultured human cells displays extreme specificity in its binding requirements 
(Sioud, 1994). The function of this protein is, as yet, unknown. 
The gp 32 protein was shown to have no effect on cleavage rates. In 
contrast hnRNP A 1, like p7, was able to increase the rate of product 
dissociation of short ribozyme/substrate complexes and to enhance ribozyme 
binding to longer substrates (Bertand and Rossi, 1994; Herschlag et al., 1994). 
Unlike p7, hnRNP A 1 did not inhibit longer ribozyme/substrate complexes 
(Bertrand and Rossi, 1994). The ribosomal protein S12, was also able to 
increase active ribozyme/substrate hybrid formation and product dissociation 
(Coatzee et al., 1994). The human protein appears to form an interaction with 
the 5' half of a ribozyme sequence directed against tumor necrosis factor 
(TNFa), but has no effect on other unrelated ribozyme sequences. This 
sequence-specific interaction confers enhanced stability and subsequently 
increases the activity of the designated ribozyme molecule (Sioud, 1994). 
These preliminary studies were carried out using all-RNA ribozymes. A 
recent study, however, has also suggested that the p7 protein can enhance the 
in vitro cleavage rates induced by ribozymes containing several ribonucleotides 
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with a chemically modified ribose moiety. In the absence of p7, this ribozyme 
produced almost no cleavage products. However, when p7 was present, 
catalytic activity of the ribozyme was significantly increased (Muller et al., 
1994). This suggests that the chemically modified ribozymes which show 
enhanced in vivo stability, such as those outlined in section 1 .6.3, could also 
display enhanced cleavage in the presence of p7. In addition to this, results 
have shown that the hnRNP A 1 protein can promote base-pairing of DNA and 
RNA, suggesting that it may also be effective in enhancing the cleavage rates 
induced by DNA/RNA chimeric ribozymes (Pontius and Berg, 1990). 
The results of these studies suggest that manipulation of proteins such 
as p7, S12 and hnRNP A 1 could enhance ribozyme activity in vivo. Since 
hnRNP A 1 is one of the most abundant proteins involved in nuclear RNA 
processing, one could envisage targeting the ribozyme to the nucleus, thus 
increasing the likelihood of interactions. Additionally, linking the ribozyme to a 
binding site for hnRNP A 1 may further increase the chances of the two 
molecules interacting. Furthermore, since there is evidence to suggest that 
hnRNP A 1 binds preferentially to sequences at the intron/exon splice junction 
(Swanson and Dreyfuss, 1988; Buvoli et al., 1990), selecting a target site close 
to this region could further enhance the chances of co-localisation. In this way, 
it may act like a chaperone by binding to the ribozyme and substrate forcing co-
localisation of the two molecules and enhancing cleavage of the substrate 
RNA. Finally, by providing ribozymes which have exhibited enhanced in vivo 
stability (such as those containing chemically modified nucleotides) it may be 
possible to further increase in vivo cleavage of the substrate RNA. 
1.8. A structural model for the hammerhead ribozyme domain 
Until very recently, the hammerhead ribozyme was depicted in a two 
dimensional manner in which the three helices radiated out from the unpaired 
core. Clearly, however, the molecule adopts a far more elaborate structure in 
which several changing secondary and tertiary interactions are involved in the 
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formation of the active complex. The work of Pley et al. (1994) is the first 
example of the three dimensional structure of the hammerhead ribozyme as 
derived from studies involving x-ray crystallography. In this structure, the 
ribozyme-substrate interaction resembles a wishbone (Fig. 1.12a) in which 
helices I and II diverge from the core at an acute angle while helix Ill points in 
the opposite direction. Unlike earlier hammerhead ribozyme depictions, the 
11
unpaired 11 core is actually made up of several non Watson-Crick base-pairing 
interactions (Fig. 1.12b). Despite these advances in the understanding of the 
three dimensional structure of the hammerhead ribozyme, it has not been 
possible to elucidate the mechanism of catalysis from this work. Most puzzling 
is the fact that clear biochemical evidence exists showing a critical divalent 
metal ion bound to the Rp oxygen between nucleotides 17 and 1 (see also 
section 1.6.4; Dahm and Uhlenbeck, 1991 ), however, such an interaction 
cannot be observed in the crystal structure. This discrepancy could be due to 
the fact that the substrate used for the crystallisation was a DNA analogue, 
hence lacking the critical 21-hydroxyl for cleavage. Clearly, further work is 
required before we are able to fully understand the mechanism of cleavage by 
the hammerhead ribozyme. 
1.9. Designing ham:merhead ribozymes for in vivo application 
Along with the large number of in vitro analyses carried out using the 
hammerhead ribozyme, many laboratories have also investigated the 
app licability of hammerhead ribozymes against specific RNA targets in vivo. 
The success of such endeavours would be very exciting as the ability to control 
target R As such as oncogenic and/or viral sequences cou!d reverse the 
termina nature of such ailments. Add'tionally, in pants, pests and d'sease 
current y destroy a sign·ficant proportion of the worlds food crops. Crop plants 
expressi g ribozymes specif cally designed to cleave and inactivate the 
essential transcripts of these organisms could mean efficient pathogen control 
Figure 1.12 
a: 3-dimensional structure of the hammerhead ribozyme reaction as determined by x-ray 
crystallography (Pley et al., 1994). The substrate RNA is shown in green; the ribozyme is in 
blue. Non Watson-Crick base-pairs are indicated in red while standard base-pairing is shown in 
black. The site of cleavage on the substrate RNA is arrowed and helices I, II and Ill are labelled. 
b: base-pairing within the catalytic domain of the hammerhead ribozyme as determined by x-ray 
crystallography (Pley et al., 1994). Color coding for substrate and ribozyme, as well as helix 
designation are as in (a). The arrow depicts the site of cleavage. 
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without the requirement for large scale chemical sprays. This would have 
world-wide economic and environmental consequences. 
Prior to the discovery of catalytic RNA molecules such as the 
hammerhead ribozyme, the most common approach for specific in vivo gene 
inactivation in eucaryotes was to employ antisense sequences (e.g. lzant et al., 
1992). While the hammerhead ribozyme is similar to antisense in that it 
anneals to the designated target sequence, it has the added advantage that it 
can also cleave, thereby permanently inactivating the target RNA. Since in 
vitro results suggest that hammerhead ribozymes with relatively short helices I 
and 111 can be designed to cleave more than one target RNA, another 
advantage over antisense could be the use of smaller doses which can achieve 
equivalent or better target gene reduction. However, to date, hammerhead 
ribozyme turnover has not been demonstrated in vivo. Despite this, many 
studies have shown an enhanced effect over that obtained for antisense 
controls. A summary of the large number of experiments involving the use of 
the hammerhead ribozymes in vivo is shown in figure 1.13. Although 
hammerhead ribozymes have been effective in reducing target gene 
expression in a number of cases (see Fig. 1.13), there have been few 
successful reports in plant cells (Steinecke et al., 1992, 1994 - Fig. 1.13 (1 ); 
Perriman et al., 1993 - Fig. 1.13 {2); Wegener et al., 1994 - Fig. 1.13 (27)). 
Therefore, the work documented in this thesis provides a valuable addition to 
the application of hammerhead ribozymes to plant systems. 
1.9.1 Optimising in vivo cleavage 
At this stage, the optimisation of the expression of hammerhead 
ribozymes for in vivo cleavage is still evolving. Clearly there are a number of 
basic principles of cell biology which need to be addressed to obtain optimal 
levels of in vivo gene inactivation (Fig. 1.14). These include intracellular 
location, stability and expression of both the substrate and ribozyme molecules. 
This section will describe the attempts and future directions toward optimising 
these aspects of the in vivo hammerhead ribozyme cleavage reaction. The 
Figure 1.13: Summary of the application of hammerhead ribozymes to target and inactivate 
specific mRNAs in vivo. The key to column 3, "Cleavage product analysis" is shown at the end 
of the table. Where targets have been referred to in the text, a bold bracketed number is 
present at the end of the target title. This number is also present in the text. 
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Target Expression Cleaved Results Reference 
system product 
analysis 
BCRABL tRNAMet in ND elimination of BCRABL Shore et al., (18) ( chronic retroviral vector expression 1993 
myelogenous 
leukemia) 
BCRABL in vitro derived 4 -50% reduction in BCRABL Snyder et al., 
ribozyme, mRNA; elimination of BCRABL 1993 
liposome delivery protein 
to human cancer 
cells 
BCRABL in vitro 3,4 5-fold reduction in BCRABL Lange et al., 
transcribed, mRNA per cell. 1993a & b 
lipofection 
delivery to human 
cancer cells 
H4 histone cis-acting in 1, 3 cis-acting Rz mediates 31 end Eckner et al., 
monkey COS formation of histone H4 1991 
cells 
H1 histone tRNATyr in ND 4-5 fold reduction in Bouvet et al., ( 19) Xenopus oocytes accumulated H1 histone 1994 
H1 histone tRNA lyr in ND -90% reduction in Kandolf, 1994 (25) Xenoous oocvtes accumulated H1A histone 
HIV-1 gag ~-actin promoter, 2 -100 fold reduction in HIV-1 Sarver et al., (human human cells pro-viral sequence 1990 immunideficie 
ncy virus) (4) 
HIV-1 leader MoMLV tat ND no HIV-1 production up to 22 Weerasinghe et (22) inducible days post infection al., 1991 promoter in 
human cells 
HIV-1 int(9) T7 in E.coli 1, 4 elimination of int protein Sioud & Drlica, 
synthesis 1991 
HIV-1 U5 MuLV, human 2,4 moderate suppression of HIV-1 Dropulic et al., 
cells infection 1992 
HIV-1 env SV40 in human ND elimination of env transcript Chen et al., ( 11) cells 1992 
HIV-1 gag in vitro 3,4 96% reduction in HIV-1 Homann et al., ( 1 5) transcribed, replication 1993 
CaP04 
tranfected human 
cells 
HIV-1 tat (23) retroviral vector in 3,4 approximately 86% reduction Crisell et al., human cells in HIV-1 replication up to 14 1993 
days post infection 
HIV-1 tat retroviral L TR in 3 delay of H IV-1 replication for up Zhou et al., human cancer to 20 days post transfection 1994 
cells 
HIV-w SV40 promoter, ND -5 fold reduction in HIV Sun et al., 1994 (packaging human cells replication 
siqnal) 
HIV-1 LTR- Va (pol Ill) 4 up to 50% reduction in CAT Ventura et al., CAT (26) promoter in activity expressed from HIV-1 1994 
human cells LTR reqion 
2/ .. 
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Target Expression Cleaved Results Reference 
system product 
,I 
analysis " 
MDR-1 human 3 up to 96o/o restoration of drug Kobayashi et 
expression vector sensitivity al., 1994 
in mammalian 
cancer cells 
MDR-1 ~-actin promoter ND - 99% restoration of drug Scanlon et al., 
I 
in human cancer sensitivity for up to 3 months 1994; Holm et 
cells al., 1994 
CAT (12) SV 40 in monkey 4 -60% reduction in CAT gene Cameron & I I 
COS cells expression Jennings, 1989 I . 
CAT (2) CaMV 35S 4 44 % reduction in CAT gene Perriman et al., 
promoter in plant expression 1993 u 
cells l.f 
CAT PGK promoter in 4 no reduction in CAT mRNA or Atkins & 
S. cerevisiae gene expression Gerlach, 1994 
CAT (16) SV 40 in monkey 4 60% reduction in CAT gene Cameron and 
COS cells expression Jennings, 1994 
GUS CaMV35S 4 No reduction in GUS activity Mazzolini et al., , 1 
promoter, plant 1992 
cells ,1 
GUS in vitro ND no reduction in GUS Evans et al., 
transcribed, PEG expression 1992 
delivery to plant 
protoplasts l. 
H-ras SV40 promoter, 3 2-fold increase in survival of Kashani-Sabet I 
(oncogene) human cancer transf ected mice et al., 1992, I 
cells 1994; Tone et I 
al., 1993 J 
c-Ha-ras RSV LTR 5 - 50% reduction in activation of Koizumi et al., I 
promoter in c-Ha-ras gene 1992, 1993 
human cancer 1 
cells 
c-fos MMaTV, human 2,3 2-1 O fold reduction in fos Scanlon et al., 
(oncogene) cancer cells protein synthesis & restored 1991, 1994 l 
(5) druq sensitivity. : I 
U7snRNA tRNAMet in ND elimination of U7snRNA Cotten & 
(13) Xenopus oocytes Birnstiel, 1989 1il 
acetyl-CoA CMV promoter, 3 30-70% reduction in fatty acid Ha & Kim, 1994 
I 
~ 
carboxylase mammalian cells synthesis II 
glucokinase rat insulin II ND up to 70% reduction in Efrat et al., 
(involved in promoter, glucokinase expression 1994 
mature onset transgenic mice 
diabetes) (8) I I 
~2M (~-2- CMV promoter in ND 80% reduction in ~2M mRNA in Larsson et al., l 
microglobulin mouse cells & cells; up to 90% (in lungs) in 1994 I 
-involved in transgenic mice mice 
immune 
system) (21) ri 
BLV- rexltax Rous sarcoma 2,3 BL V replication suppressed by Cantor et al., 
(bovine virus promoter, 92% 1993 
leukemia bat cells 
virus) (7) 
lacZ(3) MoMLV 3 90% reduction in MoMLV Sullenger & 
packaging vector, containing lacZ Cech, 1993 
mouse cells 
3/ .. I!, 
,t 
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Target Expression Cleaved Results Reference 
system product 
analysis 
NPTII (1) CaMV35S 1, 3 100% reduction in NPTII Steinecke et 
promoter, plant activity al., 1992, 1994 
cells 
NPTII (27) CaMV35S ND - 80% reduction in NPTII Wegener et al., promoter, activity 1994 
transgenic 
tobacco 
ANF-Atrial U1 snRNA or T7 3 -90% reduction in ANF mRNA DeYoung et al., 
natriuretic RNA polymerase for U1snRNA & -80% for T7 1994 factor- in monkey COS 
hypertension cells 
( 17) 
Influenza A SV 40 promoter, 4 70-80% reduction in plaque Tang et al., (segment 5) monkey COS formation 1994 
cells 
a-lactalbumin T7-vaccinia virus, 3 60-80% reduction in a-lac L1Hullier et al., (6) mouse cells mRNA 1992 
TNFa in vitro 4 90% reduction in TNFa mRNA Sioud et al., (tumour transcribed, and 85% reduction in protein 1992 
necrosis liposome delivery 
factor) (10) in human cancer 
cells 
~-gal M13 phage ND suppression of ~-gal Chuat & 
expression in cis but not in Galibert, 1989 
trans 
a-sarcm in vitro 1, 3 in vivo cleavage of a-sarcin Saxena & 
transcribed, demonstrated but no Ackerman, 
injection in difference in phenotype 1990 
Xenopus oocytes between active and mutant 
ribozyme 
/ck& fyn tRNAMet in ND 61 % (fyn) or 81 % (/cl<) Baier et al., protein retroviral vector in reduction in mRNA levels but 1994 kinases (24) human leukemia no reduction in target proteins (involved in T- cells 
cell activation) 
A2 RNA Jacllpp promoters 3,4 55% reduction in phage lnokuchi et al., 
coliphage SP in E.coli proliferation 1994 
MGMT RSV LTR 2 no MGMT mRNA or protein Potter et al., (methyl promoter in detected 1993 tranferase human cancer 
involved in cells 
loss of drug 
cytotoxicity) 
Key to Cleaved Product Analysis 
1 direct detection of cleavage products by RNase protection assays or Northern hybridisation. 
2 RT-PCB analysis of cleavage products 
3 mutant rjbozyme; control in which the ribozyme contains a base-substitution rendering it inactive 
4 antisense; same length of hybridisation as the ribozyme but lacking the catalytic domain 
5 mutant target: target site triplet contains base-substitutions producing a non-cleavable target RNA 
ND no analysis of cleavage products or control sequences reported 
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work carried out for this thesis has addressed the aspects of stability and 
expression of the hammerhead ribozyme in plant cells. 
1.9.1.1. Intracellular localisation 
While many people have recognised that a critical component of the 
hammerhead ribozyme reaction is that the ribozyme and substrate should be 
sequestered in the same compartment of the cell, the application of this notion 
is difficult. Although there are increasing data available concerning the timing, 
maturation and transport of transcripts from the nucleus to the cytoplasm, 
several aspects of the process are yet to be determined (Carter et al., 1991, 
1993; Xing et al., 1993). Most importantly, although we are able to construct a 
sequence that is transported from the nucleus to the cytoplasm, we have only 
limited knowledge on how to manipulate a sequence so that it can be 
expressed and maintained in the nucleus. Additionally, since the in vivo 
application of ribozymes is still young, there are few clues as to which part of 
the cell would be best for cleavage to occur. However, since there is data 
suggesting ribozyme mediated gene reduction for both intra and extranuclear 
targets, it may be that both compartments are suitable for obtaining in vivo 
cleavage (see Fig. 1.13). 
Sullenger and Cech (1993 - Fig. 1.13 (3)) have exemplified the notion 
that delivery of a ribozyme to the same cellular location as its target can 
substantially increase the effectiveness of the ribozyme. Their work involved 
the co-expression of two retroviral vectors, one encoding the hammerhead 
ribozyme and the second encoding the target mRNA (/acZ), inside retroviral 
packaging cells. These packaging cells were engineered to constitutively 
express the viral proteins gag, pol and env which allow co-packaging of the 
retroviral vector derived transcripts into viral particles. This means, co-
expression of the two retroviral vectors encoding the target mRNA and the 
hammerhead ribozyme results in packaging of the two transcripts into the same 
viral particle, thus ensuring their co-localisation. Using this system, Sullenger 
and Cech obtained 90°/o reduction of the target mRNA. A control sequence 
Figure 1.14: Some of the aspects of hammerhead ribozyme design which should be 
considered when designing a ribozyme for in vivo applications. The stylised cell depicts 
ribozyme (Rz) and substrate expressed from separate chromosomes. The levels of ribozyme 
and/or substrate transcripts produced, the stability of these RNAs, and their subsequent 
intracellular localisation, are all crucial aspects which should be addressed when designing a 
hammerhead ribozyme for in vivo applications. 
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encoding an inactivated ribozyme provided evidence that the effect observed 
was ribozyme mediated. 
While the results of this study prove that the co-localisation of the 
ribozyme and substrate within the cell can greatly increase target gene 
inactivation, such a system is not generally applicable. Therefore, although it is 
clear that strategies of this type are desirable, our present understanding of 
intracellular processing and transport of RNA transcripts, limits our ability to 
enhance the intracellular location of the in vivo hammerhead ribozyme. As our 
knowledge of the signals involved in intracellular trafficking of nucleic acids 
increases, the attachment of 11 localising 11 elements and/or utilisation of binding 
proteins on the hammerhead ribozyme will produce a sequence which can be 
accurately and effectively positioned within the cell. 
1.9.1.2. Stability of the ribozyme in vivo. 
Although our ability to control the intracellular location of the ribozyme is 
not yet developed, several studies have successfully tested ways of stabilising 
the ribozyme transcript, once it is expressed within the cell. Obviously such an 
attribute is desirable as it provides the ribozyme sequence with a longer time in 
which to locate, anneal and affect cleavage of the target RNA. The research 
carried out in this thesis has analysed two of these methods in plant based 
gene inactivation. 
1.9.1.2 (i). 5'-capped and 31-polyadenylated ribozymes 
RNA degradation, due to both intra- and extracellular nucleases, has 
meant that delivering a ribozyme as a simple RNA molecule is not an effective 
means of obtaining in vivo cleavage of the targeted RNA. Many experiments 
have shown that the addition of cap structures (5'-m 7 G) and termination 
sequences such as polyadenylated tails (e.g. Sarver et al., 1990 - Fig. 1.13 (4); 
Scanlon et al., 1991 - Fig. 1.13 (5); L'Hullier et al., 1992 - Fig. 1.13 (6); Cantor 
et al., 1993 - Fig. 1.13 (7); Steinecke et al., 1992 - Fig. 1.13 (1 ); Efrat et al., 
1994 - Fig. 1.13 (8)) or T7 termination signals (Sioud & Drlica 1991 - Fig. 1.13 
(9), Sioud et al., 1992 - Fig. 1.13 (1 O); De Young et al., 1994 - Fig.1.13 (17)) to 
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single hammerhead ribozymes are sufficient to obtain gene inactivation in vivo. 
Other experiments have incorporated multiple ribozyme domains within 5' and 
3' stabilised transcripts, so as to increase the number of cleavage sites on the 
substrate RNA (Chen et al., 1992 - Fig. 1.13 (11 ); Ohkawa et al., 1993). Other 
studies have suggested that, as well as 5'-m7G cap and 3'-polyadenylation, the 
ribozyme requires additional sequences which, upon entry into the cell, provide 
a further stabilising effect (e.g. Cameron and Jennings, 1989 - Fig.1.13 (12); 
Cotten and Birnsteil, 1989 - Fig.1.13 (13); De Young et al., 1994 - Fig.1.13 
(17)). This apparent inconsistency between studies probably reflects a number 
of fundamental differences within each system. One obvious factor is the 
target accessibility of different substrate RNAs. 
Cameron and Jennings (1989 - Fig. 1.13 (12)) reasoned that a ribozyme 
embedded within the 3' end of an actively transcribed mRNA, could confer 
stability to that ribozyme sequence. They incorporated a ribozyme into the 3' 
untranslated end of the gene for firefly luciferase and showed that, while the 
non-embedded ribozyme was ineffective , the luciferase embedded ribozyme 
could specifically suppress target gene expression by up to 60°/o. In this 
system, the ribozyme was estimated to be present in > 1000-fold molar excess 
over the target RNA. 
Other methods have constructed ribozymes which utilise both an 
antisense and a catalytic approach to gene inactivation by incorporating 
ribozyme domains into long stretches of antisense sequence (Heinrich et al., 
1993 - Fig.1.13 (14); Homann et al., 1993 - Fig.1.13 (15); Perriman et al., 1993-
Fig.1.13 {2); Cameron and Jennings, 1994 -Fig.1.13 (16)). Homann et al. 
(1993 - Fig.1.13 (15)) incorporated a single hammerhead domain into a 413 
base antisense targeted against the 5' leader/gag region of HIV-1. They found 
that the presence of the hammerhead domain in the antisense increased the 
ability of the molecule to reduce HIV-1 replication 4-7 fold over that obtained for 
the unmodified antisense. A hammerhead domain rendered inactive by 
deletion of U7 from the conserved core was even less effective than the 
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unmodified antisense. These results suggest that the major mechanism of 
gene inactivation in this system was cleavage of the target RNA. 
Similarly, we have previously shown that an 800 base antisense 
containing four hammerhead domains can enhance target gene reduction in 
plant cells by up to 30°/o over that obtained for the non-modified antisense 
(Perriman et al., 1993 - Fig.1.13 (2)). Using the same ribozyme-antisense 
construction in animal cells, Cameron and Jennings (1994 - Fig.1.13 (16)) have 
also shown a 25-30°/o enhancement in target gene reduction over the antisense 
control. In an attempt to further enhance the effect of this antisense-ribozyme 
construct, the initial research for this thesis involved the development of a 
modified vector construction designed to increase the expression of this 
sequence. This construction will be outlined briefly in section 1.9.1.3. and in 
more detail in chapter 3. 
An additional study by Heinrich and colleagues involved inserting a 
hammerhead domain into a 290 base antisense targeting the white gene in 
Drosophila melanogaster. Although a specific reduction in white gene 
phenotype was observed (Heinrich et al., 1993 - Fig.1.13 (14)) this study did 
not include an antisense control so the effect of the antisense sequence alone 
cannot be accounted for. 
As an alternative approach to the in vivo stabilisation of the ribozyme, 
De Young et al. (1994 - Fig.1.13 (17)) developed a small nuclear RNA (snRNA), 
U1, to express ribozymes against a peptide hormone (ANF) thought to be 
involved in hypertension. U1 genes are ubiquitously expressed under the 
control of a strong RNA polymerase II promoter but are not polyadenylated. A 
stem-loop structure and conserved 3' sequence determine correct 3' end 
formation and provide protection from 3' exonucleases (Ciliberto et al., 1986). 
Therefore, one potential advantage over polyadenylated RNA polymerase II 
RNAs, is the lack of extensive 3' sequences which may interfere with correct 
substrate-ribozyme hybrid formation. Using this approach De Young et al. 
(1994) demonstrated a 90°/o reduction in ANF mRNA levels when compared 
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with control levels. The use of catalytically inactive control ribozymes 
established that the observed effect was ribozyme mediated. 
1.9.1.2 (ii). Ribozymes transcribed by RNA polymerase Ill 
All of the systems discussed so far have taken advantage of RNA 
polymerase II based promoters (pol II) to obtain intracellular transcription of 
hammerhead ribozymes. However, several studies have now successfully 
embedded the ribozyme within an actively transcribing sequence derived from 
RNA polymerase Ill (pol Ill). At the commencement of the research for this 
thesis, one laboratory had published data in which a hammerhead ribozyme 
was expressed using a methionine tRNA-sequence in Xenopus oocytes 
(Cotten and Birnsteil, 1989 - Fig.1.13 (13)). Since this time, several reports 
have demonstrated the efficacy of using a tRNA-ribozyme (Yuyama et al., 
1992; Shore et al., 1993 - Fig.1.13 (18); Bouvet et al., 1994 - Fig.1.13 (19); 
Baier et al., 1994 - Fig.1.13 (24); Kandolf, 1994 - Fig.1.13 (25)) or related RNA 
polymerase Ill transcribed sequences (Ventura et al., 1994 - Fig.1.13 (26)). 
The work carried out in this thesis is based on the work of Cotten and Birnsteil 
(1989 - Fig.1.13 (13)) and has also involved the development of a plant tRNA 
transcription system for delivery of ribozymes to plant cells. 
tRNAs have several advantages as delivery systems for ribozymes. 
They are abundantly expressed (Darnell, 1986) and extremely stable molecules 
(Karnail and Wasterneck, 1992) therefore meeting two of the requirements for 
in vivo optimisation of ribozymes. Additionally, unlike RNA polymerase II 
transcripts, they are small and do not contain long transcription leaders or 
polyadenylation sequences. These sequences, which stabilise the RNA 
polymerase 11 transcript in vivo, may also reduce the ribozymes efficiency by 
folding into inactive conformations (Rossi et al., 1991 ). Since the structure of 
the tRNA is known, ribozyme insertion sites can be situated to minimise any 
reduction in cleavage due to interactions with the surrounding tRNA sequence. 
Three sites within tRNA molecules have been successfully used to 
express hammerhead ribozymes in both Xenopus oocytes and a human cell 
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line. Cotten and Birnsteil (1989 - Fig.1.13 (13)) incorporated a hammerhead 
ribozyme into the anticodon loop of a methionine tRNA. Using this construction 
they were able to demonstrate transcription of the tRNA-embedded ribozyme 
and specific reduction of a cytoplasmic target RNA in Xenopus oocytes. This 
was despite the fact that the tRNA-ribozyme remained predominantly in the 
nucleus. The ribozyme: substrate ratio in this system was found to be at least 
1000 : 1. Additionally, the tRNA-ribozyme showed enhanced stability over the 
non tRNA-embedded ribozyme when assayed in nuclear extracts. The 
enhanced stability of a similar tRNA-ribozyme construction has also been 
shown by Yuyama et al. (1992). They found that the tRNA-ribozyme was 
approximately 10-fold more stable in fetal bovine serum than the analogous 
non-embedded ribozyme. 
Another region of the tRNA was used by both Bouvet et al. ( 1994 -
Fig.1.13 (19)) and Kandolf (1994 - Fig. 1.13 (25)) who introduced a ribozyme 
into the intron of a tyrosine tRNA and successfully reduced accumulation of the 
H1 histone protein in Xenopus oocytes. Microinjection of 1 Ong of the tRNA-
ribozyme led to a four-five fold reduction of H1 protein synthesis. Shore et al. 
(1993 - Fig.1.13 (18)) have expressed a ribozyme at the 3' end of a human 
methionine tRNA (tRNAMet) targeting the BCRABL oncogene associated with 
human chronic myelogenous leukemia. In vivo expression of the tRNA-
ribozyme resulted in the elimination of BCRABL gene activity. An identical 
approach to this was also used by Baier et al. (1994) in targeting two protein 
kinases involved in T-cell activation. Expression of the tRNAMeLribozyme 
constructs resulted in 61-80°/o reduction in target mRNA. 
Another RNA polymerase 111 transcribed ribozyme sequence has been 
used recently against a human immunodeficiency virus-CAT construction. The 
Va gene from human adenovirus 2 provides RNA polymerase Ill based 
transcription from internal A and 8 box promoter elements in the same way as 
tRNA genes are transcribed. A ribozyme, inserted at the 3' end of Va was able 
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to reduce HIV-CAT activity by up to 50°/o over control levels (Ventura et al., 
1994). 
The research in this thesis has developed a plant tyrosine-tRNA to act 
as a hammerhead ribozyme delivery system to plant cells. We have used the 
approach of Cotten and Birnsteil (1989 - Fig.1.13 (13)) and incorporated our 
ribozyme into the anticodon loop of the tRNA sequence. As well as analysing 
tRNA-ribozymes in vitro and in vivo, this thesis has compared a tRNA-
antisense and the analogous non-embedded ribozyme and antisense 
sequences. 
1.9.1.3. Enhancing expression levels by delivery 
While it is important to equip the ribozyme with sequences which can 
enhance its in vivo stability, maximising the levels of expression (i.e. 
transcription) are also important. I have already discussed the tRNA vector 
system which can enhance both the expression and stability of the 
hammerhead ribozyme. However, systems such as the tRNA or any of the 
RNA polymerase II constructions can be further enhanced by maximising the 
number of DNA templates from which ribozyme transcription, pol II or pol Ill, 
can occur. 
Obviously the stable integration of sequences encoding ribozymes is 
one approach, however this method can produce transgenic organisms in 
which the expression of either the transgene or endogenous mRNAs are 
altered as a result of insertional inactivation. In plants this approach is still 
suitable as many individual transgenic lines can be produced and screened. At 
this stage, there is only one published report describing transgenic plants 
expressing specific ribozyme sequences (Wegener et al., 1994). Although the 
study reported a reduction in target gene expression, no control antisense or 
inactive ribozyme sequences were included. As part of the research for this 
thesis, several independent tRNA-ribozyme and tRNA-antisense expressing 
transgenic plants have been analysed. 
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In animal systems, where most ribozyme target sequences are ultimately 
aimed towad human applications, the production of a transgenic organism is 
not appropriate. In some studies however, aspects of cellular function and 
development are being analysed by producing transgenic laboratory organisms 
expressing hammerhead ribozymes designed to reduce the expression of 
specific gene products. Two reports have produced transgenic Drosophila 
melanogasterexpressing ribozymes against the white eye phenotype (Heinrich 
et al., 1993 - Fig.1.13 (14)) and a developmental gene, ftz, (Zhao and Pick, 
1993 - Fig.1.13 (20)). Additionally, two other studies have produced transgenic 
mice expressing ribozymes against a glucokinase involved in mature onset 
diabetes (Efrat et al., 1994 - Fig.1.13 (8)) and an mRNA encoding P2M, a 
protein thought to play an important role in the immune system (Larsson et al., 
1994 - Fig.1.13 (21 )). Unfortunately, while all studies did observe an altered 
phenotype, only the work of Zhao and Pick (1993 - Fig.1.13 (20)) included 
antisense and inactivated ribozyme controls. 
As an alternative, several methods have been tested for the exogenous 
delivery of hammerhead ribozymes to cultured cell-lines. While some of these 
provide transient expression of the ribozyme, others can be manipulated so 
that stable expression can be obtained. As well as analysing transgenic plants 
expressing the tRNA-ribozyme, this thesis describes a new mode of delivering 
hammerhead ribozymes to plant cells. This method is analogous to the many 
viral-based vectors available in animal systems. 
Retroviral vectors containing the ribozyme sequence are the most widely 
used for high level expression of hammerhead ribozymes in mammalian cells. 
Upon infection of the cell, the single stranded RNA genome of the retrovirus is 
reverse transcribed and integrated into the genome. Once integrated, the 
sequence is transcribed by host-cell polymerases, infectious RNAs are 
produced, encapsidated and bud from the infected cells. Retroviral vectors 
have been engineered so that they are defective in their replication function. 
This means that once they are integrated, the retroviral sequences will actively 
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transcribe but are unable to form infectious viral particles. In this way stably 
transformed cell-lines expressing the ribozyme sequences can be produced. 
Using this approach several independent cell-lines can be screened until the 
desired phenotype is observed. This transfected cell-line can then be re-
implanted into an organism where the hope is that it will replace the defective 
cell-types with the ribozyme expressing ones. Retroviral vectors encoding 
ribozymes against HIV-1 (Weerasinghe et al., 1991 - Fig.1.13 (22); Crisell et 
al., 1993 - Fig.1.13 (23)), BCRABL oncogene (Shore et al., 1993 - Fig.1.13 
(18)), bovine leukemia virus (Cantor et al., 1993 - Fig.1.13 (7)) and the c-fos 
proto-oncogene (Scanlon et al., 1991 - Fig.1.13 (5)) have been effectively 
delivered to cultured cell-lines. The work of Shore et al. (1993 - Fig.1.13 (18)) 
and Baier et al. (1994) which were discussed in section 1.9.1.2(ii) have 
incorporated both the tRNA delivery mechanism and the retroviral vector. At 
this stage there is no published data on the re-introduction of these transfected 
cell-lines into whole organisms. 
The research carried out in this thesis has also taken advantage of a 
replicating viral system to deliver ribozymes to plant cells. The plant 
geminivirus, African cassava mosaic virus (ACMV- see Stanley, 1993) has 
been adapted to deliver ribozyme or antisense sequences. ACMV is a single 
stranded DNA plant virus which relies on host components for replication, is 
localised within the nucleus and can replicate to high levels (see Davies et al., 
1987 for review). In this way, it is similar to the retroviral vectors used in the 
mammalian systems. However, as distinct from the retrovirus, ACMV 
autonomously replicates to produce extremely high levels of viral DNA which is 
maintained as an episome in the nucleus of plant cells. Chimeric viral 
sequences containing either the antisense-ribozyme or tRNA-ribozyme 
sequences have been constructed. In this way, both the high level expression 
obtained from the self-replicating ACMV and the stability conferred by either the 
antisense or tRNA sequences can be utilised. The ACMV vector will be 
discussed in more detail in the following chapters. 
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1.10. Conclusions and aims of this thesis 
The discovery of RNA molecules such as the hammerhead ribozyme 
has provided a powerful tool for the potential manipulation of gene expression 
in living organisms. The initial excitement regarding the application of 
ribozymes has now developed into a wide area of study, as researchers have 
recognised that in order to successfully apply ribozymes to living cells, several 
areas need to be addressed. These include the determination of the structural 
and chemical basis of the cleavage reaction, and techniques aimed at 
optimising intracellular expression. 
The main objective of this thesis has been to optimise the expression 
and stability of hammerhead ribozyme transcripts in plants. While the research 
in this thesis has been carried out in plant cells, many of the results obtained 
can be applied to future ribozyme design in both animal and plant systems. 
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CHAPTER 2 
MATERIALS & METHODS 
All oligonucleotides were synthesised on an Applied Biosystems model 
392 DNA synthesiser by Lynda Graf (CSIRO Division of Plant Industry) or John 
Gardner (University of California, Davis). Molecular cloning and related 
techniques were carried out essentially as described by Sambrook et al. 
(1989). Plasmid constructions outlined below are all depicted on figures 
contained in an envelope at the back of this thesis. These figures are 
detachable and show all constructions used in the data presented in Chapters 
3, 4 and 5. 
PLASMID CONSTRUCTIONS 
2.1. pApoly {Fig 2.1 a) 
A clone of the A component of the geminivirus African cassava mosaic 
virus (ACMV), pET012 was obtained from John Stanley (John Innes Institute, 
Norwich, UK). This plasmid contains a 727bp deletion within the coat protein 
open reading frame (nucleotides 467-1194, Ward et al., 1988) and a unique 
EcoRV site at the site of this deletion. The DNA A was cloned as a BamHI 
insert in M 13. Modifications to this vector were carried out by Paul Feldstein 
and Cathy Chay (University of California, Davis). These included the insertion 
of a pUC19-derived plasmid, p129C, carrying the colE1 bacterial origin of 
replication and chloramphenicol resistance gene and the removal of the M 13 
vector. p129C was inserted at the Clal site to make pACMV and allowed for 
amplification in E.coli. A 946bp BamHI/Clal fragment of the ACMV A genome 
containing the putative origin of replication (2124 - 2779 and 1 - 291) was 
isolated and re-inserted in a head-to-tail orientation to produce a 1 .3 copy of 
the ACMV genome (minus the coat protein ORF). In addition, T7 and SP6 
RNA polymerase promoter sequences were inserted to flank a 549bp insert. 
This insert was placed between the coat protein promoter and polyadenylation 
Figure 2.1 
a: pApoly vector used for expression of CAT target, ribozyme and antisense sequences in 
plant cells. p129C, (blue box), is the bacterial plasmid containing co/Et bacterial origin of 
replication and chloramphenicol resistance gene (Cmr). This plasmid was inserted at the C/al 
site as indicated. Red boxes are 2 copies of the region containing the viral origin of replication 
with the internal arrows indicating the direction of replication of 11 sense 11 viral sequence. The 
endogenous coat protein promoter region is indicated with sites of 11 TATA 11 , transcription start 
(t start), initiation codon (AUG), transcription termination (t stop) and polyadenylation 
signals (poly A). t,.,. CP represents the region of the coat protein open reading frame which has 
been deleted and replaced with polylinker sequence as indicated. Numbers in bold are 
nucleotides on the viral sequence while italicised numbers are the polylinker sequence. 
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signals so that expression was obtained from these sequences. Subsequently, 
I removed the 549 base insert as a Hindi 11/ Sst1 fragment and replaced it with a 
Hindlll/Sst1 fragment of the polylinker derived from pUC19. This made the 
construct pApoly (Fig. 2.1 a - nos. in italics, 1-108, represent insert flanked by 
T7 and SP6 RNA polymerase promoter sequences). Any sequences 
subcloned within this region could also be expressed using the coat protein 
promoter. 
2.2. CaMV-35S CAT & pA CAT, long ribozyme and antisense 
(i) pJ35SCATN (Fig 2.1 b) The plasmid pJ35SN (Bogusz et al., 1990) 
was digested with BamHI and a 773 bp BamHI fragment from pGEMCAT 
(Haseloff and Gerlach, 1988) containing the CAT open reading frame was 
subcloned to make pJ35SCATN. 
(ii) pACAT (Fig 2.1 b) To allow for the directional cloning of the CAT 
fragment into pApoly, a 773 bp BamHI CAT fragment was subcloned into 
BamHI digested pG7CAT and orientated so that a Hindlll/Sst1 fragment would 
produce a CAT fragment in the sense orientation. This Hindlll/Sst1 CAT 
fragment from pG7CAT was inserted into like digested pApoly to make pACAT 
(Fig. 2.1 b). 
(iii) pAAsCAT/RzCAT (Fig 2.1c) A reverse orientation clone of the 773 
bp CAT insert in pGEM7zf+ (pG7AsCAT) was digested with Hindlll/Sst1 and the 
fragment subcloned into like digested pApoly to make the clone pAAsCAT (Fig. 
2.1c). 
To incorporate the four hammerhead ribozyme domains into the 
antisense sequence, site-directed mutagenesis was carried out (Kunkel et al., 
1987) using pGEMAsCAT as the template. Single stranded plasmid DNA 
isolated from an ung- dut- strain of E.coli was annealed with four 
oligonucleotides each containing hammerhead ribozyme domains and specific 
flanking sequence. Replication of the plasmid was completed with dNTPs, T4 
DNA polymerase and T 4 DNA ligase and introduced into E.coli strain DH5a. 
Figure 2.1 
b: Subcloning of CAT into pJ35SN and pApoly expression vectors for analysis in N.tabacum 
plant cells. pJ35SN contains a 430-bp segment of the 35S promoter from cauliflower mosaic 
virus (35S - shown in green), Bamf-11, Smal and EcoRI restriction sites followed by termination 
signals from nopaline synthase (NOS-t - shown in red). Expression from pApoly is obtained 
from the ACMV coat protein promoter (ACMV-CP-dark blue) and termination signals (ACMV-t-
yellow). The vertical arrows indicate the sites of the four GUC triplets in the CAT RNA that are 
targeted by ribozyme sequences contained in the long ribozyme RNA. The horizontal arrows 
indicate the direction of transcription in vivo. 
c: Subcloning of CAT antisense (AsCAT) and long ribozyme (RzCAT) into pApoly expression 
vector. As in b expression of AsCAT and RzCAT are obtained from the ACMV coat protein 
promoter (dark blue) and termination signals (yellow) with the direction of transcription indicated 
by horizontal arrows. The four ribozyme sequences on RzCAT are indicated (1-4) with numbers 
corresponding to the target sites on the CAT RNA. 
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The resultant plasmid, pGRzCAT, encoded a ribozyme capable of cleaving the 
target CAT RNA sequence 3' of 11 GUC 11 trinucleotides at positions 110, 464, 615 
and 630 (Fig. 2.1 c). The nucleotide component of each ribozyme domain was 
confirmed by dideoxy -sequencing. A Hindlll/Sstl fragment of the RzCAT 
construct was subcloned into like digested pApoly to make pARzCAT (Fig. 
2.1c). 
2.3. tRNAs (Fig. 2.2) 
(i) A clone of the tyrosine tRNA (tRNA Tyr) was obtained from the lab of 
Hildberg Beier (Bayerische Julius-Maximilians University, Wurzburg, Germany) 
and subcloned as a Sspl end-filled/ Accl fragment into Small Accl digested 
pGEM3zf- to make pG3tRNA (Fig. 2.2a). This clone contains a 256bp insert 
which encodes the RNA polymerase II I recognition sites of the tRNA insert (A 
and B box), an endogenous 13 base intron (hatched box), upstream and 
downstream flanking sequences and the mature tRNA. Figure 2.2a shows 
transcript start sites for T7 RNA polymerase (bold) and RNA polymerase 111 
(italics). 
(ii) A short oligodeoxyribonucleotide, containing three restriction enzyme 
recognition sites, BamHI, Smal, EcoRI, was inserted within the anticodon loop 
of the tRNA by site directed mutagenesis to make pGtRNAp (Fig. 2.2a). The 
position of insertion is at 112 in pG3tRNA(Fig. 2.2a) or 31 in the mature tRNA 
molecule (Fig. 2.2b). 
(iii) The ribozyme Rz12 is a single hammerhead motif designed to target 
and cleave the CAT RNA at the second GUC from the 5' end (position 464). 
This ribozyme has 12 bases of hybridisation 5' and 31 of the hammerhead 
domain (Fig. 2.2c). The construct pGRz12 was made by Haseloff and Gerlach 
(1988). An EcoRI/Pstl fragment containing the Rz12 ribozyme sequence was 
end-filled and subcloned into Smal digested pGtRNAp to make the clone 
pGtRNARz12. 
Figure 2.2 
a: Subcloning of 256 bp tRNATyr sequence into pGEM3zf-. Boxes labelled A in green and Bin 
red are RNA polymerase Ill promoter recognition sites; the yellow region represents a 13 base 
intron within the tRNA sequence. The transcription start site for T7 RNA polymerase is shown 
by numbers in bold; the internal arrow and numbers in italics represent RNA polymerase Ill 
transcript start. The arrow at position 112/31 on pGtRNAp indicates the site of insertion of 
BamHI, Smal and EcoRI restriction sites (hatched black box). This is within the anticodon loop as 
shown in figure 2.2b. 
b: Clover leaf motif of tRNA Tyr sequence. Nucleotides comprising the A and B boxes, and the 
13 base intron are color coded as in (a). The arrow shows the site of insertion of BamHI, Smal 
and EcoRI restriction sites. The red circled C56 nucleotide was mutated to a G for mutagenesis 
of the RNA polymerase Ill promoter (see section 2.7). Nucleotide numbering is depicted for the 
mature tRNA Tyr sequence. \Jf at positions 35 and 55 are pseudouridines. 
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(iv) The antisense sequence, As24 was made by Cameron and 
Jennings (1989). This sequence contains the same extent of hybridisation to 
the CAT gene as Rz12 but lacks the hammerhead domain. This antisense 
sequence was subcloned as a BamHI/SnaBI fragment into BamHI/Smal 
digested pGtRNAp to make the clone pGtRNAAs24. 
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(v) The ribozyme RzCA targets the same region of the CAT gene as 
Rz12 but has extended hybridisation (31 bases 51 and 33 bases 31). This 
ribozyme also contains internal restriction enzyme recognition sites which 
produce mismatches within the hybridising arms as shown in Fig. 2.2d. RzCA 
was subcloned as a blunt EcoRI/Hindlll fragment from pG3RzCA (Perriman et 
al., 1992) into Smal digested pGtRNAp to make pGtRNARzCA. 
(vi) The antisense, AsGUC, has the same length of hybridisation to the 
CAT gene as the long ribozyme. It also contains the same mismatches so that 
the effect of the addition of the hammerhead domain could be accurately 
measured. AsGUC was subcloned from pGAsGUC (Perriman et al., 1992) as 
a blunt EcoRI/Hindlll fragment into Smal digested pGtRNAp to make 
pGtRNAAsGUC. 
(vii). intron-minus tRNAs. 
As shown in Fig. 2.2a, the tyrosine tRNA contains an endogenous 13 base 
intron which is spliced out during processing of the tRNA from the pre to the 
mature form. To investigate the splicing efficiencies of the recombinant tRNAs, 
the intron was removed from the five recombinant tRNA constructs by site 
directed mutagenesis. These intron-minus tRNAs are designated 11 111 following 
the construction name (i.e. pGtRNApl, pGtRNARz121, pGtRNAAs241, 
pGtRNARzCAI, pGtRNAAsGUCI). 
2.4. Mutant CAT target-CM2 (Fig. 2.3) 
The GUC target site at position 464 on the CAT gene in the clone 
pG7CAT was mutated to a GUG by site directed mutagenesis. A GUG target 
triplet has been previously shown to be a noncleavable target under in vitro 
Figure 2.2 
c: Sequence of Rz12 ribozyme which is designed to anneal and cleave at position 464 on the 
CAT mRNA. The ribozyme confers complementarity of 12 bases 5' and 12 bases 3' of the target 
site. 
d: Sequence of RzCA ribozyme which targets the same region on the CAT mRNA as c but has 
extended 5' and 3' hybridisation (31 bases 5' and 32 bases 3'). The internal nucleotides in blue 
are restriction sites ( Smal and EcoRV) which produce mismatches in the hybridising arms. 
Hindlll and EcoRI restriction sites were used for subcloning into pGEM3zf+ (Perriman et al., 
1992) and pACMV vectors. 
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conditions (Koizumi et al., 1988a; Ruffner et al., 1990a; Perriman et al., 1992). 
This mutation maintains codon usage within the CAT open reading frame. The 
plasmid bearing the mutated CAT sequence is called pGCM2. A Hindlll/Sst1 
fragment containing the CM2 insert was subcloned into like digested pApoly to 
make the plasmid pACM2. 
2.5. Modified pApoly vector (Fig. 2.4). 
The original pApoly construct contained the coat protein AUG start 
codon and 21 residues of the coat protein at the s· end (Fig. 2.1 a). The 
modified pApoly vector was produced to remove these upstream bases and 
used to express all tRNA and non-embedded antisense and ribozyme 
sequences. BstXI digested pApoly was treated with T 4 DNA polymerase to 
form a blunt end. This was digested with Smal and the plasmid religated to 
produce pApolyM (Fig. 2.4). 
2.6. pApolyM expressing tRNA and non-embedded ribozyme/antisense 
sequences. 
The six tRNA constructs were all subcloned into the Ecl13611 site (an 
isoschizomer of Sst1 which produces blunt ends) of pApolyM vector as blunt 
Ecl13611/ Accl fragments. These plasmids are: pAtRNA, pAtRNAp, 
pAtRNARz12, pAtRNAAs24, pAtRNARzCA, pAtRNAAsGUC. 
The non-embedded ribozyme and antisense sequences were also 
subcloned into the Ecl13611 site of pApolyM. Rz12 was subcloned as a blunt 
EcoRI/ Pst1 fragment, As24 was a blunt Barn HI/ SnaBI fragment and RzCA and 
AsGUC were both end-filled Hindlll/EcoRI fragments. 
2.7. Mutant RNA polymerase II and Ill pAtRNARz12 constructs (Fig. 2.5). 
Mutations designed to inactivate either the RNA polymerase 11 or RNA 
polymerase Ill promoter of the pAtRNARz12 construct were made by site 
directed mutagenesis (Kunkel et al., 1987). Mutagenesis of the RNA 
Figure 2.3: Mutagenesis of the GUC target site at position 464 (arrowed) on the CAT RNA. 
Boxed region shows sequence alteration from GUC to GUG to create CM2 target construct with 
mutated nucleotides highlighted in red. CAT initiation codon [24(AUG)], ACMV coat protein 
promoter (ACMV-CP [dark blue]) and termination signals (ACMV-t [yellow]) are indicated. 
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Figure 2.4: Construction of modified pApoly vector (pApolyM). The features of pApolyM are 
as for pApoly (figure 2.1 a) except for the deleted 152bp region between BstXI - Smal shown in 
the boxed region labelled 6. BstXI - Smal. Within this box, the nucleotides in bold italics green 
represent the 5' and 3' ends of the deleted 152bp sequence. The nucleotide sequence after 
deletion of the 152 bp is shown to the right of the arrow within the 6. BstXI - Smal boxed region. 
Restriction sites remaining within the inserted polylinker are indicated beneath the 6. BstXI -
Smal box. 
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polymerase II promoter for the pAtRNARz12 constructs was obtained by first 
subcloning an Apal!Sstl fragment from pAtRNARz12 (see Fig. 2.4) into 
pGEM7zf + which contains the f1 ori for single-stranded DNA production using 
an M 13 (AKO?) helper phage. This fragment contains the 11T ATA 11 box of the 
coat protein RNA polymerase II promoter (situated at position 251 on pApoly as 
shown in Fig. 2.4). To monitor the extent of the reduction in RNA polymerase II 
transcription, the pACAT construct was also mutated at the same site. Site 
directed mutagenesis changed the sequence at position 251 from "TATATA" to 
"GGGGTG" producing a Dralll site. Once mutagenised the Apal/ Sstl fragment 
containing the mutant TAT A box was inserted into Apal/ Sstl digested 
pAtRNARz12 to produce pAtRNARz12MA (Fig. 2.5a) and Apal/ Sstl digested 
pACAT to produce pACATMA. CAT enzyme activity equal to background 
levels were obtained using the pACATMA construct (data not shown). 
Mutagenesis of the RNA polymerase Ill promoter was carried out on the 
pGtRNARz12 construct. A single base change from C to G at position 56 in 
the highly conserved B box of the mature tRNA was chosen (circled in red in 
Fig. 2.2b). This mutation had been previously shown to reduce RNA 
polymerase Ill transcription by 94°/o (Allison et al., 1983). The mutated 
tRNARz12 was subcloned into Ec/13611 digested pApolyM as an Ec/13611/Accl 
(blunt) to make pAtRNARz12MB (Fig. 2.5b). 
The double mutant, in which both promoter sequences have been 
inactivated was made by subcloning the Apal/ Sstl fragment containing the 
mutant RNA polymerase II promoter into pAtRNARz12MB to produce 
pAtRNARz12MAB . 
IN VITRO ANALYSIS 
2.8 In vitro RNA transcription 
CAT, ribozyme and antisense RNAs for the in vitro cleavage and splicing 
reactions were prepared by in vitro transcription using linearised plasmid DNAs. 
1 µg of linearised plasmid DNA was incubated with the following: 40mM Tris-
Figure 2.5 
a: Mutagenesis of coat protein promoter on pAtRNARz12 construct. The tRNARz12 insert is 
the boxed region between Ss~(Ec/13611) and EcoRI restriction sites. The Rz12 ribozyme insert 
is depicted by the triangle. A (green) and B (red) are RNA polymerase Ill promoter regions and 
the yellow box is 13 base intron. The coat protein start (pol II start) and termination (pol II 
termination) signals are shown as strike-through lettering to indicate their loss of function. The 
arrow pointing to the boxed region above the figure shows the approximate site of the 
sequence mutated to produce the mutant coat protein promoter (MA): TATATA at position 251-
256 (shown in red italics) was changed to GGGTG creating a Dralll restriction site. The RNA 
polymerase Ill start (pol Ill start) and termination (pol Ill termination) signals are also shown. The 
distance (in bp) between the RNA polymerase II and Ill transcription start and termination sites 
are shown beneath the figure. 
b: Mutagenesis of the RNA polymerase Ill promoter on pAtRNARz12 construct. Construct 
features are as outlined in (a) except that RNA polymerase Ill transcription start (pol Ill start) and 
termination (pol 111 termination) signals are now shown as strike-through lettering to indicate their 
loss of function. As for (a), the arrow pointing to the boxed region above the figure shows the 
site of the mutation to produce the mutant RNA polymerase Ill promoter (MB): the Cat position 
56 (shown in red italics) was changed to a Gas shown on the right side of the boxed 
nucleotides. The 'V at position 55 is a pseudouridine. 
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HCI (pH 7.5), 6mM MgCl2, 2mM spermidine, 10mM NaCl, 10mM OTT, 80 units 
RNasin, 1 mM ATP, CTP and GTP and 0.25mM UTP + 60pmoles of a-32P-UTP 
(for substrate RNAs) or 1 mM UTP for non-radioactive RNAs and 50 units of T7 
RNA polymerase. Reactions were incubated at 370c for 1-2 hours and then 
treated with 2 units of DNAase I at 370c for a further 15 minutes to remove the 
DNA template. 
Transcript yields were determined using 5°/o trichloroacetic acid (TCA) 
precipitation. For the non-radioactive transcripts, transcript yield was 
determined by TCA precipitation on a control radioactive transcript transcribed 
from the same template DNA at the same time. RNAs were checked by 
electrophoresis through 6-8°/o denaturing polyacrylamide gel to ensure that the 
transcripts were the correct size and that yields were as determined by the TCA 
precipitation. 
2.9 In vitro cleavage reactions 
0.5pmole (pm) of substrate RNA was mixed with 3pm of ribozyme in the 
presence of 1 OmM MgCl2, 50mM Tris-HCI, pH7.4 in a final volume of 5µ1. The 
reaction was placed at 300c for 1 hour and stopped by the addition of EDTA to 
a final concentration of 50mM. An equal volume of 100°/o formamide 
containing bromophenol blue and xylene cyanol dyes was added and the 
reactions were resolved on 6°/o polyacrylamide 7M urea denaturing gels using 
180mM Tris-borate, pH8.3, 4mM EDTA running buffer. 
2.10 Wheatgerm S100 extraction. 
S 100 wheatgerm extracts for cell free processing of the tRNA constructs 
(Stange & Beier, 1987) was obtained by floating 20g of crude wheatgerm in a 
mixture of 110ml cyclohexane + 500ml chloroform three times. The wheatgerm 
was dried overnight at room temperature and 5g was ground with an equal 
weight of acid-washed sand to a fine powder. 25ml extraction buffer (1 OmM 
Tris-acetate, pH7.6; 3mM Mg acetate; 50mM K acetate; 1 mM OTT) was added 
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and the mixture was centrifuged at 23,000 x g for 10mins. This centrifugation 
was repeated (after taking off supernatant and respinning) and then the 
resulting supernatant was spun at 100,000 x g for 2 hours. The supernatant 
was dialysed on ice in extraction buffer for 24 hours and then spun at 23,000 x 
g for 1 O mins. The protein concentration was determined using a Bradford 
protein determination kit (Bio-rad) and the extracts were snap-frozen in liquid 
nitrogen and stored at -70°C. The protein concentration was approximately 
24mg/ml. 
2.11 tRNATyr processing in S100 wheatgerm extracts. 
Cell free processing was carried out based on the protocol described in 
Stange & Beier ( 1987). In vitro transcribed recombinant tRNAs were 
resuspended at 1 µM. 2µ1 of the tRNA was mixed with 2µ1 of S100 wheatgerm 
extract and splicing buffer (6mM Mg acetate; 80mM spermine; 1 OOmM K 
acetate; 20mM Tris-acetate, pH7.5; 1 SmM OTT; 0.8°/o Triton-X 100; 1 OOµM 
CTP; 1 mM ATP) in a volume of 1 OµI. The reactions were incubated at 300c for 
90 mins. Following this, the reaction was phenol extracted and the phenol 
phase back-extracted to ensure that maximum recovery of the tRNAs was 
obtained. The tRNAs were ethanol precipitated and resuspended in 1 OOo/o 
formamide containing bromophenol blue and xylene cyanol loading dye. The 
tRNAs were analysed by electrophoresis through 8°/o denaturing 
polyacrylamide gel. Radioactive products were detected by autoradiography 
and then quantified using a Phosphoimager (Molecular Dynamics). 
IN VIVO EXPRESSION 
2.12 (i) Protoplast isolation: 
A cell culture of Nicotiana tabacum ( c. v. Xanthi) was used for protoplast 
isolation. The cell culture was maintained by subculturing every three days. 
5ml was subcultured into 50ml of supplemented liquid KCMS media (MS 
organics; 0.1 mg kinetin/ml; 0.2mg 2-4-D/ml, 1.SmM KH2P04; O.Smg/ml each of 
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nicotinic acid, pyroxidine and thiamine; 1 OOµg cefotaxime/ml; 2.5µg 
amphotericin/ml). Protoplast isolation was always carried out three days after 
subculture. 10-20ml of the 3 day old culture was spun down at 100 x g for 1 O 
mins and resuspended in enzyme mix (1 °/o cellulysin (Calbiochem); 1 °/o 
Driselase (Sigma); 1 °/o macerozyme (Yakult-Onzaka) in an equal ratio of ASW 
(311mM NaCl; 6.9mM KCI; 18.SmM MgS04; 16.7mM MgCl2; 6.8mM CaCl2; 
1.75mM NaHC03; 10mM MES, pH 6.0) and 0.6mM mannitol (i.e. ASWM). The 
suspension was transferred to deep Petri dishes and rocked gently at 300c for 
three hours (dark) with protoplast release assayed by analysis under an 
inverted microscope. Usually >80°/o cells were present as single protoplasts 
after a three hour incubation. Protoplasts were filtered through 150 micron 
mesh to isolate single cells, an equal volume of ASW was added and the cells 
were spun down at 100 x g for 10 mins. Cells were washed twice in 20ml of 
ASWM and spun at 100 x g for 10 minutes between each wash. After the 
second wash cells were resuspended in 20ml of ASWM and 50µ1 spotted on a 
haemocytometer for counting. Cell concentration was determined and the cells 
were spun down at 100 x g and resuspended in Zap media (1 OmM HEPES; 
10mM NaCl; 120mM KCI; 4mM CaCl2; 200mM mannitol, pH 7.2) at a 
concentration of 1 .2 x 106 cells/ml. 
(ii) Transfection 
700µ1 aliquots of protoplasts were used per transfection. Transfection 
was obtained by electroporation using a Hoefer PG200 progenitor 11. Each 
electroporation involved the co-electroporation of 5µg of the target construct 
with 1 Sµg of either a control, antisense or ribozyme construct so that each 
event involved the same amount of input DNA. Each construct pairing was 
repeated a minimum of three times for each protoplast isolation. The 
conditions used for electroporation were 490µF capacitance, 330volts, single 
8msec pulse with the electrodes in the electroporation chamber separated by 
0.4mm. Following electroporation, cells were transferred to culture dishes and 
incubated in 3ml growth media (5°/o coconut water, 95o/o KCMS, 265mM 
45 
mannitol; 1 OOµg cefotaxime/ml; 2.5µg amphotericin/ml) at 250c for 1-8 days. 
Cells were harvested and assayed for CAT activity, ACMV DNA replication and 
mRNA/tRNATyr levels. 
Cells were harvested by transferring to sterile 15ml Corex Tm tubes and 
spinning down at 100 x g for 10 mins. Generally 200µ1 of the growing culture 
were snap-frozen for CAT assays and the remainder was used to isolate DNA 
and/or RNA. DNA and RNA were always isolated from fresh unfrozen cells. 
(iii) CAT assays on transiently expressing cells 
After pelleting, the cells were resuspended in 200µ1 of 0.25M Tris-HCI 
(pH 7.4) before being transferred into 1.5ml Eppendorf tubes. The cells were 
sonicated and extracts centrifuged at 14,000 x g for 10 mins at 40c to remove 
cell debris. Protein concentrations were determined using a Bradford assay kit 
(Bio-rad). Equivalent amounts of protein for each extract were incubated at 
370c for 1.5 hours in the presence of 5µ1 of 1 OmM acetyl-coenzyme A and 
18pmol of 14c chloramphenicol. Reactions were stopped by the addition of . 
700µ1 of ethyl acetate. The ethyl acetate phase was extracted, dried and 
resuspended in 1 OµI of ethyl acetate for separation on silica gel thin-layer 
chromatography in 5°/o methanol and 95°/o chloroform. Radioactive products 
were detected by autoradiography and then quantified using an AMBIS Image 
Acquisition analyser to determine the proportion of 14c chloramphenicol that 
had been acetylated. The average rates of acetylation were plotted using 
Lotus Freelance graphics. 
(iv) DNA isolation from transiently expressing cells 
Cells were collected as for the CAT assays and resuspended in 200µ1 
TE. An equal volume of 2 x SOS extraction buffer (0.1 mM Tris, pH 7.4; 2mM 
EDTA; 2°/o SOS) was added and the solution mixed. Proteinase K was added 
to 1 OOµg/ml and the solution incubated at 370c for 30 minutes. Following this, 
samples were extracted with equal volumes of phenol/chloroform and then 
nucleic acids precipitated in ethanol/sodium acetate. Nucleic acid samples 
were treated with 1 Oµg of RNaseA to remove contaminating RNA prior to 
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restriction enzyme digestion. DNAs were suspended at a concentration of 
0.5mg/ml. 1-2µg of total DNA was digested with either Dpnl or Mbol and 
analysed by Southern hybridisation. 
(v) Southern blotting 
Following digestion, DNAs were electrophoresed through 1-2°/o agarose 
(depending on the size of the fragment being analysed) containing 0.5µg/ml 
ethidium bromide. DNA bands were visualised under UV light and 
photographed. DNA was denatured in 1.5M NaCl; 0.5M NaOH for 40 mins, 
rinsed in H20 and neutralised in 1.5M NaCl; 1 M Tris-HCI, pH 8.3. Transfer of 
the digested DNAs to Hybond N+ membrane was obtained in 10 x SSC ( 1 x 
SSC - 150 mM NaCl; 15mM Na3 citrate, pH 7.0) and the wick method of 
transfer (Sambrook et al., 1989). Following transfer the DNAs were fixed to the 
membrane by UV crosslinking at 1200 mjoules for 100 secs and briefly rinsed 
in 2 x SSC prior to prehybridisation. Prehybridisation and hybridisation was 
carried out at 420c in hybridisation buffer (7°/o SOS; 0.25mM NaH2P04; 50°/o 
formamide; 1 mM EDTA; 0.25M NaCl). Radioactive DNA probes were made 
using an Amersham multiprime kit by incorporating a-32P-dCTP and using 
agarose gel-isolated DNA fragments of the desired sequence as templates. 
Following overnight hybridisation the blots were rinsed in 2 x SSC;0.1 °/o SOS 
and then washed in 25mM NaH2P04; 1 mM EDTA; 1 °/o SOS at 600C for 2 x 20 
minutes. Bands were visualised by autoradiography and aligned with the 
photographed gel for interpretation. 
(vi) RNA isolation from transiently expressing cells 
Cells used for RNA isolation were pelleted as for DNA isolation. Total 
RNA was isolated from cells using 1 ml of Trizol solution (Gibco, BRL) per 5-10 
x 106 cells. Cells were lysed by repeated pipetting and the homogenised 
samples were incubated at room temperature for 5 mins. 200µ1 of chloroform 
was added and the samples mixed then incubated at room temperature for 2-3 
mins. Samples were centrifuged at 12,000 x g for 15 mins at 40c. The upper 
aqueous phase containing the RNA was transferred to a fresh tube and the 
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RNA precipitated by the addition of 0.5ml isopropanol. RNA was suspended at 
a final concentration of 1 mg/ml and analysed by electrophoresis through non-
denaturing 1 °/o agarose. 
(vii) Ribonuclease protection assays 
RNase protection assays were performed according to the protocol 
RPAII (Ambion). 7-20µg (depending on the fragment to be protected - see 
results) of total RNA were used for the protection assays. A radiolabelled 
probe was produced by in vitro transcription of the antisense sequence of 
tRNARz12, tRNAAs24 or CAT using linearised plasmid templates as follows: 
200ng linearised DNA (i.e. pAtRNARz12 or pAtRNAAs24/Dral or 
pACAT/Pvull); 1mM ATP,GTP,UTP; 50µM CTP; 5mM OTT; 1 unit RNasin 
(Promega); 5 x Buffer (40mM Tris-HCI, pH 8; 25mM NaCl; 8mM MgCl2; 2mM 
spermidine); 30µCi a-32P-CTP (800 Ci/mmol); 20 units SP6 RNA polymerase 
in a volume of 1 OµI. Approximately 2 x 1 o5 cpm of radiolabelled probe was 
mixed with total RNA and incubated at 450c overnight in hybridisation buffer 
(80°/o formamide; 1 OOmM Na3 citrate, pH 6.4; 300mM Na acetate, pH 6.4 and 
1 mM EDTA). An equal volume of digestion buffer containing RNaseT1 (100 
units/ml) and RNaseA (5µg/ml) was added and the samples incubated for 30 
mins at 370c. Reactions were precipitated and resuspended in 100°/o 
formamide loading dye. Protected RNAs were resolved on 6-10°/o 
polyacrylamide gel electrophoresis and visualised by autoradiography. Assays 
were quantified using a Phosphoimager (Molecular Dynamics). 
(viii) Reverse transcriptase-PCR (RT-PCR) of in vivo CAT mRNA. 
The sequence of all PCR primers is shown in Fig. 2.8. First strand 
cDNA synthesis was carried out as follows: 5 µg total RNA and 0.5mg of oligo 
dT-TAG primer were incubated at 550c for five minutes and then transferred to 
ice. To this were added 1st strand buffer (250mM Tris-Cl, pH 7.5; 375mM KCI; 
15mM MgCl2; 50mM OTT; 500mg/ml BSA); 0.5mM dNTP's, 0.5 units RNasin 
and 200 units Superscript reverse transcriptase (Gibco-BRL). The reaction 
was incubated at 450c to minimise any effect of secondary structure on the 
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RNA. After 1 hour at 450c, the RT reaction was diluted to 200µ1 with H20 and 
20µ1 used for the PCR reactions. The first strand primer was oligo dT with an 
18 base unique sequence ("TAG 11 -Lincoln and Karrer, unpublished - Fig. 2.6 & 
2.8) at the 5' end of the primer. This TAG sequence was used to prime for 
subsequent PCR amplifications. Dual PCR reactions were carried out on 
reaction samples. Primer 1 which anneals at positions 198-216 on the CAT 
sequence was designed to amplify full length CAT sequence (Fig. 2.6 & 2.8). 
Primer 2 anneals at positions 470-488, 3' of the ribozyme cleavage site and 
acts as a positive control for the presence of CAT RNA, cleaved or uncleaved 
(Fig. 2.6 & 2.8). To ensure that any reduction in accumulation of CAT RT-PCR 
products was not due to ribozyme cleavage during RNA extraction or cDNA 
synthesis, parallel RT-PCR experiments were done on mock transfected total 
RNA to which in vitro transcribed CAT +/- ribozyme were added ( data not 
shown). Conditions were verified to be within linear range of amplification and 
were as follows: 520c 2 mins, 720c 40 mins, 30 cycles of 940c 40 secs, 520c 
2mins, 720c 3 mins followed by 720c for 15 mins. Amplification was carried 
out using either 1 + TAG or 2 + TAG primer pairs (Fig. 2.6). 1/6 of the PCR 
reactions were loaded on agarose gels and southern blotted to determine the 
extent of amplification of the CAT sequence by the two primer pairs. Filters 
were analysed by autoradiography and total counts were determined using an 
AMBIS image acquisition analyser. 
TRANSGENIC PLANT ANALYSIS 
The plasmids pGtRNAAs24 and pGtRNARz12 were linearised with 
Hindi II (see Fig. 2.2a) and inserted into Hindi II digested binary vector pGA470 
(obtained from Danny Llewellyn, CSIRO Division of Plant Industry). 
Transformation of these constructs into tobacco line,Nicotiana tabacum Tl68, 
was carried out by Judy Gaudron and Rob de Feyter (CSIRO Division of Plant 
Industry). A homozygous Tl68 plant expressing 35S promoter driven CAT, line 
7-41, was obtained from Danny Llewellyn. 
Figure 2.6: Method for PCR amplifying cleaved and/or uncleaved CAT mRNA isolated from 
N.tabacum plant cells and N.tabacum transgenic plants. For plant cells, first strand cDNA 
synthesis was carried out using the oligo dT-TAG primer (red). The 'TAG" sequence is an 18 
base unique sequence at the 5' end of the oligo dT-TAG primer which was used to prime off in 
subsequent PCR amplifications. Dual PCR reactions were carried out on each reaction pair. 
Primer 1 + TAG amplifies only uncleaved CAT mRNA. In contrast Primer 2 + TAG amplifies from 
both cleaved and/or uncleaved CAT mRNA. In the analysis of CAT mRNA from transgenic 
plants, primer 3 was used for first strand cDNA synthesis instead of the oligo-dT-TAG primer. 
Subsequent PCR amplifications for these reactions used primers 1 + 3 or 2 + 3. The numbers 
beneath primers 1, 2 and 3 indicate the priming sites on the CAT mRNA. 
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Figure 2.6 
2.13 {i) Crossing CAT and tRNAAs24 or tRNARz12 transgenic tobacco 
lines. 
Pollen from the CAT parent line, 7-41, was used to pollinate the stigma 
of emasculated tobaccos containing either the tRNAAs24 or tRNARz12 
transgenes. Emasculation was carried out as follows. Flowers on the 
transgenic tobaccos expressing the tRNAAs24 or tRNARz12 transgene were 
slit open prior to maturation and the five stamen removed by hand. Anthers 
from a single flower from the CAT 7-41 parent were used to pollinate each 
individual tobacco line expressing the tRNAAs24 or tRNARz12 transgenes. 
This was to minimise the chance that any variation in expression within the 
CAT parent would not cause variation in the crossed lines. Pollination was 
achieved by holding the pollen-containing anther between forceps and gently 
dusting the stigma. Pollinated flowers were tagged and left on the tobacco 
plant until the seed pod had fully developed and dried (approximately 6 weeks 
after pollination). At this time the pods were harvested and stored at room 
temperature until the seed was required for germination. 
{ii) Seed germination 
Transgenic tobacco seeds were planted in pots containing H20 soaked 
potting compost and covered with plastic film to provide a humid environment. 
Seeds were incubated at 200c -14 hour day 11 soc night for about 3 weeks 
until seedlings had reached 3-4 leaf stage. They were then transferred to H20 
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soaked potting compost (4 per pot) and transferred to the greenhouse (230C -
14 hour day/ 15°C night). Plants were left to grow for 2-3 weeks and then leaf 
samples taken for GUS assays, CAT assays, DNA and RNA extraction. 
{iii) Histochemical GUS assays 
GUS assays were carried out on single leaf samples from transgenic 
tobacco lines as follows. A leaf weighing approximately 100mg was 
homogenised using a Dynamax homogeniser in 200µ1 extraction buffer (1 OOmM 
Tris-HCI, pH 6.8; 10°/o glycerol; 5°/o p-mercaptoethanol). Samples were ground 
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by adding acid washed sand (a few grains) until homogenous. Samples were 
centrifuged at 14,000 rpm for 1 O minutes at 40c. 20µ1 of the supernate was 
transferred to an ELISA plate and mixed with 20µ1 of X-Glu solution (5mM 
ferricyanide; 5mM ferrocyanide; 0.3o/o Triton X-100; 0.1 M Phosphate buffer, pH 
7.0; 0.3°/o X-Glucuronidase). The reaction was covered and incubated at 370c 
overnight. 
(iv) CAT assays 
A leaf piece weighing approximately 100mg was collected from each 
plant assayed. Every attempt was made to collect leaf samples of similar age 
and size to reduce any internal variation in CAT activities. 300µ1 of extraction 
buffer (0.5M sucrose; 0.25M Tris; 0.1 °/o ascorbic acid; 0.1 °/o cysteine-HCI) and 
a few grains of acid washed sand was added to each 100mg leaf sample. The 
samples were ground until homogenised and then centrifuged at 14,000 rpm 
for 1 O mins at 40c. Protein concentrations were determined using Bradford 
protein reagent (Bio-rad). Each CAT assay contained 60µg total protein 
extract. This amount of extract was determined to be within the linear range for 
the CAT assay. Assays were carried out as described for the transient system 
(see section 2.12 (iii)) except that the reactions were incubated at 370c for 15 
mms. 
(v) DNA extraction 
Approximately 1 gm of leaf tissue was frozen in liquid nitrogen and 
ground, with sand, to a fine powder in a mortar and pestle. 15ml of extraction 
buffer was added (100mM Tris, pH 8.0; 50mM EDTA, pH 8.0; 100mM NaCl; 
1 °/o SDS;1 OmM P-mercaptoethanol) and the samples incubated at 550c for 10 
mms. 5ml of K acetate was added and the extract incubated on ice for 20 
mms. The samples were spun at 25,000 x g for 20 mins and the supernatant 
poured through Miracloth into 30 ml tubes. 10ml isopropanol and 1 ml 5M NH4 
acetate was added and the DNAs precipitated at -2ooc for 20 mins. The DNA 
was pelleted at 20,000 x g for 20 mins and the pellets washed in 70°/o ethanol. 
DNAs were dried and resuspended in 4ml H20. DNAs were further purified by 
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CsCI -ethidium bromide gradient centrifugation as follows: 3.9g CsCI and 240µ1 
of 1 Omg/ml ethidium bromide was added to 4 ml of DNA solution. The samples 
were transferred to quick seal tubes and spun at 55,000 rpm in VTl65.2 rotor 
(Beckman) for 16 hours. DNAs were removed from the gradient and dialysed 
against three changes of H20. Absorbance at 260nm was measured and the 
DNAs ethanol-precipitated and resuspended at 0.5mg/ml. 
(vi) PCR analysis 
1 Ong of total DNA from each tRNAAs24 and tRNARz12 transgenic line 
was analysed for the presence of tRNAAs24 and tRNARz12 transgenes by 
PCR. Primers t5 and t6 (Fig. 2. 7a and 2.8) were specific for the amplification of 
the tRNAAs24 transgene. Primers t7 and t6 (Fig. 2. 7b and 2.8) amplified the 
tRNARz12 transgene. Conditions of the PCR reactions were: (940C 1 '; 520c 
2'; 720c 3') x 25 cycles. PCR reactions were electrophoresed through 2°/o 
agarose containing 0.5µg/ml ethidium bromide in 1 xTBE buffer. DNAs were 
transferred to Hybond N+ and southern blotted to ensure the amplified 
sequence was the tRNA transgene. Transfer and southern hybridisation 
techniques were as described in 2.12 (v). 
(vii) RNA extraction 
Total RNA extractions were carried out as described for the transient 
system (see section 2.12(vi)) except for the following: 100mg of leaf tissue was 
ground in 1 ml of Trizol reagent. Due to the high concentration of 
polysaccharides in the leaf tissue, it was necessary to centrifuge the samples 
at 14,000 rpm for 10 mins prior to the addition of chloroform. The supernatant 
was transferred to a new tube and the chloroform added to the clarified sample. 
RNAs were treated with 4 units of DNAase I by incubating at 370c for 30 mins 
in the presence of 5mM Tris.HCI, pH 8.0; 5mM NaCl; 1 mM MgCl2; 1 OmM OTT; 
50 units RNasin. This was followed by phenol:chloroform-isoamyl alcohol 
(24:24: 1) extraction and 2. 7M LiCI precipitation. Finally, the RNAs were 
precipitated with ethanol/sodium acetate and resuspended at a concentration 
of 1 mg/ml. 
Figure 2.7 
a: Primers t6 and ts positions for PCR analysis of tRNAAs24 transgene and transcript in 
N.tabacum transgenic plants. The horizontal arrows show 5' to 3' direction for each primer; the 
left hand arrow shows start of RNA polymerase Ill tRNATyr transcript. Numbers in bold are sites 
on the complete tRNA sequence (i.e including 5' and 3' flanking sequences) derived from the 
T7 promoter, while numbers in italics represent the same sites on the tRNA Tyr transcript derived 
from the RNA polymerase Ill promoter (see also Fig. 2.2b). A (green), B (red) and yellow box are 
as described in Fig. 2.2a and 2.5. The vertical arrow shows position of As24 insertion (see also 
Fig . 2.2a). 
b: Primers t7 and t5 positions for PCR analysis of tRNARz12 transgene and transcript in 
N.tabacum transgenic plants. Numbers and arrows are as for tRNATyr and tRNAAs24; note that 
primer t5 is situated 21 bp further 3' than on tRNAAs24 although this primes off the same region 
of the tRNA. This is because the Rz12 insert is 21 bp larger than the As24 insert. 
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{viii) RT-PCR analysis of transgenic CAT mRNA 
RT-PCR analysis of CAT mRNA was carried out as for the transient 
system except for the following: 1 µg of total RNA was used for 1st strand cDNA 
reactions. 1st strand cDNA reactions were carried out using primer 3 (Fig. 2.6 
& 2.8). This primer annealed at positions 766 - 749 on the CAT sequence. 
Initial attempts to carry out RT-PCR using the oligo dT-TAG primer used in the 
transient system yielded "dimerised" bands which hybridised to the CAT probe. 
Although these bands were not fully investigated, we were able to ascertain 
that their presence was due to 1st strand synthesis using the oligo dT-TAG 
primer. When 1st-strand synthesis was carried out using primer 3, the 
subsequent PCR reaction yielded a single correct size amplification product. 
As primer 3 was an internal primer (and therefore could also anneal to any 
contaminating DNA) "no reverse transcriptase" (no RT) controls were carried 
out for each RT-PCR reaction. Although the RNA samples had been DNAase I 
treated (see RNA extraction), we still observed a small amount of amplification 
in the no RT reactions suggesting that contaminating DNA was still present in 
our total RNA samples. Since the amplification product corresponding to the 
no RT reaction was considerably less than that in the RT-PCRs, it was treated 
as background and subtracted from the plus reverse transcriptase reactions 
after quantitation of the southern hybridisation. 
{ix) RT-PCR analysis of transgenic tRNAAs24 and tRNARz12 RNAs 
Primers for the RT-PCR analysis of the expression of the tRNAAs24 and 
tRNARz12 transgenes were as for the PCR analysis (2.13 (vi) - see Figs. 2. 7 & 
2.8). To enable the specific amplification of the tRNAAs24 and tRNARz12 
RNAs, in the presence of the endogenous tRNATYr, primers t6 (As24 see Fig. 
2.7a) and t7 (Rz12 - see Fig. 2.7b) were used. RT-PCR for the tRNA 
transgenes was carried out as for the CAT mRNA (2.13 (viii)). The sequence 
of all tRNA primers is shown in Fig. 2.8. The priming position for ts includes 
the 13 base intron since this sequence is not removed from the tRNAAs24 and 
tRNARz12 transcripts during processing. 
Figure 2.8: Sequence of all primers used for CAT and tRNA PCR and RT-PCR analysis. See 
sections 2.12 (viii), 2.13 (vi), (viii) and (ix) and Figures 2.6 and 2.7 for specific details of use. 
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Primer t7 
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Figure 2.8 
CHAPTER 3 
ENHANCED IN VIVO EXPRESSION OF LONG RIBOZYME, ANTISENSE 
AND CAT TARGET SEQUENCES USING A SELF-REPLICATING VIRAL-
BASED VECTOR. 
INTRODUCTION 
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Three aspects of intracellular expression are important in the design of 
hammerhead ribozymes for their successful delivery to cells. These include the 
stability, concentration and intracellular location of both the ribozyme and 
substrate RNAs. One method for increasing the stability of the ribozyme 
transcript is to incorporate it within a long antisense sequence (Heinrich et al., 
1993; Homann et al., 1993; Perriman et al., 1993; Cameron and Jennings, 
1994). We have previously shown that a long antisense with four hammerhead 
domains targeting CAT mRNA, can reduce CAT activity in plant cells by up to 
54°/o. The analogous antisense sequence reduced CAT activity by 24°/o. To 
obtain this level of suppression, the ribozyme containing plasmid was delivered 
in 360 fold excess over the target expressing plasmid, indicating the need for 
high concentrations of the ribozyme molecule (Perriman et al., 1993). A similar 
level of CAT gene reduction has been obtained in animal cells using the same 
ribozyme sequence (Cameron and Jennings, 1994). 
The aim of the present study was to establish a system in which 
ribozyme-antisense gene expression could be increased without increasing the 
amount of ribozyme containing plasmid delivered to the cell. The approach 
chosen was a transient system in which the ribozyme-antisense (RzCAT), 
chloramphenicol acetyl transferase (CAT) target and control antisense (AsCAT) 
sequences were expressed from a self-replicating vector based on the plant 
virus, African cassava mosaic virus (ACMV). 
ACMV (Stanley, 1983) is a bipartite ssDNA virus which is a member of 
the geminivirus group (see Stanley, 1993 for review). Of these two DNA 
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components, DNA A can replicate autonomously and assemble virus particles 
in the absence of DNA B which is required for both cell-to-cell spread and 
symptom production. Thus, in a protoplast system, DNA A can be maintained 
without the presence of DNA B, and has been effectively developed as an 
independent, self-replicating vector (Ward et al., 1988). 
Geminiviruses have been shown to replicate to high levels within the 
nucleus of dividing plant cells (Harrison, 1985; Timmermans et al., 1992). 
Replication of ACMV is tightly linked to the cells replication cycle (Accotto et al., 
1993), therefore the advantages of using geminivirus-based vectors over a 
non-replicating approach include high level and prolonged expression of 
incorporated sequences. A 60-fold increase in expression level obtained from 
geminiviruses has been reported by Brough et al. (1992a) who assayed gene 
expression from replicating and non-replicating derivatives of another bipartite 
geminivirus, tomato golden mosaic virus (TGMV). This suggests that ribozyme 
or antisense sequences expressed in a geminivirus vector could be enhanced 
several fold over that obtained from the non-replicating vectors. 
The development of the ACMV viral vectors was dependent on the 
characterisation of a coat protein deficient mutant of ACMV A which did not 
affect replication or viral spread in plants (Stanley and Townsend, 1986). A 
727bp deletion, which removed most of the coat protein gene, was infectious 
when replaced with the CAT gene (Ward et al., 1988). In addition, high levels 
of CAT expression were detected, thus displaying the efficacy of ACMV A as 
an autonomously replicating vector for expressing foreign gene sequences in 
plant cells. 
The experiments outlined in this chapter were designed to evaluate the 
efficacy of expressing the RzCAT construct from an ACMV A self-replicating 
vector. This was done by replacing the coat protein sequence of ACMV A with 
a pUC19-derived polylinker (see materials and methods; Fig. 2.1 a). CAT 
target, RzCAT and AsCAT sequences were then sub-cloned into this region 
, I 
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and expressed using the endogenous RNA polymerase 11 coat protein promoter 
and polyadenylation signals ( see Fig. 2.1 b & c). 
RESULTS 
In vitro cleavage assays of the RzCAT ribozyme used in this study were 
published in Perriman et al. (1993). These results showed that, when this 
ribozyme was present in a 6-fold molar excess over the CAT target, the t1 /2 ( 
i.e. the time required for half of the available substrate to be cleaved) was 18 
minutes at 370c. When expressed in a 360-fold excess in the transient 
system, CaMV35S driven RzCAT (35SRzCAT) was able to reduce CAT activity 
by up to 52°10; 30°10 more than that observed for the analogous AsCAT 
(35SAsCAT) construct. 
To determine if the self-replicating ACMV vector could increase and 
prolong gene expression, CAT activity was compared from either non-
replicating 35SCAT or replicating ACMVCAT constructs (see Fig. 2.1 b). 
3.1 Comparison of CAT activities from pJ35SCATN and pACAT vectors 
Nicotiana tabacum protoplasts were electroporated with 5µg of either 
pACAT or pJ35SCATN constructs. Aliquots were removed at 1, 3, 5 and 8 
days post transfection and assayed for relative CAT activities. Across three 
independent experiments pACAT expression increased 30 fold from 1 to 3 days 
and maintained this level of expression to the final time point of 8 days. In 
contrast, pJ35SCATN expression was maximum at 1 day, halved by three days 
and equivalent to background levels at 5 and 8 days (Fig. 3.1 ). A comparison 
of CAT activities when both constructs were showing maximum expression, i.e. 
pJ35SCATN at 1 day and pACAT at 5 days, showed that expression from the 
pACAT vector was approximately 19-fold greater than that from the 
pJ35SCATN construct. Thus, the pACAT vector was able to confer a 19-fold 
increase in CAT expression levels, and to maintain this level of expression for 
up to 8 days post transfection. 
Figure 3.1: Time course of CAT activities from pJ35SCAT and pACAT constructs. Relative 0/o 
acetylations (y) are plotted against days post transfection (x). The table shows mean and 
standard errors for the two constructs at 1 (red), 3 (yellow), 5 (white) and 8 (blue) days after 
transfection into N.tabacum plant cells. 
Figure 3.2: Example of replication of ACMVCAT constructs in vivo. Southern blot analysis of 
pACAT DNA isolated from N.tabacum plant cells 0, 1, 3, 5 and 8 days post transfection. The 
blot, probed with radiolabelled CAT sequence, shows Dpnl and Mbol digestion for each time 
point. The lanes labelled 1-10 represent the following for pACAT analysis: lane 1, 1 day Dpnl; 
lane 2, as for lane 1 but Mbol; lane 3, 3 day Dpnl; lane 4, as for lane 3 but Mbol; lane 5, 5 day 
Dpnl; lane 6, as for lane 5 but Mbol ; lane 7, 8 day Dpnl ; lane 8, as for lane 7 but Mbol; lane 9, 
plasmid pACAT Dpnl ; lane 10, as for lane 9 but Mbol. The DNA products of digestion by 
restriction endonucleases are: CAT 1, bacterial gene for chloramphenicol resistance from 
pACAT construct, this fragment is lost as ACMVCAT replicates and accumulates (see Fig. 2.1 a 
and section 2.1 for further details); CAT 2, CAT target sequence insert; HMW, undigested 
pACAT sequence. 
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As further evidence of autonomous replication of pACAT, DNA was 
isolated from transfected protoplasts and analysed for the replicated 
ACMVCAT sequence. Isolated DNA was digested with methylation sensitive 
isoschizomers, Dpnl and Mbol. Dpnl cleaves only dam methylated DNA, as 
recovered from E.coli, while Mbol can digest only unmethylated sequence such 
as DNA replicated in plant protoplasts. The bacterial CAT gene, expressed 
from the p129C insert (see Fig. 2.1 a and CAT 1 in Fig. 3.2), does not present 
difficulty in this analysis as it migrates as a distinct band and is lost during 
ACMV replication. As shown in figure 3.2, replicated forms of the pACAT 
construct were evident at 3, 5 and 8 days post transfection showing that 
pACAT replication can be maintained for up to 8 days post transfection. 
3.2 Co-transfection of ACMVAsCAT/RzCAT with ACMVCAT constructs. 
The ACMV vector system was capable of producing increased and 
extended levels of expression over that obtained with the non-replicating 
vector. However, the pACAT construct did not increase its expression until 
three days post transfection, at which point CAT activity from the pJ35SCATN 
construct was reduced by 50°/o. As CAT protein has an intracellular half-life of 
about 30 hours (Thompson et al., 1991 ), the CAT enzyme activity observed 
after 3 days in the pJ35SCATN transfected cells (see Fig. 3.1) was probably 
derived from residual protein rather then newly translated CAT protein. It was 
thus decided to use the ACMV vector to deliver both target and ribozyme or 
antisense sequences. In this way the co-transfected molecules would be 
actively transcribing and expressing at the same time. 
A series of five independent experiments were carried out in which 5µg 
of pACAT target was co-transfected together with 15µg of either a control 
construct, or the pAAsCAT or pARzCAT constructs. Transfected cells were 
assayed for relative CAT activities at both one and three days post transfection. 
There was no significant difference in the inhibition of CAT activity in the 
presence of the pAAsCAT or the pARzCAT constructs at either time point. At 
Figure 3.3: Relative expression of CAT gene in the presence of pApoly (control - red), 
pAAsCAT (antisense - yellow), or pARzCAT (long ribozyme - green) in N.tabacum plant cells. 
Shown are the averaged results from 5 independent experiments assayed either 1 or 3 days 
post transfection. Each bar represents the mean relative 0/o acetylation observed from 5µg of 
pACAT, on addition of 15 µg of either pAAsCAT antisense or pARzCAT long ribozyme, when 
control CAT expression is normalised at 100°/o. Standard errors are shown for each construct 
pairing at both time points. Each experiment involved at least triplicate samples of each of the 
three construct combinations: CAT+ control, CAT+ antisense, and CAT+ long ribozyme. 
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one day post transfection, both constructs reduced CAT activity to around 50°/o 
of control values while by three days CAT activity had further decreased to 35°/o 
of control values (Fig. 3.3). Analysis of co-transfected protoplasts at five days 
post transfection showed that the 35o/o level of reduction was maintained ( data 
not shown). 
3.3 Altering the ratio of pARzCAT/pAAsCAT to pACAT. 
The ratio of electroporated pARzCAT or pAAsCAT : pACAT was 
changed to determine if this altered the efficiency of inhibition induced by either 
construct. This was based on the work of Cameron and Jennings (1994) who 
had used the same ribozyme and antisense sequences in animal cells. They 
observed an increase in the effectiveness of the RzCAT construct in reducing 
CAT activity, when the ratio of ribozyme or antisense : substrate was reduced. 
The ratio of input ACMV constructs expressing RzCAT or AsCAT : CAT 
was reduced from 3: 1 to 2: 1 or 1: 1, and CAT activities assayed three days post 
electroporation. The reduction of RzCAT or AsCAT : CAT had no effect on the 
level of reduction of CAT gene expression with either the ACMV-ribozyme or 
ACMV-antisense construct (Fig. 3.4). 
3.4 Replication of pARzCAT and pAAsCAT. 
To show that replication of the pAAsCAT and pARzCAT constructs was 
occurring, DNA was isolated from transfected plant cells three days post 
transfection and assayed with methylation sensitive isoschizomers, in an 
identical manner to that used to monitor pACAT replication in section 3.1. Both 
constructs showed Mbol digestible molecules indicating that replication was 
occurring in both instances (Fig. 3.5). Hence, the lack of enhanced inhibition 
by the pARzCAT construct did not appear to be due to a lower replication level 
of this sequence. 
Figure 3.4: Altering the ratio of pACAT : pAAsCAT antisense or pARzCAT ribozyme plasmid 
transfected into N.tabacum plant cells. As for Fig. 3.3, the relative expression of pACAT is 
shown in the presence of control (red), antisense (yellow) and long ribozyme (green) 
constructs. The amount of pACAT construct was fixed at 5 µg while the pAAsCAT and 
pARzCAT were reduced to either 1 Oµg (i.e. 2 : 1) or 5 µg (i.e. 1 : 1 ). CAT activities were 
measured 3 days post transfection. 
,JI• 
I 
I 
r 
Ii 
!1,· 
11 ' 
I, 
I 
I 
JI 
JI 
; I 
I 
-n
 
-
·
 
c
c
 
C
:
 
.
.
.
.
 
C
D
 
w
 
.
 
.
,
:
.
 
p
A
C
A
T
 
I
\
.
)
 
p
A
A
s
C
A
T
 
~
 
p
A
R
z
C
A
T
 
p
A
C
A
T
 
-
-
"
 
p
A
A
s
C
A
T
 
-
-
"
 
p
A
R
z
C
A
T
 
r
e
l
a
t
i
v
e
 
0
/
o
 
a
c
e
t
y
l
a
t
i
o
n
s
 
-
-
"
 
-
-
"
 
I
\
.
)
 
w
 
~
 
r
n
 
m
 
~
 
o
o
 
©
 
o
 
0
 
0
 
0
 
0
 
0
 
0
 
0
 
0
 
0
 
0
 
o
 
Figure 3.5: Examples of the replication of pAAsCAT (antisense) and pARzCAT (long 
ribozyme) constructs. Southern blot analysis of DNAs isolated three days post transfection. As 
for figure 3.2, the blots, probed with radiolabelled CAT sequence, show Opnl and Mbol 
digestion for pAAsCAT or pARzCAT transfected N.tabacum plant cells. The lanes labelled 1-5 
represent the following: lane 1, plasmid pAAsCAT Dpnl; lane 2, pAAsCAT Opnl; lane 3, as for 
lane 2 but Mbol; lane 4, pARzCAT Dpnl; lane 5, as for lane 4 but Mbol. The DNA products are: 
CAT 1, as in figure 3.2; RzCAT, pARzCAT long ribozyme insert; AsCAT, pAAsCAT 
antisense insert; HMW, undigested pAAsCAT or pARzCAT sequence. 
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DISCUSSION 
The results show that sequences delivered within the replicating vector, 
pACMV, have increased and prolonged expression in dividing plant cells. 
Analysis of CAT activity expressed from the coat protein promoter of the 
pACMV vector showed that expression was increased up to 19-fold over that 
obtained from a non-replicating 35S driven construct. Additionally, this high 
level expression was maintained for the 8 day duration of the experiment. 
Autonomous replication of the recombinant pACMV vector, containing the CAT 
open reading frame, was also observed with replicative forms of the ACMVCAT 
construct maintained to 8 days. In contrast, the non-replicating 35SCAT 
construct, produced maximum CAT activity at around 24 hours post 
transfection and was reduced to half of this level by three days. Consequently, 
CAT, as well as the ribozyme and antisense constructs, were all expressed 
from the pACMV vector. 
In contrast to previous work using the non-replicating 35S vector, in 
which the RzCAT construct reduced CAT activity to a significantly greater level 
than the AsCAT sequence (Perriman et al., 1993), the co-transfection of 
pARzCAT or pAAsCAT sequences with pACAT, resulted in equivalent levels of 
CAT gene reduction. This suggested that an antisense mechanism and not 
ribozyme cleavage was the primary mode of gene inactivation in the present 
study. 
One possible explanation, which could account for the difference 
between the data presented here and our previous results, is the greater 
effectiveness of the CAT antisense to reduce CAT activity when expressed 
from pACMV, rather than the 35S vector. The action of the antisense RNA in 
the present study may have masked any apparent cleavage by the ribozyme 
construct. 
Alternatively, the increased level of RNA transcripts from the ACMV 
vectors (i.e. both CAT and AsCAT or RzCAT) could affect the interactions 
between these mRNAs. For example, it is possible that, instead of enhancing 
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in vivo ribozyme-cleavage rates, higher levels of both CAT and RzCAT 
transcripts within the cell could increase the probability that the two RNAs 
interact in various "inactive" conformations (i.e. either inter- or intramolecular) 
thus diminishing the chances of forming the active CAT/RzCAT hybrid (Fedor 
and Uhlenbeck, 1990; Heus et al., 1990; van der Vlugt et al., 1993). Such 
interactions, although not able to enhance the reduction of CAT gene 
expression by ribozyme mediated cleavage, could still reduce expression by 
blocking translation in the same way as an antisense mechanism. 
Another possible explanation may lie in the different ratios of ribozyme: 
substrate plasmid used in each study. Using the 35S vector, a 360-fold excess 
of ribozyme to substrate plasmid provided conditions in which ribozyme-
mediated CAT gene inhibition was greater than control antisense delivered at 
the same molar excess (Perriman et al., 1993). In the present study, using the 
pACMV vector, this plasmid ratio was lowered to 3: 1, 2: 1 or 1: 1. Under these 
conditions, the antisense increased in effectiveness, and both the antisense 
and ribozyme constructs reduced CAT activity to equivalent levels. These 
results are in contrast with the data of Cameron and Jennings (1994). Using 
the same ribozyme, antisense and target sequences in animal cells, they found 
that a > 1 o3 excess of the RzCAT or AsCAT RNA reduced CAT activity to the 
same level, whereas decreasing this ribozyme/antisense : substrate ratio to - 4 
: 1, led to an increased level of suppression by the RzCAT, compared with the 
AsCAT construct. 
Although all three studies used the same ribozyme, antisense and target 
sequences, several differences do exist. The different promoter and 
termination signals used within each study means that the constructions 
contain different 51 and 31 untranslated sequences. These sequences may alter 
the relative transcript stabilities within each system. In addition, the different 
promoters probably produce different transcript levels, leading to varied RNA 
concentrations. These variations between systems could produce the 
contrasting results obtained. It is possible that to obtain ribozyme-mediated 
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CAT inhibition using a ribozyme of this type, specific RNA concentrations of the 
substrate and/or ribozyme RNAs are required. The determination of RNA 
levels in both animal and plant systems would help to address this. In addition, 
determining the RNA levels would make the comparison between the ACMV 
and 35S delivery mechanisms easier to interpret, since it would indicate how 
critical the overall transcript levels are in obtaining CAT mRNA inhibition. 
To minimise the influence of antisense effects in reducing CAT activity, 
the following chapters describe experiments in which the pACMV vector was 
used to express ribozyme sequences containing much shorter helices I and Ill. 
To enhance the stability of these molecules, ribozyme and antisense 
sequences were embedded within a plant tyrosine-tRNA. 
CHAPTER 4 
IN VITRO ANALYSIS OF tRNA-EMBEDDED RIBOZYME & ANTISENSE 
RNAs 
INTRODUCTION 
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The inability of the long ribozyme to enhance antisense reduction of CAT 
gene expression, prompted us to investigate other means of obtaining 
ribozyme mediated inhibition in plant cells. Two single hammerhead 
ribozymes, both targeting GUC-464 (see Fig. 2.1 b) and containing either 24 
(Rz12) or 60 (RzCA) bases of hybridisation to this region of the CAT RNA, 
were developed. These were designed to reduce the influence of antisense 
effects and possible inactive conformations of the ribozyme and target RNAs. 
One potential disadvantage of short ribozyme transcripts such as these, 
is their intracellular instability (Cameron and Jennings, 1989). To address this 
aspect, the ribozymes were embedded within the anticodon loop of a tobacco 
tyrosine tRNA (tRNATYr-Stange and Beier, 1986). These chimeric constructs 
may also provide a further means of enhancing ribozyme expression through 
the use of the endogenous tRNA promoter. This chapter will describe the in 
vitro analysis of these tRNATyr_ribozymes, as well as the control tRNA-
antisense sequences. 
Unlike mRNAs which are transcribed by RNA polymerase II, tRNAs, as 
well as 5s rRNA, U6 snRNA and several other small RNAs, are transcribed by 
RNA polymerase Ill (for review see Geiduschek, 1988). RNA polymerase Ill 
transcripts contain two highly conserved sequence blocks, A and B, 
downstream of the transcription start site, both of which are essential for active 
transcription. A and Bare separated by a region ranging from 31 to 93 bases 
for different tRNAs. Engineered A-B box separations have extended this range 
to 21-365 bases (Baker et al., 1986; Fabrizio et al., 1987), however, this 
separation may vary for different tRNA sequences. Thus, the ribozymes were 
inserted between the A and B boxes and correspond to the anticodon loop of 
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the tobacco tRNATyr molecule. This region of a methionine tRNA (tRNAMet) 
had been previously adapted to successfully deliver a ribozyme to Xenopus 
oocytes (Cotten and Birnsteil, 1989) (Fig. 4.1 ). 
As the main objective of this study was to express these recombinant 
tRNAs in vivo, one aspect of the in vitro assays involved the analysis of 
maturation of both the wildtype (i.e. the tRNA without any inserts) and 
recombinant tRNAs. The steps involved in the maturation of tRNAs follow a 
sequential series of events (Fig. 4.2). Initially, the primary tRNA transcript is 
processed at its 5' and 3' ends. Following this, a 5'CCA 3' triplet is ligated to 
the mature 3' end. In most eukaryotic tRNAs, these two steps are all that is 
required for the formation of a mature tRNA. However tRNA Tyr, such as the 
tobacco tRNATyr used in this study, contain an endogenous intron which 
requires an additional processing step. In these tRNAs, the intron is spliced 
and the two tRNA halves are religated to form a mature tRNATyr molecule (Fig. 
4.2 - van Toi et al., 1987). 
Complete maturation of the tRNA transcript is probably essential for 
export from the nucleus to the cytoplasm {Tabian et al., 1985). Therefore, the 
loss of any one of the processing steps may be critical in determining the 
intracellular location of that tRNA. This could determine the types of substrate 
RNAs a chimeric tRNA-ribozyme could successfully target and inactivate. For 
example, the genome of RNA viruses, which are exclusively cytoplasmic, may 
not be accessible to a tRNA-ribozyme which is maintained in the nucleus. For 
this reason, the efficiency of each of the processing steps was analysed for 
both recombinant and wildtype tRNA Tyr sequences. This work involved the use 
of a wheatgerm extract, which can accurately process and splice tobacco 
tRNATyr into the mature form (Stange and Beier, 1987). 
The second aspect of the in vitro analysis involved only the ribozyme 
sequences. These experiments were designed to analyse the effect that the 
additional tRNA Tyr sequences had on the in vitro cleavage rates catalysed by 
Rz12 and RzCA ribozymes. In addition, the effect that processing of the 
Figure 4.1: Sequence of tobacco tyrosine-tRNA (tRNA Tyr) used to express ribozyme and 
antisense sequences. Nucleotides in green are the A box, red are the B box, and yellow are a 
13 base intron. Nucleotides 'If at positions 35 and 55 are modified nucleotides; 
pseudouridines. The arrow indicates the site of insertion of ribozyme or antisense sequences 
within the anticodon loop. Nucleotide numbering is for the mature tRNA sequence. The boxed 
region labelled "D stem" indicates one of the critical regions implicated in complete maturation of 
pre-tRNA Tyr sequences (see discussion). 
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red and intron in black. The numbers next to the vertical arrows refer to steps in the maturation 
process listed above the figure. 
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tRNATyr_ribozymes had on cleavage rates was also determined. The results of 
these in vitro analyses were used as a guide to the potential effectiveness of 
the Rz12 and RzCA ribozymes for subsequent in vivo applications. 
RESULTS 
4.1 Maturation of recombinant and wildtype tRNATyr transcripts in 
wheatgerm extracts. 
The maturation of the recombinant tRNATyr transcripts was determined 
by measuring the conversion of the recombinant pre-tRNATyr into putative 
mature products. This analysis established that the accumulation of putative 
mature tRNA Tyr products took place for all constructs and that these products 
were dependent upon the addition of wheatgerm extract (Fig. 4.3). 
The extent of processing of the recombinant tRNAs was determined by 
assaying the three processing steps. These are outlined below. 
4.2 Analysis of steps I and II - 51 and 31 processing and the addition of the 
51CCA 31 triplet to the mature 31 end. 
Steps I and II of the tRNATyr maturation pathway (see Fig. 4.2) were 
assayed by processing non-radioactive transcripts of each of the recombinant 
tRNAs. These processing reactions were incubated in the presence of p32_ 
CTP so that the addition of the S'CCA 31 triplet to the mature 31 end could be 
monitored. To ensure that the accumulated product band was equivalent to 
that observed in the original processing assays, radiolabelled recombinant 
tRNA Tyr transcripts were also processed and analysed alongside the non-
radioactive transcripts. As shown in figure 4.4 all the recombinant tRNA 
constructs processed to step II of the maturation pathway. 
4.3 Analysis of step Ill - splicing the endogenous 13 base intron. 
Complete processing of the recombinant tRNAs was assayed by first 
removing the 13 base intron from the wildtype and each of the five recombinant 
Figure 4.3: Analysis of the in vitro maturation of recombinant and wildtype tRNA Tyr transcripts 
using a wheatgerm extract. Radiolabelled in vitro transcripts of each of the 6 tRNA Tyr constructs 
(i.e. tRNA, tRNAp, tRNAAs24, tRNARz12, tRNAAsGUC, tRNARzCA) were incubated at 30°C 
for 1.5 hours in the presence (+ ; lanes 2, 4, 6, 8 and 10) or absence (lanes 1, 3, 5, 7 and 9) of 
the wheatgerm extract. Products were analysed· on 8°/o polyacrylamide/7M urea gels as outlined 
in materials and methods (section 2.11 ). Arrowed bands represent the following: P1, putative 
mature tRNA (wildtype); P2, putative mature tRNAp (+ polylinker); P3, putative mature 
tRNAAs24 (+ antisense, As24); P4, putative mature tRNARz12 (+ ribozyme, Rz12); PS, 
putative mature tRNAAsGUC (+ antisense, AsGUC); P6, putative mature tRNARzCA (+ 
ribozyme, RzCA); P7, processed 5' and 3' flanking sequences. 
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Figure 4.4: Analysis of the processing of recombinant and wildtype tRNA Tyr to step 2 of the 
maturation pathway (see Fig. 4.2). Lanes 1 -18 are as follows: lane 1, radiolabelled tRNA; lane 
2, radiolabelled tRNA+ wheatgerm extract; lane 3, tRNA+ wheatgerm extract+ radiolabelled 
CTP; lane 4, radiolabelled tRNAp; lane 5, radiolabelled tRNAp + wheatgerm extract; lane 6, 
tRNAp + wheatgerm extract+ radiolabelled CTP·; lane 7, radiolabelled tRNAAs24; lane 8, 
radiolabelled tRNAAs24 + wheatgerm extract; lane 9, tRNAAs24 + wheatgerm extract+ 
radiolabelled CTP; lane 10, radiolabelled tRNARz12; lane 11, radiolabelled tRNARz12 + 
wheatgerm extract; lane 12, tRNARz12 + wheatgerm extract+ radiolabelled CTP; lane 13, 
radiolabelled tRNAAsGUC; lane 14, radiolabelled tRNAAsGUC + wheatgerm extract; lane 15, 
tRNAAsGUC + wheatgerm extract+ radiolabelled CTP; lane 16, radiolabelled tRNARzCA; lane 
17, radiolabelled tRNARzCA + wheatgerm extract; lane 18, tRNARzCA + wheatgerm extract+ 
radiolabelled CTP. Arrowed bands are as in figure 4.3 and represent the following: P1, putative 
mature tRNA (wildtype); P2, putative mature tRNAp (+ polylinker); P3, putative mature 
tRNAAs24 (+ antisense, As24); P4, putative mature tRNARz12 (+ ribozyme, Rz12); PS, 
putative mature tRNAAsGUC (+ antisense, AsGUC); P6, putative mature tRNARzCA (+ 
ribozyme, RzCA); P7, processed 5' and 3' flanking sequences. 
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constructs. These constructs are differentiated from the original tRNA 
sequences by an 'T' following the construct name. A comparison of the 
processing of intron-plus (i+) and intron-minus (i-) forms of each construct 
showed that none of the recombinant tRNAs were able to splice out the 13 
base intron (Fig. 4.5). In contrast, 8o/o of the wildtype tRNATyr sequence 
underwent complete processing (Fig. 4.6). 
4.4 Processing rates of intron and intronless recombinant tRNAs 
Although none of the recombinant tRNA Tyr underwent complete 
maturation, processing rates for all of the constructs were determined (Fig. 
4.6). For each recombinant tRNATYr, processing of the i- construct was more 
efficient than that of the corresponding i+ construct. Furthermore, the 
processing rates for the tRNAp construct (i+ and i-) were consistently higher 
than any of the other tRNAs (including the wildtype tRNATYr). 
As the insert size increased, the extent of processing for the 
recombinant tRNAs was reduced (Fig. 4.6). 
4.5 Analysis of in vitro cleavage efficiencies by tRNATYr-embedded and 
non-embedded Rz12 and RzCA ribozymes 
The in vitro cleavage efficiencies of the tRNA Tyr _embedded (i+ and i-) 
and non-embedded Rz12 and RzCA ribozymes were measured by the 
conversion of full length CAT transcript into the predicted 5' and 3' cleavage 
products. The analysis established that cleavage was dependent upon the 
addition of either the non-embedded or tRNATYr-embedded ribozyme 
sequences and that all six constructs cleaved the CAT RNA at the expected 
site (Fig. 4.7). 
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In three independent experiments, in which ribozyme was present in a 
six-fold molar excess, 72°/o and 38°/o of the CAT RNA was cleaved by the non-
embedded Rz12 and i+ tRNARz12 ribozymes respectively. In the same series 
of experiments, the RzCA ribozyme in the non-embedded and i+ tRNATyr_ 
Figure 4.5: Examples of in vitro analysis of processing of the intron-plus (i+) and intron-minus 
(i-) recombinant tRNA Tyr constructs to step 111 (i.e. splicing of the 13 base intron) using 
wheatgerm extract. The lanes 1-16 show the following radiolabelled recombinant tRNA Tyr 
transcripts: lane 1, tRNAAs241 (i-) + wheatgerm extract; lane 2, tRNAAs241(i-) ; lane 3, 
tRNAAs24 (i+) + wheatgerm extract; lane 4 tRNAAs24 (i+); lane 5, tRNApl (i-) + wheatgerm 
extract; lane 6, tRNApl (i-); lane 7, tRNAp (i+) + wheatgerm extract; lane 8, tRNAp (i+ ); lane 9, 
tRNARz12 (i+) ; lane 10, tRNARz12 (i+) + wheatgerm extract; lane 11 , tRNARz121 (i-); lane 12, 
tRNARz121 (i-) + wheatgerm extract; lane 13, tRNAAsGUC (i+); lane 14, tRNAAsGUC (i+) + 
wheatgerm extract; lane 15, tRNAAsGUCI (i-); lane 16, tRNAAsGUCI (i-) + wheatgerm extract. 
The processed products are: P2, "mature" tRNAp (+ intron); P2A, "mature tRNApl (- intron); 
P3 , "mature" tRNAAs24 (+ intron); P3A, "mature" tRNAAs241 (- intron); P4, "mature" 
tRNARz12 (+ intron); P4A, "mature" tRNARz121 (-intron); PS, "mature" tRNAAsGUC (+ intron); 
PSA, "mature" tRNAAsGUCI (- intron); P7, processed 5' and 3' flanking sequences. 
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embedded forms, induced 32°/o and 26°/o cleavage respectively (Fig. 4.8). In 
addition, the cleavage rates induced by the i- tRNA-ribozymes were also 
determined. The i- tRNARz12 ribozyme had a slightly increased rate of 
cleavage over that of the i+ tRNARz12 (48°/o compared with 38°/o). In contrast, 
both the i+ and i- tRNARzCA ribozyme produced similar cleavage rates (32°/o 
for i- and 27°/o for i+). No cleavage products were produced by either of the 
non-embedded, i+ or i- tRNATYr-antisense constructs (data not shown). 
A mutant CAT transcript, CM2, which contained an inactive cleavage 
site (GUG instead of GUC; see Fig. 2.3; Perriman et al., 1992) remained 
uncleaved in the presence of any one of the six ribozyme sequences (Fig. 4.7). 
4.6 In vitro cleavage efficiencies of processed and unprocessed 
tRNARz12 and tRNARzCA ribozymes 
The in vitro cleavage efficiencies of the processed i+ and i- tRNARz12 
and tRNARzCA ribozymes were also determined. These tRNATyr_ribozyme 
constructs were processed and precipitated prior to the cleavage assays. 
Figure 4.6 shows that, in vitro, 15-20°/o of the tRNARz12 and tRNARzCA 
sequences are processed (to step 11). Therefore, the cleavage reactions 
involving these processed tRNATyr_ribozymes contained a mix of processed 
and unprocessed tRNA Tyr sequences. 
For the tRNARz12 ribozyme, pre-processing of the i+ ribozymes 
significantly increased cleavage rates (38°/o for unprocessed and 58°/o for 
processed) while the cleavage rates for the i- ribozyme were marginally 
reduced (48°/o for unprocessed and 40°/o for processed-Fig. 4.9). In contrast, 
processing of both the i+ and i- forms of the tRNARzCA ribozyme produced 
significantly reduced cleavage rates (Fig. 4.9). 
DISCUSSION 
This chapter has investigated the in vitro efficiencies of a series of short 
ribozyme and antisense constructs which have been embedded within a 
Figure 4.7: In vitro hammerhead-ribozyme mediated cleavage of CAT and CM2 (mutant CAT) 
targets by non-embedded and tRNA-embedded ribozymes. An autoradiograph of a dried 
electrophoresis gel containing products of in vitro cleavage reactions. The in vitro transcripts of 
the CAT and CM2 substrates, but not the ribozymes were radioactively labelled. Reaction 
conditions were 1 hour at 30°C. The lanes labelled 1-7 for both CAT and CM2 represent: 1, 0.5 
pmole CAT/CM2 RNA incubated alone; 2, 0.5 pmole CAT/CM2 RNA+ 3 pmole Rz12 (non-
embedded); 3, 0.5 pmole CAT/CM2 RNA+ 3 pmole tRNARz12 (tRNA-embedded [i+]); 4, 0.5 
pmole CAT/CM2 RNA+ 3 pmole tRNARz121 (tRNA-embedded [i-]); 5, 0.5 pmole CAT/CM2 
RNA+ 3 pmole RzCA (non-embedded); 6, 0.5 pmole CAT/CM2 RNA+ 3 pmole tRNARzCA 
(tRNA-embedded [i+]); 7, 0.5 pmole CAT/CM2 RNA+ 3 pmole tRNARzCAI (tRNA-embedded [i-
]). The RNA species are as follows: Sub, CAT/CM2 target; S'P, cleavage product 5' of the 
target site; 3'P, cleavage product 3' of the target site. 
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tobacco-tRNATYr. The analyses showed that all the recombinant tRNAs could 
successfully process the 5' and 3'ends, and add the 5' CCA 3' triplet sequence 
to the 3' end (Fig. 4.4). However, in all cases, the 13-base intron contained 
within the recombinant tRNATyr was not spliced from the tRNA intermediates 
(Fig. 4.5). 
To obtain intron splicing of tRNATYr, critical secondary and tertiary 
interactions must be maintained. Disruption of base-pairing within the 
anticodon stem structures of three eucaryotic tRNATyr have been shown to 
reduce intron splicing efficiency (Shapero and Greer, 1992; Szweykowska-
Kulinska and Beier, 1991 ). The intron secondary structure has also been 
implicated in determining the specificity of splicing (Stange et al., 1992). In 
addition, the nucleotides located within the D stem (see Fig. 4.1 ), as well as the 
correct formation of this region have also been shown to influence intron 
splicing (Shapero and Greer, 1992; Stange et al., 1992). 
In a similar design to the constructs used in this study, Shapero and 
Greer (1991) produced in vitro transcripts of a yeast tRNATyr from an upstream 
E.coli RNA polymerase. When comparing these transcripts with those made in 
vitro by yeast RNA polymerase Ill, they observed a greatly reduced rate of 
intron splicing for the E.coli RNA polymerase transcripts. This reduced level of 
intron splicing could be restored to that observed for the yeast RNA polymerase 
Ill transcripts after a high temperature pre-incubation in 20mM MgCl2, 
suggesting that a conformational transition of E.coli RNA polymerase 
transcripts, but not yeast RNA polymerase Ill transcripts, was required 
(Shapero and Greer, 1991 ). These pre-incubation conditions had no effect on 
intron splicing of recombinant tRNATyr in our study (data not shown), 
suggesting that even under optimal splicing conditions these tRNAs cannot 
form the correct structure for binding and activation of the tRNA endonuclease. 
The lack of splicing, and therefore complete maturation, of the 
recombinant tRNAs is likely to also influence the transport of these chimeric 
sequences from the nucleus to the cytoplasm. Recent work analysing a 
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tRNAMet sequence in Xenopus oocytes found that mutations which affected 
tRNA processing also affected transport. It was concluded that tRNA transport, 
like maturation must see the correct tRNA shape (Tobian et al., 1985). This is 
further supported by the results of Cotten and Birnsteil (1989) who embedded a 
ribozyme within the anticodon loop of the same Xenopus tRNAMet. While 
tRNAMeLribozyme transcripts were readily found within the nucleus, no 
transcript was detected in cytoplasmic extracts. These results suggest that the 
tRNATyr_ribozyme and tRNATYr-antisense constructs used in this study are also 
likely to be maintained in the nucleus. 
All recombinant tRNA Tyr constructs demonstrated processing to step 11 of 
the maturation pathway (see Fig. 4.4). A slight decrease in processing 
efficiencies to this step were observed when the insert size was 85 bases or 
larger. The processing rates for the i- constructs when compared to the i+ 
sequences were uniformly increased. In addition, the construct containing the 
1 Obp polylinker, tRNAp, consistently produced a greater percentage of 
processed forms than any of the other constructs, including the wildtype 
tRNATyr sequence (Fig. 4.6). 
The analysis of the cleavage rates catalysed by the non-embedded and 
tRNATYr-embedded ribozymes suggested that the secondary and tertiary 
interactions involving these molecules can also have an effect on the cleavage 
rates. Embedding the Rz12 ribozyme in the tRNATyr sequence reduced 
cleavage rates from 72°/o to 38°/o (Fig. 4.8). In contrast, cleavage rates in the 
presence of the RzCA ribozymes were only marginally reduced from 32°/o to 
27°/o, upon embedding within the tRNATyr sequence (Fig. 4.8). The extended 
length of the hybridisation sequences conferred by the RzCA ribozyme 
probably means that this sequence is able to form the active hybrid at the same 
rate, in the presence or absence of the tRNA Tyr sequences. 
This is supported by the data for the i- and, in part, by the processed 
tRNATyr_ribozymes. The removal of the intron from the tRNARz12 ribozyme 
increased the rates of cleavage, suggesting that the presence of this additional 
'I 
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sequence in the original construct was inhibiting the formation of the active 
substrate-ribozyme hybrid. The cleavage rates of the i+ tRNARz12 ribozyme 
were further increased by processing the transcript, thus removing 5' and 3' 
nucleotides and further reducing the surrounding sequence which could 
interfere with hybrid formation. For the tRNARzCA ribozyme, the removal of 
the intron had little effect on the rate of cleavage, again suggesting that the 
substrate-ribozyme hybrid for the RzCA ribozyme was unaffected by the 
tRNATyr sequence (Fig. 4.8). 
One unexpected result was the small decrease in cleavage rates 
observed when the processed form of the i- tRNARz12 ribozyme was the active 
molecule. Previous results had suggested that cleavage by the Rz12 ribozyme 
was increased when the surrounding 5' and/or 3' nucleotides decrease. The 
processed i- tRNARz12 ribozyme has the least number of nucleotides 
surrounding the ribozyme sequence and therefore was expected to induce 
higher rates of cleavage than the other tRNARz12 constructs. In addition, 
processing of both the i+ and i- tRNARzCA ribozymes dramatically reduced 
cleavage rates induced by both these molecules. As was the case with the 
tRNARz12 ribozyme, the cleavage rates for the processed i- tRNARzCA 
ribozyme were lower than the i+ form (Fig. 4.9). 
Although only a small percentage of the tRNATyr_ribozymes were 
observed to undergo processing, these results suggest that this action can 
have a significant effect on the cleavage rates. It is possible that during 
processing of some of the tRNATyr_ribozymes, modified nucleotides were 
introduced at sites within the hammerhead sequence thereby reducing its 
activity. It is known that approximately 10°/o of the nucleotides within eucaryotic 
tRNA molecules are post-transcriptionally modified. This modification generally 
involves specific nucleotides and does not appear to be a random process 
(McClain, 1993), however, it is unknown what the effect of additional 
nucleotides such as the ribozyme sequences in this study would have on the 
position and extent of the nucleotide modification process within tRNAs. This 
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explanation is possible for the tRNARzCA ribozymes as the processed forms of 
both the i+ and i- constructs showed greatly reduced cleavage rates. For the 
tRNARz12 ribozyme, however, only the processed i- construct showed reduced 
cleavage rates. It is unlikely that nucleotide modifications affecting cleavage 
rates would occur in the i- but not the i+ forms of this ribozyme. 
Processing of the i- forms of both tRNA-ribozymes reduced cleavage 
rates. This suggests that the synthetic removal of the intron and the 
subsequent processing of these tRNA-ribozymes has affected the ability of the 
ribozyme to induce cleavage. For the tRNARzCA ribozymes, the additive effect 
of the modified nucleotides and removing the intron could explain the further 
reduction observed when the i- tRNARzCA ribozyme was processed. 
Extensive further analysis would be required to determine exactly what aspect 
of the maturation pathway of these tRNATyr_ribozymes is affecting their 
subsequent rates of cleavage. 
These in vitro assays have provided valuable information regarding the 
potential effectiveness of the Rz12 and RzCA ribozymes expressed as non-
embedded or tRNATYr-embedded ribozymes. The cleavage assays involving 
the tRNA Tyr_ribozymes and non-embedded ribozymes have suggested that the 
tRNATyr sequence can reduce the rate of cleavage of a short (Rz12) ribozyme 
but have little effect on a longer (RzCA) ribozyme. Additional information for 
the tRNATyr_ribozymes was obtained by processing the molecules prior to 
cleavage analyses. The tRNARz12 i+ ribozyme showed increased rates of 
cleavage upon processing, while the tRNARz12 i- showed a small decrease. In 
contrast, cleavage rates for the tRNARzCA i+ and i- constructs were 
significantly reduced following processing. On the basis of these in vitro 
results, the tRNARzCA and i- tRNARz12 ribozymes may not provide the most 
effective means of reducing target gene expression in vivo. For this reason, 
only the Rz12 and tRNARz12 ribozymes, and their corresponding antisense 
constructs, As24 and tRNAAs24, were tested in subsequent in vivo assays. 
CHAPTER 5 
EXPRESSION OF tRNATyr_EMBEDDED AND NON-EMBEDDED 
RIBOZYME AND ANTISENSE SEQUENCES IN PLANT CELLS 
INTRODUCTION 
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While hammerhead ribozymes have been used to cleave many target 
RNAs in vitro (e.g. Haseloff and Gerlach, 1988; Saxena & Ackerman, 1990; 
Lamb and Hay, 1990; Evans et al., 1992; Mazzolini et al., 1992), there has 
been much less success in ribozyme mediated gene inactivation in vivo (see 
Fig. 1 .13 for examples). This is particularly the case for plant systems with only 
four reports of ribozyme-induced gene reduction (Steinecke et al., 1992, 1994; 
Perriman et al., 1993; Wegener et al., 1994). 
As outlined in chapter 1 , several animal-based studies have now 
developed actively transcribing tRNA sequences for in vivo ribozyme 
expression (Cotten and Birnsteil, 1989; Yuyama et al., 1992; Shore et al., 1993; 
Bouvet et al., 1994; Kandolf, 1994; Baier et al., 1994). While these studies 
have been successful in achieving target gene reduction and high level RNA 
polymerase 111 expression of tRNA-ribozymes, the lack of antisense or inactive 
ribozyme controls has meant that the source of target gene reduction has not 
been clearly established. The aim of this research was to investigate the 
effectiveness of a tRNA-ribozyme or control tRNA-antisense sequence for 
reducing target gene expression in plant cells. 
An additional control, in which the GUC-464 triplet on the CAT target 
was mutated to a non-cleavable GUG (CM2; Perriman et al., 1992; see Fig. 
2.3), provided a further means of differentiating ribozyme and antisense 
mediated inhibition in this system. In vitro cleavage assays (see Fig. 4.7) 
established that this target could not be cleaved by the ribozymes used in this 
study. To further increase the levels of ribozyme and antisense transcripts, the 
sequences were delivered to plant cells using the self-replicating ACMV vector 
described in previous chapters. 
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In chapter 4, in vitro cleavage assays involving both the 
tRNA-embedded and non-embedded ribozymes showed that site-
specific cleavage of the CAT RNA transcript occurred. The Rz12, ribozyme 
was the most active, and, although this ribozyme showed reduced cleavage 
rates when embedded within the tRNATYr, this rate could be significantly 
increased, to approach that of the non-embedded ribozyme, following tRNA 
processing. Cleavage rates with the RzCA ribozyme, were lower, but were not 
affected by the presence of the unprocessed tRNATyr sequence. In contrast to 
the tRNARz12 ribozyme however, cleavage rates for the tRNARzCA ribozyme 
were significantly decreased when these transcripts were processed. 
Therefore, only the Rz12 and tRNARz12 ribozymes were analysed in vivo . 
An additional aspect of the in vivo tRNARz12 design was the presence 
of two potentially active promoters: the RNA polymerase 11 promoter derived 
from the coat protein of the ACMV sequence and the endogenous RNA 
polymerase Ill promoter (see Fig. 5.5a). The results also detail the 
effectiveness of ribozyme transcripts in reducing CAT gene expression when 
derived from either or both of these promoters. 
RESULTS 
5.1 CAT activities from the mutant and normal CAT targets. 
To establish the CM2 construct as a valid control to monitor ribozyme-
mediated inhibition of CAT mRNA, CAT activities for either the GUG-containing 
CM2 target or the GUC-containing CAT target were determined. This was to 
ensure that equivalent levels of CAT activity were expressed from either target, 
making their direct comparison in the presence of ribozyme and antisense 
constructs valid. A series of independent transfections, in which either pACAT 
or pACM2 constructs were electroporated into protoplasts, showed similar CAT 
activities for both target sequences (Fig. 5.1 ). 
Figure 5.1: In vivo CAT activities for GUC-containing CAT, and GUG-containing CM2 
constructs assayed 3 days post transfection. The CAT assays labelled 1-7 are: 1, mock 
inoculated N.tabacum cells; 2 - 4, three independent transfections of 5µg pACAT + 15µg 
pAtRNA; 5-7, three independent transfections of 5µg pACM2 + 15µg pAtRNA. The assay 
species are: A, unacetylated 14c-chloramphenicol; B, C, acetylated 14c-chloramphenicol. 
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5.2 Analysis of replication of ACMV constructs in vivo. 
To determine the effectiveness of the non-embedded and 
tRNA-embedded ribozymes in vivo, CAT target together with antisense or 
ribozyme constructs were delivered to plant cells in the ACMV vectors. To 
ensure that any reduction in CAT activity observed in this system was not due 
to inhibition of replication of the target ACMV constructs, DNA was isolated 
from transfected protoplasts and digested using methylation sensitive 
isoschizomers, Dpnl and Mbol as for the analysis of pACAT, pARzCAT and 
pAAsCAT replication outlined in chapter 3. 
CAT and CM2 sequence-containing ACMV DNA accumulated to similar 
levels regardless of whether they were electroporated singly or co-
electroporated with a ribozyme or antisense ACMV construct (Fig. 5.2). In 
addition, the ribozyme and antisense-containing ACMV constructs showed 
replication products in the presence of either the ACMVCAT or ACMVCM2 
sequences (Fig. 5.3). 
5.3 In vivo efficiencies of non-embedded and tRNA-embedded ribozymes. 
Having shown that all pACMV constructs were replicating, the relative 
effects of the two ribozymes on CAT and CM2 gene expression were 
examined. The presence of the tRNARz12 ribozyme reduced CAT activity to 
less than 20°/o of the control. The non-embedded ribozyme reduced activity to 
40°/o of the control. The two antisense constructs were less effective, reducing 
CAT activity to 60°/o-70°/o of the control (Fig. 5.4a). These results contrast with 
the in vitro assays presented in chapter 4 (Fig. 4.7 & 4.8), in which Rz12 was 
more effective than the tRNARz12 ribozyme. 
When the CM2 target was assayed, all the antisense and ribozyme 
constructs reduced CAT activity to about 60°/o of the control (Fig. 5.4b). This 
reduction is likely to be due entirely to an antisense mechanism. 
In the presence of the non-embedded ribozyme, the CAT target showed 
a slightly reduced level relative to the mutant CM2 target suggesting some 
Figure 5.2: Example of replication of ACMVCAT constructs in vivo. Southern blot analysis of 
pACAT DNA isolated from N.tabacum cells three days post transfection. The blots, probed with 
radiolabelled CAT sequence, show Dpnl and Mbol digestion for each construct pairing. The 
lanes labelled 1-7 represent the following: 1, plasmid pACAT Dpnl; 2, pACAT + pAtRNA Dpnl; 
3, as for 2 but Mbol; 4, pACAT + pAtRNARz12 Dpnl; 5, as for 4 but Mbol; 6, pACAT + 
pAtRNAAs24 Dpnl; 7, as for 6 but Mbol. The DNA products are: CAT 1, bacterial gene for 
chloramphenicol resistance from pACMV constructs (see chapter 2, Fig. 2.1 a), this fragment is 
lost as ACMV replicates and accumulates; CAT 2, CAT target sequence insert; HMW, 
undigested pACAT sequence. 
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but Mbol; 4, pAtRNAAs24 Dpnl; 5, pACAT + pAtRNAAs24 Dpnl; 6, as for 5 but Mbol; 7, 
pARz12 Dpnl; 8, pACAT + pARz12 Dpnl; 9, as for 8 but Mbol; 10, pAAs24 Dpnl; 11, pACAT + 
pAAs24 Dpnl; 12, pACAT + pAAs24 Mbol. The products of digestion for each 
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ribozyme contribution (Fig. 5.4a & b). In the presence of the tRNA-
embedded ribozyme, the CAT activity of the normal CAT target was 
significantly lower than the CM2 target (Fig. 5.4a & b). This shows that the 
further reduction observed for the CAT target in the presence of the tRNARz12 
sequence is ribozyme-mediated. 
5.4 Analysis of tRNA-embedded ribozyme and antisense transcripts 
The ACMVtRNA constructs contain two potentially active promoters: the 
ACMV coat protein polymerase 11 promoter and the internal polymerase 111 
promoter of the tRNA-encoding sequence. The transcripts from these 
promoters are distinguishable by size (Fig. 5.5a). RNase protection assays 
showed that the predominant transcript for both the tRNARz12 and tRNAAs24 
constructs was the pol Ill transcript (Fig 5.5b). Densitometric scanning of the 
autoradiographs determined that the pol Ill transcript for both the tRNARz12 
and tRNAAs24 transcripts was at least 150 fold more abundant than the pol 11 
transcript. 
RNA polymerase 111 expression of the ACMVtRNA Tyr constructs did not 
appear to be affected by the insertion of the As24 or Rz12 sequences. RNase 
protection assays comparing the expression of tRNATYr, tRNARz12 and 
tRNAAs24 sequences, all derived from the ACMV vector, showed no significant 
differences between the transcript levels for all three constructs (Fig. 5.6). The 
protection assay on the tRNA Tyr sequence also protected endogenous tRNA Tyr 
(Lane 3, Fig. 5.6). This result showed that expression of this sequence was 
significantly enhanced when delivered to cells within the ACMV vector. 
5.5 Effect of mutagenising coat protein and/or tRNA promoter sequences 
on tRNA-embedded ribozyme 
To determine whether the pol Ill transcript of the tRNARz12 construct 
was the active molecule cleaving the CAT mRNA, the effect of mutagenising 
and inactivating one or both of the promoter sequences was examined (Fig. 
Figure 5.5: 
a: Map of pAtRNARz12 or pAtRNAAs24 constructions showing transcription start and stop 
sites for RNA polymerase II (i.e. pol II start and pol II termination) and RNA polymerase Ill (i.e. pol Ill 
start and pol Ill termination) derived transcripts. The distance in bp between pol II and pol Ill start 
and stop sites is indicated beneath the figure. The approximate length of the riboprobe 
transcript used for RNase protection assays in figures 5.5b, 5.6 and 5.7b is also shown as a 
hatched line. 
b: RNase protection assay for the relative abundance of pol II and pol Ill transcripts of tRNARz12 
{1-4) and tRNAAs24 (5-8). Lanes 1-8 are: 1, undigested tRNARz12 riboprobe; 2, RNase A/T1 
digested tRNARz12 riboprobe; 3, tRNARz12 probe + 1 Oµg RNA from mock transfected 
N.tabacum; 4, tRNARz12 probe+ 1 Oµg RNA from pACAT + pAtRNARz12 transfected 
N.tabacum; 5, undigested tRNAAs24 riboprobe; 6, RNase A/T1 digested tRNAAs24 
riboprobe; 7, tRNAAs24 probe + 1 Oµg RNA from mock transfected N.tabacum; 8, tRNAAs24 
probe+ 1 Oµg RNA from pACAT + pAtRNAAs24 transfected N.tabacum. RNA species are: pol 
II, RNA polymerase 11 derived tRNARz12 or tRNAAs24 transcripts; pol Ill, RNA polymerase 111 
derived tRNARz12 or tRNAAs24 transcripts; undig, undigested tRNARz12 or tRNAAs24 
riboprobe. RNA molecular weight markers are indicated. 
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Figure 5.6: RNase protection assay for the relative abundance of RNA polymerase Ill 
transcripts from ACMV vectors expressing tRNA (lanes 1-4), tRNAAs24 (lanes 5-8) or 
tRNARz12 (lanes 9-12) sequences. Lanes 1-12 are: 1, undigested tRNA riboprobe; 2, RNase 
A/T1 digested tRNA riboprobe; 3, tRNA probe+ 10µg RNA from mock transfected N.tabacum; 
4, tRNA probe + 1 Oµg RNA from pACAT + pAtRNA transfected N.tabacum; 5, undigested 
tRNAAs24 riboprobe; 6, RNase A/T1 digested tRNAAs24 riboprobe; 7, tRNAAs24 probe+ 
10µg RNA from mocktransfected N.tabacum; a·, tRNAAs24 probe+ 10µg RNA from pACAT + 
pAtRNAAs24 transfected N.tabacum; 9, undigested tRNARz12 riboprobe; 10, RNase A/T1 
digested tRNARz12 riboprobe; 11, tRNARz12 probe + 1 Oµg RNA from mock transfected 
N.tabacum; 12, tRNARz12 probe+ 10µg RNA from pACAT + pAtRNARz12 transfected 
N.tabacum. RNA species are: pol II, RNA polymerase II derived tRNARz12, tRNAAs24 and 
tRNA transcripts; pol Ill, RNA polymerase Ill derived tRNARz12, tRNAAs24 and tRNA 
transcripts; undig, undigested tRNARz12, tRNAAs24 or tRNA riboprobe. RNA molecular 
weight markers are indicated. 
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5.7a). RNase protection assays showed that transcripts derived 
from either the pol 111 (MB), pol 11 (MA) or both promoters (MAB) 
were significantly decreased after mutagenising (Fig. 5.7b). 
Mutagenesis of the pol Ill promoter of the tRNARz12 construct restored 
CAT activity to control levels. In contrast, mutagenesis of the pol II promoter 
did not significantly alter the level of reduction in CAT activity (Fig. 5.7c). Thus, 
the pol 111-ribozyme provided the major ribozyme-mediated reduction in CAT 
mRNA. 
. 
5.6 Analysis of accumulation of CAT mRNA and ribozyme cleavage 
products in vivo. 
RNase protection assays were used to try to visualise ribozyme 
cleavage products from the transfected plant cells. These assays showed that 
full length CAT mRNA could be protected in control transfections containing the 
ACMV constructs expressing CAT and the empty tRNA vector, but that no full 
length CAT mRNA was protected in the presence of the tRNARz12 construct. 
We were not able to detect RNA sequences representing the cleavage 
products (Fig. 5.8). 
Ribozyme cleavage products were assayed in the plant cells using a 
reverse transcriptase-PCR (RT-PCR) approach with primers which amplified 
either full length CAT mRNA or RNA 3' of the cleavage site. This enabled us to 
estimate the relative levels of cleaved and uncleaved CAT mRNA molecules. 
In the cells containing the normal CAT target and the tRNARz12 construct, the 
proportion of cleaved molecules, as judged by the ratio of the 3' product to the 
full length CAT product, was 3.3 (Fig. 5.9). This was significantly higher than 
any of the other ribozyme or antisense-target combinations. This increased 
proportion of amplification products representing the 3' cleavage product, in the 
presence of the tRNARz12 construct, demonstrates that in vivo cleavage of 
CAT mRNA was occurring. 
.... 
Figure 5.7: 
a: Map of pAtRNARz12 construction indicating base substitutions carried out to produce 
defective RNA polymerase II (MA) and/or RNA polymerase Ill (MB) promoter sequences (see 
chapter 2, Fig. 2.5). For the construction of pAtRz12MA plasmid, the TATATA sequence at 
position 251-256 was altered to GGGTG (see MA box above plasmid map). For the construction 
of pAtRz12MB plasmid, the Cat position 56 was altered to a G (see MB box). A (green) and B 
(red) are RNA polymerase Ill recognition signals and the light blue box is 13 base intron. Pol II 
and 111 start sites are indicated as in previous figures except that lettering is strike through 
indicating loss of function. 'Vat position 55 in the transcript of pAtRNARz12MB is a 
pseudouridine. The plasmid pAtRNARz12MAB (not shown) contains both promoter mutations. 
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Figure 5.7 
b: RNase protection assay showing relative abundance of pol II and/or pol Ill derived tRNARz12 
transcripts for mutant promoter constructs. Lanes 1-7 are: 1, undigested tRNARz12 riboprobe; 
2, RNase A/T1 digested tRNARz12 riboprobe; 3, tRNARz12 probe + 1 Oµg RNA from mock 
transfected N.tabacum; 4, tRNARz12 probe+ 10µg RNA from pACAT + pAtRNARz12 
transfected N.tabacum; 5, tRNARz12 probe+ 10µg RNA from pACAT + pAtRNARz12MA 
transfected N.tabacum; 6, tRNARz12 probe + 1 Oµg RNA from pACAT + pAtRNARz12MB 
transfected N.tabacum; 7, tRNARz12 probe + 1 Oµg RNA from pACAT + pAtRNARz12MAB 
transfected N.tabacum. RNA species are as for5.5b and 5.6: pol II, RNA polymerase II 
transcripts; pol Ill, RNA polymerase Ill transcripts; undig, undigested tRNARz12 riboprobe. 
c: Expression of CAT from the ACMV vector in the presence of tRNARz12 constructs 
containing mutant RNA polymerase II and/or Ill promoter sequences. As for Fig. 5.4, 
chloramphenicol acetylation in the presence of control (grey), tRNARz12 (green), 
tRNARz12MA (red), tRNARz12MB (yellow) and tRNARz12MAB (white) was expressed as a 
percentage of the acetylation of co-transfected ACMVtRNA plasmid, and the results of three 
independent preparations averaged. The table presents the mean and standard error for each 
combination. 
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Figure 5.8: RNase protection for the relative abundance of CAT mRNA in the presence or 
absence of the ACMVtRNARz12 construct. Lanes 1-5 are: 1, undigested CAT probe; 2, 
RNase A/T1 digested CAT probe; 3, CAT probe + 20µg RNA from mock transfected 
N.tabacum; 4, CAT probe+ 20µg RNA from pACAT + pAtRNA transfected N.tabacunr, 5, CAT 
probe + 20µg RNA from pACAT + pAtRNARz12 transfected N.tabacum. The RNA species is: 
CAT, CAT riboprobe and protected CAT mRNA·tragment. The figure above the RNase 
protection shows the CAT riboprobe derived from SP6 RNA polymerase transcription of 
pACAT/Pvull plasmid. The dotted line shows the approximate probe length. 
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Figure 5.9: Analysis by RT-PCR of accumulation of uncleaved and cleaved CAT mRNA. 
Southern hybridisation blot of reverse transcriptase- and PCR-generated products with total 
RNA extracted from transfected N.tabacum cells as template, for CAT or CM2 target constructs. 
Co-transfected constructs were: lanes 1 and 2, pAtRNA; lanes 3 and 4, pAtRNARz12; lanes 5 
and 6, pAtRNAAs24; lanes 7 and 8, pARz12; l'anes 9 and 10, pAAs24. Band 1 is the 
product corresponding to uncleaved CAT mRNA (primers 1 + TAG; odd numbered lanes), and 
band 2 is the product of cleaved or uncleaved CAT mRNA (primers 2 + TAG; even numbered 
lanes) . The numbers beneath each pair of 1 + TAG and 2 + TAG amplification products 
represent the ratio of band 2 : band 1 for each construct pairing. 
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DISCUSSION 
These results have demonstrated that transfection of 
tobacco protoplasts with self-replicating vectors expressing a CAT target 
sequence and a tRNA-embedded ribozyme resulted in an 80°/o reduction in 
CAT activity. In the presence of the mutant target, CM2, in which a known 
cleavable GUC target site was mutated to a non-cleavable GUG (Perriman et 
al., 1992), the tRNARz12 sequence reduced CAT activity to the same level as 
that observed for the antisense constructions, suggesting that the greater 
reduction observed with the normal CAT target is probably due to ribozyme 
cleavage of the CAT mRNA. 
This conclusion is also supported by the assay of cleavage products in 
vivo. While no cleavage products were observed directly by RNase protection 
assays, RT-PCR on CAT mRNA showed that, in the presence of the tRNA-
ribozyme, the ratio of PCR product from cleaved and uncleaved CAT mRNA to 
product from uncleaved CAT mRNA was significantly greater than 1. This is 
consistent with intracellular cleavage. The ratio of 3.3 in this study is similar to 
that obtained by Cantor et al. (1993) and Dropulic et al. (1992) in in vivo assays 
using a ribozyme against bovine leukemia virus and human immunodeficiency 
virus RNA respectively A ratio of 3.3 corresponds to about 70°/o of the 
available CAT mRNA sequences being cleaved in vivo. Previous studies have 
suggested that the CAT mRNA is inherently unstable in vivo (Seldon et al., 
1986; Cameron and Jennings, 1989). Since it is likely that the CAT mRNA 
cleavage products are even less stable than the CAT mRNA itself, the detected 
amount of cleavage product may be lower than the actual extent of cleavage of 
CAT mRNA by the tRNA-ribozyme. This would also explain why the RNase 
protection assays did not detect in vivo derived ribozyme cleavage products. 
As shown in chapter 4, the tRNARz12 ribozyme was less effective than 
the non-embedded Rz12 ribozyme in vitro, but in the in vivo experiments 
presented in this chapter, the tRNA-ribozyme was more effective. The three 
likely ways in which a tRNA molecule could enhance a ribozymes effectiveness 
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in vivo, are increased transcription, increased stabilisation and/or 
optimal intracellular localisation of the transcript. No direct 
evidence has been obtained for the increased stability of the tRNA-ribozyme in 
this system. In addition, there is no evidence regarding the intracellular 
location of the tRNA-ribozyme transcripts. Based on previous studies (Tabian 
et al., 1985; Cotten and Birnstiel, 1989), the modifications to the tertiary 
structure of the tRNA used in this study are likely to diminish transport to the 
cytoplasm. Therefore, it is probable that the tRNA-embedded ribozyme is 
nuclear, perhaps giving it greater target accessibility. 
The steady state levels of this ribozyme derived from the polymerase 111 
promoter, are in large excess (-150 times) over the RNA polymerase II 
transcript levels. A similar chimeric pol I I/pol 111 tRNA construction in yeast 
cells, also showed a high ratio of pol Ill to pol II transcripts (Kinsey and 
Sandemeyer, 1991 ). Inactivation of the RNA polymerase Ill promoter in our 
system decreased ribozyme activity confirming that a high level of the 
tRNARz12 transcript was necessary for ribozyme effectiveness (Fig. 5.7). The 
Rz12 and tRNARz12 transcripts expressed from the same RNA polymerase 11 
promoter produced different levels of reduction in CAT activity. While the non-
embedded ribozyme did reduce CAT activity (Fig. 5.4a- CAT+ Rz12), the RNA 
polymerase II derived tRNA-embedded ribozyme had only minimal effect (Fig. 
5.7c - CAT+ tRNARz12MB). These results suggest that the increased 
effectiveness of the tRNARz12 construct is due primarily to the high level 
transcription of this molecule from the RNA polymerase 111 promoter. They also 
demonstrate that, when both the non-embedded and tRNA-embedded 
ribozyme are expressed at equivalent levels in vivo, the non-embedded 
ribozyme is the more efficient molecule. In this respect, the in vitro and in vivo 
cleavage assays for the two ribozyme constructs are in agreement. 
A comparison of the relative levels of transcription of the wildtype and 
recombinant tRNA Tyr constructs revealed no significant difference in expression 
between the three sequences. Interestingly, the transcript levels of the normal 
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tRNA Tyr were considerably higher when expressed from the ACMV 
vector than the endogenous tRNA Tyr levels. The possible 
implications of this will be discussed in more detail in chapter 6. 
By combining RNA polymerase Ill transcription of a chimeric tRNA 
sequence and an autonomously replicating vector, we have obtained high 
levels of ribozyme RNAs in plant cells. These high levels of ribozyme RNAs 
showed enhanced reduction of CAT activity that is consistent with ribozyme-
mediated cleavage. Similar results for tRNA delivery systems have also been 
achieved in Xenopus oocytes (Cotten and Birnstiel, 1989; Bouvet et al., 1994; 
Kandolf, 1994) and a human cell culture (Shore et al., 1993; Baier et al., 1994). 
Based on the results presented here, chapter 6 will detail experiments which 
assay the effectiveness of the tRNARz12 construct in reducing target gene 
activity in transgenic plants. 
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CHAPTER 6 
ANALYSIS OF tRNARz12 AND tRNAAs24 CONSTRUCTS IN TRANSGENIC 
TOBACCO. 
INTRODUCTION 
The results presented in chapter 5 established the effectiveness of 
delivering the hammerhead ribozymes using the tRNA Tyr sequence in a 
transient system. The aim of the present study was to extend this work so as 
to use the tRNA-ribozyme constructs to produce target gene inactivation in 
stably transformed plants. The tRNARz12 and tRNAAs24 constructs were 
integrated into the genome of tobacco Nicotiana tabacum, Ti68, and analysed 
for their effectiveness in reducing CAT gene activity in whole plants. 
A number of independent tobacco lines expressing either the tRNARz12 
or tRNAAs24 transgenes were established. These ribozyme and antisense 
constructs used the endogenous RNA polymerase 111 promoter of the tRNA Tyr 
sequence. These constructs also co-expressed the p-glucuronidase (GUS) 
reporter gene, which was used to monitor whether the plants were transformed. 
The target CAT sequence was expressed in an independently 
transformed Ti68 tobacco line, using the CaMV35S promoter (Guilley et al., 
1982). One CAT expressing line, which segregated as a single insertion event, 
was self-pollinated for four generations and homozygous F4 seed used to cross 
with F1 tRNARz12 or tRNAAs24 transformants (depicted as tRNARz12 x 
35SCAT and tRNAAs24 x 35SCAT in the text). The sibling progeny of each of 
these crosses contained a mix of tRNA Tyr transgene + and - individuals, while 
all plants contained the 35SCAT gene. This allowed us to assay for the effect 
on CAT activity of the presence and absence of the tRNA Tyr constructs in the 
families derived from each independent transformant. Data is presented for 16 
independent tRNARz12 lines and 14 independent tRNAAs24 lines. 
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RESULTS 
6.1. The tRNA-ribozyme or tRNA-antisense co-segregates with GUS 
activity 
To ensure that GUS+ plants contained either of the tRNATYr-transgenes, 
and that GUS- did not, PCR analysis was carried out on randomly selected 
individual GUS+ and GUS- plants from each independent transformant. PCR 
reactions showed that all GUS+ plants contained the corresponding tRNA-
transgene while none of the GUS- plants tested positive (Fig. 6.1 ). This meant 
that our primary GUS screen for the presence or absence of the tRNARz12 or 
tRNAAs24 transgene was valid. 
6.2 Analysis of CAT expression in transgenic plants 
8 sibling progeny from each of the 16 tRNARz12 x 35SCAT and 14 
tRNAAs24 x 35SCAT crosses were initially assayed for GUS activity. CAT 
activities were subsequently determined and the mean °/o acetylation was 
plotted for GUS+ and GUS- plants within each cross (Fig. 6.2). The results 
showed that none of the 16 independent transformants containing the 
tRNARz12 or 14 containing the tRNAAs24 sequences had significantly reduced 
CAT activity compared to that in sibling plants lacking the corresponding 
transgene. 
6.3 CAT mRNA levels in transgenic plants: a comparison with pACAT 
transfected plant cells 
It was possible that a small reduction in CAT mRNA levels might not 
have been detected by assaying for CAT enzyme activity. GUS+ and GUS-
progeny from 5 independent tRNARz12 x 35SCAT (i.e. lines 15, 20, 35, 43 and 
49; see Fig. 6.2) transformants and 3 independent tRNAAs24 x 35SCAT lines 
(i.e. 27, 28 and 30; see Fig. 6.2) were selected for the analysis of CAT mRNA 
levels. These lines were chosen because they showed a slight reduction in 
CAT enzyme activity in the presence of either transgene. The ratio of amplified 
Figure 6.1: Example of co-segregation of tRNATyr transgene with GUS activity. PCR analysis 
of GUS + and GUS - individuals from 9 independent tRNARz12 and 9 independent tRNAAs24 
Ti68 lines. Lanes represent tRNARz12 lines 1, 3, 15, 16, 19, 20, 21, 35 and 43 and tRNAAs24 
lines 3, 4, 8, 15, 16, 24, 27, 28 and 30. GUS+ and GUS - individuals are indicated above the 
gel. Molecular weight markers are pUC19/Hpall (Bresatec). The arrows indicate the tRNARz12 
or tRNAAs24 amplification products (see chapter 2; section 2.13 (vi) for details of primers and 
PC R protocol). 
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Figure 6.2: Analysis of CAT enzyme activity in 16 (tRNARz12 x 35SCAT) and 14 (tRNAAs24 x 
35SCAT) lines. The mean% acetylation (y axis) is plotted for GUS+ and GUS - sibling progeny 
from each cross (x axis). This represents the o/o acetylation from 8 individuals within each cross. 
Bars in red are GUS + (tRNARz12) plants, bars in blue are GUS + (tRNAAs24) plants and bars in 
yellow are GUS - . Error bars represent 2 standard deviations. 
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CAT product from GUS-: GUS+ plants within each transformed line 
approximated 1 (Fig. 6.3). This suggests that there was no significant 
reduction in the levels of CAT mRNA between GUS+ and GUS- progeny from 
any of the 8 transformants (Fig. 6.3). 
Quantitative RT-PCR analyses were carried out to determine the 
comparative levels of CAT m RNA expressed in either the pACAT-transfected 
plant cells or the 35SCAT-transgenic plants. In combination with the 
tRNARz12 expression levels (see section 6.4), these results were used to 
determine the approximate ratios of target : ribozyme in each system. The 
plant cells were expressing - 8 picograms (pg) of CAT mRNA/µg of total RNA 
while the transgenic plants were expressing - 4 pg/µg (Fig. 6.4). Hence there 
was a 2-fold difference in the level of CAT mRNA between the two systems. 
6.4 tRNARz12 and tRNAAs24 expression in transgenic plants: a 
comparison with pAtRNARz12 transfected plant cells. 
The RNA levels of the tRNARz12 and tRNAAs24 constructs were 
analysed. RNase protection assays were carried out as for the equivalent 
expression assays in the transfected plant cells (see chapter 5). We were not 
able to detect any expression of either the tRNARz12 or tRNAAs24 transgenes 
using these assays. This suggested that the high level expression obtained in 
the plant cells was not occurring in the transgenic plants. 
To determine whether any tRNATyr transgene expression was taking 
place, RT-PCR was carried out on GUS+ progeny from 5 independent 
tRNARz12 x 35SCAT lines (i.e. 15, 20, 35, 43 and 49; see Fig. 6.2). These 
assays revealed that low level tRNARz 12 expression was present in most of 
these transgenic lines (Fig. 6.5). Quantitative RT-PCR analysis determined 
that this expression was in the range of 0-0.5 pg/µg of total RNA. In contrast, 
RT-PCR analysis on total RNA from the transfected plant cells expressing the 
pAtRNARz12 sequence, revealed that the expression of this construct was 
approximately 930 pg/µg total RNA (Fig. 6.5). 
Figure 6.3: RT-PCR and southern hybridisation analysis of CAT mRNA levels from GUS + and 
GUS - progeny in 5 (tRNARz12 x 35SCAT: i.e; 15, 20, 35, 43 and 49) and 3 (tRNAAs24 x 
35SCAT: i.e; 27, 28 and 30) lines. GUS + plants are in odd numbered lanes, GUS - are in even 
numbered lanes. Lanes 1-10 are tRNARz12 x 35SCAT lines and lanes 11-16 are tRNAAs24 x 
35SCAT lines. The arrow indicates the PCR amplified CAT product. Values beneath lane 
numbering are the ratio of CAT amplification products from GUS-: GUS+ plants within each line. 
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Figure 6.4: Comparison of CAT mRNA levels from pACAT + pAtRNA transfected plant cells 
and 35SCAT transgenic plants by RT-PCR analysis and southern hybridisation. Lanes 1-3 are: 
1, RNA from pACAT + pAtRNA transfected plant cells; 2, RNA from GUS- tRNARz12 x 35SCAT 
(line 20); 3, RNA from GUS - tRNARz12 x 35SCAT (line 35). The arrow indicates the PCR 
amplified CAT product. The numbers beneath the gel are picograms (pg) of CAT mRNA per 
microgram (µg) of total RNA (see chapter 2; section 2.13(viii) for further details of quantitation of 
PCR products). 
Figure 6.5: Comparison of tRNARz12 RNA levels from pACAT + pAtRNARz12MA (i.e. 
mutant coat protein promoter construct; see chapter 5) transfected plant cells and 5 (tRNARz12 
x 35SCAT) lines using RT-PCR and southern hybridisation analysis. Lanes 1-6 are: 1, RNA 
from tRNARz12 x 35SCAT (line 15); 2, as for 1 but line 20; 3, as for 1 but line 3; 4, as for 1 but 
line 43; 5, RNA from pACAT + pAtRNARz12MA; 6, as for 1 but line 49. The tRNARz12 PCR 
amplified product is indicated. As for Fig. 6.4, the numbers beneath the figure are pg of 
tRNARz12 RNA per µg of total RNA. 
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In molar terms, the tRNA-ribozyme : substrate ratio in the plant cells was 
approximately 620: 1, whereas in the transgenic plants this ratio was in the 
range of 0-0.7:1. 
DISCUSSION 
Despite the results obtained in the transfected plant cells, in which 
tRNARz12 ribozyme mediated reduction of CAT gene expression was 
observed, we were not able to obtain a similar result when the tRNARz12 
construct was expressed from an integrated sequence in transgenic tobacco 
lines. This lack of CAT gene reduction in the transgenic plants was most likely 
due to the significantly reduced levels of expression of the tRNARz12 
construct. In the transfected plant cells, a molar ratio of tRNARz12 ribozyme : 
CAT substrate of approximately 620 : 1 was sufficient to obtain > 80°/o 
reduction in CAT gene expression. In contrast, the corresponding ratio in the 
transgenic plants was in the range of 0-0. 7 : 1. 
The large reduction in recombinant tRNA Tyr transcript levels was 
observed in each independent tRNARz12 and tRNAAs24 transformant. This 
suggests that a general lack of expression, rather than an effect due to the site 
of transgene integration was responsible. In addition, this large reduction 
occurred only in the recombinant tRNATyr constructs. The level of the target 
CAT mRNA sequence showed a modest two-fold reduction between the plant 
cells and the transgenic plants (i.e. 8pg/µg in plant cells and 4pg/µg in 
transgenic plants). This suggests that the lack of activity of the tRNATyr 
constructs is specific to these sequences and is likely to involve the level of 
transcription from the RNA polymerase Ill promoter within these recombinant 
tRNA Tyr sequences. 
One mechanism which may explain the differences in tRNARz12 and 
tRNAAs24 RNA levels between the two systems maybe that the use of the 
ACMV vector causes elevated expression of the tRNA Tyr-constructs in the plant 
cells due to the . In mammalian systems, viruses and their associated viral 
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gene products can sometimes increase the level of RNA polymerase 111 
expression by increasing the activity of one of the transcription factors, 
transcription factor IIIC {TFIIIC). Specific examples of this effect include the 
adenovirus E1A protein (e.g. Datta eta!., 1991), SV40 (White eta!., 1990), 
hepatitis B virus X-gene protein (Aufiero and Schnieder, 1990), herpes simplex 
virus protein "ICP27'' (Jang and Latchtein, 1992) and the human 
immunodeficiency virus Tat protein (Jang et al., 1992). Two of these studies 
also observed a simultaneous increase in tRNA transcription upon viral 
infection (Datta et al., 1991; White et al., 1990). 
It is possible that African cassava mosaic virus, on which the ACMV 
vector is based, influences the expression of RNA polymerase Ill based 
transcripts by increasing TFIIIC expression. Such an increase could lead to 
high levels of RNA polymerase Ill encoded sequences such as was observed 
for the recombinant tRNATyr used in the studies detailed in chapter 5. 
Furthermore, RNase protections (see chapter 5, Fig. 5.6) comparing 
wildtype tRNA Tyr expression in mock inoculated plant cells, with that of the 
pAtRNA Tyr inoculated cells, showed that expression from the pAtRNA Tyr 
construct was significantly higher than that observed for the endogenous 
tRNA Tyr_ This could simply be due to the increased number of templates (i.e. 
due to the replication of the ACMV vector) from which transcription of this 
sequence can occur. Alternatively the virus and/or its gene products could be 
affecting tRNATyr gene expression. 
Future studies in which the endogenous tRNA transcript levels (i.e. as 
distinct from those derived from the ACMV vector) are monitored, in response 
to ACMV infection, will establish if increased steady state levels of tRNA 
transcripts are evident. Should this be the case, the manipulation of the 
ACMV-tRNA vector to provide a delivery system for whole plants may provide 
an ideal means of obtaining high level RNA polymerase Ill-based expression of 
incorporated sequences. 
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A second mechanism for the differential tRNATyr gene expression could 
involve a specific reduction in RNA polymerase 111 transcription of the 
recombinant tRNAs in the transgenic plants. This could result from methylation 
of the cytosine residues on the integrated tRNARz12 and tRNAAs24 
sequences. Methylation of plant genomes occurs at the carbon-5 of cytosine 
residues in the sequences CG and CNG (Gruenbaum et al., 1981 ), whereas 
mammalian genomes are only methylated in the sequence CG. This means 
that, in general, plant genomes are methylated to a much greater degree than 
mammalian genomes (reviewed in Finnegan et al., 1993). 
There are several examples of gene silencing correlating with DNA 
methylation of RNA polymerase II transcribed transgenes in both plants (e.g. 
Matzke et al., 1989; Meyer et al., 1993; lngelbrecht et al., 1994) and animals 
(e.g. Doerfler, 1990). However, relatively few reports exist on the effects of 
methylation on transcription of RNA polymerase I I I-based transgenes in either 
system (Besser et al., 1990; Jutterman et al., 1991; Doerfler, 1993). 
One study in which in vitro methylated tRNA-lysine (tRNALY5 ) genes 
were microinjected intoXenopus oocytes, showed that transcription of the 
tRNALys gene was inhibited 80°/o when compared with the non-methylated 
sequence (Besser et al., 1990). Methylation sensitive restriction enzyme 
analysis established that, of the five CG sites contained within the tRNALys 
coding region, two sites were not methylated and therefore not responsible for 
the down-regulation. However, of the three remaining CG sites, one was 
contained within one of the promoter regions (B box) and two others 
immediately adjacent, therefore making them good candidates for methylation-
based transcriptional inactivation. In another study, Juttermann et al. (1991) 
showed that the transcription of a related RNA polymerase 111 transcribed gene 
(i.e. VA 1 gene of adenovirus type 2 DNA) was also reduced by in vitro 
methylation when it was subsequently transfected into Hela cells. The 
methylation of three CG sequences within the A box was shown to be 
responsible for the down-regulation of the VA 1 transcription (Doerfler, 1993). 
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These reports show that cytosine-methylation of RNA polymerase 111 
based sequences can have an effect on the subsequent transcription rates of 
these genes. If cytosine-methylation is the cause of transcriptional down-
regulation of the tRNATyr transgenes in our system, the universal nature of this 
reduction suggests that these sequences display an elevated susceptibility to 
being methylated. 
Transcriptional regulation due to cytosine-methylation of the ACMV-
tRNATyr sequences in the transfected plant cells is unlikely. Previous studies 
on geminivirus replication have shown that ACMV (Ermak et al., 1993) and the 
related virus, tomato golden mosaic virus (TGMV-Brough et al., 1992b) can 
both replicate their genomes, and maintain them, free of cytosine-methylation. 
This indicates that if methylation is causing the down-regulation of the 
tRNARz12 and tRNAAs24 sequences in the transgenic plants, then their 
delivery to the plant cells using the methylation-resistant ACMV vector was 
fortunate. 
Although the RNA levels of the tRNARz12 transgene were low, we did 
observe a range in expression levels between independent transformants (0-
0.5 pg/µg RNA). This range could be explained by differential methylation of 
the independent transgenes. Should this be the case, however, we would have 
expected to observe some transgenic lines expressing the recombinant 
tRNA Tyr at equivalent, or close to endogenous tRNA Tyr levels. Since most 
tRNAs are multigene families, it is difficult to elucidate the exact concentration 
of tRNA transcripts from an individual tRNA gene. The tRNATyr gene used in 
this study belongs to a family of at least 11 members (Fuchs et al., 1992). 
The molar ratio of ribozyme : substrate RNAs in the transgenic plants 
was significantly diminished compared with that obtained in the plant cells. If 
this contrasting ribozyme : target ratio is the primary cause of the lack of 
ribozyme effectiveness in the transgenic plants, methods aimed toward 
increasing tRNA-ribozyme transgene expression should also result in 
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successful target gene reduction. These will be discussed in more detail in 
chapter 7. 
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CHAPTER 7 
THE APPLICATION OF HAMMERHEAD RIBOZYMES FOR TARGETED IN 
VIVO GENE INACTIVATION 
7.1. Conclusions of this study 
86 
The aim of this project was to develop hammerhead ribozymes for 
targeted gene inactivation in plants. These ribozymes were designed so as to 
increase their expression and stability in vivo. The initial in vivo screening was 
done using transient expression in N. tabacum plant cells. The following 
sections summarise the results obtained. 
(i). A long antisense containing 4 hammerhead domains (i.e. RzCAT) 
directed against CAT mRNA, was the first ribozyme tested. Previous results, 
using the 35S promoter and non-replicating vectors, had shown that, when 
delivered in 360-fold excess, the RzCAT ribozyme reduced CAT activity to 54°/o 
of control levels. This was 30°/o more than the equivalent antisense control 
(Perriman et al., 1993). 
To further enhance this level of CAT gene suppression without 
increasing the amount of ribozyme containing plasmid delivered to the cell, a 
self-replicating viral-based vector, pACMV, was developed. Increased 
expression from this ACMV vector was evidenced by the analysis of CAT 
activity, which was 19 times greater than that obtained from the non-replicating 
35S-vector (Chapter 3; Fig. 3.1 ). Co-transfection of pACMV expressing CAT 
and either RzCAT, or control antisense RNAs (i.e. at a ratio of 1 CAT : 3 
RzCAT or AsCAT plasmids) gave significant but equivalent reductions in CAT 
enzyme activity. This suggested an antisense mechanism rather than 
ribozyme cleavage was the primary mode of gene inactivation (Chapter 3; Fig. 
3.3, 3.4). 
(ii). To reduce the influence of antisense effects, and gain a measure of 
the extent of ribozyme-mediated gene inactivation, ribozyme sequences 
containing short hybridising arms were made. To enhance the stability of these 
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sequences in vivo, ribozyme and control antisense were embedded within the 
anticodon loop of a tyrosine-tRNA from tobacco (i.e. tRNATYr). 
(iii). The potential of these ribozymes to cleave CAT m RNA when 
embedded in the tRNATyr structure, was assayed in vitro, and compared to the 
non-tRNA Tyr embedded ribozymes. These assays showed that, when the 
tRNATyr_ribozymes and non-embedded ribozymes were expressed at equal 
concentrations, the most efficient ribozyme was the non-embedded ribozyme, 
Rz12, with the analogous tRNARz12-ribozyme 50°/o less efficient (Chapter 4; 
Fig. 4.7, 4.8 & 4.9). 
These in vitro cleavage assays were analysed at a fixed time point ( 1 .5 
hours) with ribozyme in a 6-fold molar excess. The cleavage rates induced by 
these molecules could be further analysed by determining the enzymatic 
turnover and other kinetic parameters. The determination of these values could 
further explain the observed rates of in vitro cleavage. In addition, they may 
define the rate-limiting step for each ribozyme-substrate reaction therefore 
providing a more accurate means of predicting in vivo efficiencies. 
(iv). The in vivo efficiency of the tRNARz12-ribozyme was analysed by 
co-transfection of pACMV expressing the tRNATyr_ribozyme and CAT. CAT 
enzyme expression was reduced 85°/o, which was significantly more than the 
reduction in the presence of non-embedded ribozyme, or tRNATYr-embedded 
and non-embedded antisense constructs (Chapter 5; Fig. 5.4a). 
Cleavage activity by the tRNATyr_ribozyme was further distinguished 
from an antisense effect by mutating the single non-base paired nucleotide in 
the target sequence (i.e. "C") to a guanosine. This rendered the substrate 
uncleavable (Chapter 4; Fig. 4.7) but did not affect CAT expression (Chapter 5; 
Fig. 5. 1 ), or alter the effects induced by the antisense (Chapter 5; Fig. 5.4). 
When this mutant CAT target, CM2, was assayed for CAT activity, there was 
no difference between the antisense and ribozyme constructs. This suggested 
that the greater reduction seen for the tRNATyr_ribozyme with the normal CAT 
target was ribozyme-mediated (Chapter 5; Fig. 5.4b). CAT mRNA analysis 
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supported this view by showing, in the presence of the tRNATyr_ribozyme, a 
reduction in full length message and a significant accumulation of RNA 
representing the 3' cleavage product (Chapter 5; Fig. 5.9). 
(v). The tRNATyr_ribozyme construct expressed from the pACMV vector, 
contained two active promoters. Mutagenesis of either or both of these 
promoters revealed that the predominant and active ribozyme transcript in 
reducing CAT expression in the plant cells, was derived from the RNA 
polymerase Ill promoter of the tRNA insert (Chapter 5; Fig. 5.7b & c). A molar 
ratio of ribozyme derived from RNA polymerase 111 transcription and CAT 
substrate from ACMV-coat protein transcription of 620 ribozyme: 1 substrate 
RNA was determined (Chapter 6; Fig. 6.4 & 6.5). 
(vi). Following the transient studies, the tRNA Tyr _ribozyme and tRNA Tyr _ 
anti sense constructs were transformed into N. tabacum Ti68 plants. The CAT 
target was present in a separate Ti68 plant as a homozygous single insertion. 
CAT x tRNATyr_ribozyme or tRNATYr-antisense crosses were carried out and the 
progeny assayed for relative CAT activity. No reduction in CAT enzyme activity 
or CAT m RNA levels were observed in the presence of either tRNA Tyr 
transgene (Chapter 6; Fig. 6.2 & 6.3). Analysis of the tRNATyr_ribozyme 
transcripts revealed significantly diminished levels relative to the transient 
expression obtained from the replicating vectors in plant cells. This resulted in 
a reduced molar ratio of ribozyme RNA in the transgenic plants ranging from an 
undetectable level to 0. 7 ribozyme : 1 substrate, and probably explains the lack 
of reduction in observed CAT expression (Chapter 6; Fig. 6.4 & 6.5). 
7.2. The in vivo requirement for high molar concentrations of ribozymes. 
The apparent requirement for a large ribozyme:substrate ratio shown in 
this study is not surprising. As outlined in chapter 1 (section 1.9), an important, 
yet poorly defined, aspect of the design of hammerhead ribozymes for in vivo 
applications, is the optimisation of their intracellular location. The co-
localisation of the ribozyme and target used in the present study was not 
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addressed. This means that many, or perhaps most, of the ribozyme 
transcripts may never interact with the target RNA. 
Based on previous studies (Tobian et al., 1985; Cotten and Birnstiel, 
1989), and the in vitro analysis of the maturation process of the chimeric 
tRNATyr sequences in this study (Chapter 4), it is likely that these transcripts 
are largely confined to the nucleus. For the CAT target, and other nuclear 
target RNAs, this may be useful as it may provide optimal target accessibility. 
However, nuclear-entrapment could limit the types of substrate RNAs a 
chimeric tRNA-ribozyme could successfully target and inactivate (i.e. nuclear 
verses cytoplasmic). In addition, tRNAs which do not undergo the normal 
maturation and transport processes could be more susceptible to nuclease 
attack, thus rendering them less stable than normal tRNA sequences. 
7.3. The delivery of tRNA-ribozymes. 
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If tRNA-ribozyme constructions are to be further developed, an important 
area of future research is the determination of their intracellular location. Other 
types of tRNA-ribozyme constructions, such as tRNA-ribozyme sequences in 
which the ribozyme has been inserted in positions other than the anticodon 
loop, could be tested. These types of chimeric tRNAs might behave more like 
their endogenous counterparts, and provide a means of delivering 
hammerhead ribozymes for targeted gene inactivation in either the nucleus or 
the cytoplasm. Chimeric tRNA-ribozyme sequences in which the ribozyme has 
been incorporated within the intron (Bouvet et al., 1994; Kandolf, 1994) or the 
3' end (Shore et al., 1993; Baier et al., 1994) of the tRNA molecule have been 
produced, although no data has been published regarding the intracellular 
location of these molecules. Another region for ribozyme insertion, not yet 
investigated but which could also be considered, is the variable region of the 
tRNA motif. 
An alternative approach to developing chimeric tRNA-ribozyme 
constructs, might be to simply use the high level transcription of the tRNA 
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promoter sequences, and have alternative stabilising sequences (i.e. other 
than the tRNA motif) at the 5' and 3' ends of the ribozyme. This may help to 
circumvent low tRNA-ribozyme expression, such as that observed in the 
transgenic plants analysed in this study. It is possible that the plant may 
recognise recombinant tRNAs as 11 misfunctioning 11 tRNAs, and respond by 
rapidly removing these transcripts. However, if the ribozyme construct was not 
behaving as a tRNA, the cell may "allow" higher levels of these transcripts to 
accumulate. 
Several other ribozyme delivery systems could also be adapted to plant-
based gene inactivation. It is possible that some of these might provide high 
steady-state levels of ribozyme transcripts when expressed in both plant cells 
and transgenic plants. These include the addition of stabilising stems and/or 
loops (e.g. Sioud and Drlica, 1991 ), or the delivery within small nuclear RNAs 
(i.e. snRNAs; DeYoung et al., 1994), RNA polymerase I transcripts (Menke et 
al., 1995) or self-circularising RNAs (Kisich et al., 1995). 
7.4. The ACMV-tRNA system as an in vivo screen. 
The combination of the ACMV-based self-replicating vector and pol Ill 
expression provided the high levels of tRNA-ribozyme production required to 
induce ribozyme-mediated target gene reduction in plant cells. At present, 
however, the ACMV-tRNA system is limited to use in plant cells. Vector 
instability and variable levels of viral infection has led to only limited use of 
geminivirus-vectors as a means of delivering sequence to whole plants. 
However, this system is ideal for the rapid assay of several aspects of 
ribozyme/substrate design in plant cells. Such assays can circumvent the 
necessity for the large scale production of transgenic plants by providing a 
rapid primary in vivo screen of a large number of ribozyme sequences. One 
application could be the in vivo analysis of substrate target-site accessibility. In 
addition, ribozymes containing base substitutions (i.e. such as some of those 
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outlined in chapter 1, section 1.6) and which have demonstrated enhanced 
catalytic activities in vitro, could be tested for relative in vivo capabilities. 
7.5. Prospects for in vivo gene inactivation using hammerhead 
ribozymes. 
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Although hammerhead ribozyme activity has been extensively studied iri 
vitro (see chapter 1 ), the parameters for efficient in vivo use are poorly defined. 
In particular, there have been only three publications demonstrating ribozyme-
mediated reduction of gene expression in plant cells (Steinecke et al., 1992; 
Perriman et al., 1993; Steinecke et al., 1994) and one in transgenic plants 
(Wegener et al., 1994), although the latter lacked appropriate controls to 
discount an antisense mediated inhibition. The studies presented here have 
extended the application of ribozymes in vivo, with the inhibition of CAT activity 
in plant cells by the delivery of a ribozyme as a tRNA-modified transcript 
expressed from the ACMV self-replicating vector. 
The research presented in this thesis has demonstrated, that using the 
current ribozyme design, and techniques of intracellular expression and 
delivery, a high molar excess of ribozyme is required to obtain ribozyme-
mediated target gene inactivation in vivo. The results showed that an 
abundantly expressed tRNA-embedded ribozyme increased CAT gene 
inhibition over that obtained in the presence of a less abundant non-embedded 
ribozyme. This finding was supported by mutagenesis of the tRNA promoter, 
which led to diminished levels of the tRNA-embedded ribozyme and no longer 
reduced CAT activity in the plant cells (Chapter 5; Fig. 5.7). Additionally, 
significantly reduced tRNA-ribozyme transcript levels failed to reduce CAT 
enzyme activity in the transgenic plants (Chapter 6). These results are 
consistent with the successful application of ribozymes in animal cells ( e.g. 
Cotten and Birnstiel, 1989: 500-1000 ribozyme : substrate; Cameron and 
Jennings, 1989: 1000 ribozyme: substrate). 
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The current requirement for high molar concentrations of ribozyme limits 
the application of hammerhead ribozymes as gene therapy agents. Future 
optimisation of in vivo ribozyme activity will therefore require several areas of 
research. In addition to the in vivo aspects of intracellular location and 
enhanced stabilities, analyses aimed toward defining ribozymes with increased 
catalytic efficiencies (i.e. such as those outlined in chapter 1 ; section 1 .6) are 
also important. Improving these aspects of ribozyme design should provide 
conditions in which lower ratios of ribozyme : substrate will be sufficient for 
ribozyme-mediated inactivation of gene expression in vivo. 
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